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ABSTRACT 
This research compared a traditional drug development approach with an 
enhanced "Quality by Design" (QbD) approach to foster greater process and 
formulation understanding. Propranolol HCl extended release capsules and 
Metoprolol Succinate extended release tablets served as targets for development. 
The formulation and process parameters utilized well-established techniques, such as 
wet granulation, extrusion, spheronization, and fluid bed processing with 
commercially available aqueous or organic polymeric systems. 
Propranolol HCl extended release capsules were a benchmark for current 
generic pharmaceutical process development to identify basic parameters for a 
suitable product. Metoprolol Succinate extended release tablets utilized the ICH Q8 
annex guidelines approach to identify target profiles, and then; define, test, and link 
Critical Quality Attributes (CQAs). Preliminary data supported factor and level 
selections for the 23 full factorial and Box-Behnken experimental designs for 
elements of a conceptual design space. 
Physical and chemical characterization of commercially available 
competitors established product target profiles. Particle size distribution, sphericity, 
moisture content, and dissolution profiles were studied as CQA's. Preliminary 
studies for the immediate release beads identified the water quantity during 
granulation, kneading time during granulation, and the duration of spheronization as 
significant factors for particle size generation, and sphericity. The traditional 
approach determined an organic system was necessary for Propranolol HCl to yield a 
stable extended release product. The aqueous sustained release coating studies for 
Metoprolol Succinate found the polymer coating level, humidified curing condition, 
and curing duration were important factors . Altering the excipient blend formulation 
during initial tabletting trials minimized segregation and bead damage. 
The full factorial design for the development of immediate release beads identified 
spheronization time as a statistically significant factor in determining the standard 
deviation and relative standard deviation for sphericity. The Box-Behnken design 
for sustained release beads found the polymer coating levels to be a statistically 
significant main effect for the dissolution profile. Significant surface damage was 
apparent throughout the full factorial tabletting design, with a "best case" approach 
yielding an improved dissolution profile. Traditional approaches incorporated into 
the QbD approach facilitate variable and level selection throughout the development 
process. Data generated via these statistical methods supports process understanding 
and future decision-making. 
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Chapter 1 Study Overview 
1.0 Introduction 
This chapter serves to orient the reader with the challenges associated with 
drug development and the use of organic solvents in the pharmaceutical industry. 
The objectives and overview of the approach to the research proposed are described. 
Additionally, the potential benefits of this work for the pharmaceutical community 
and the general public are presented. 
1.1 Statement of the Problem 
Tablet manufacturing has been described as a "paradox"; formulating and 
manufacturing a mass of raw materials into a usable product is complicated, and then 
upon administration, the tablet must release the active ingredients in the desired 
manner requiring additional design considerations (Swarbick 2007). To improve 
formulation and process understanding during development, aspects of the Quality 
by Design (QbD) approach described by the International Conference on 
Harmonization (ICH) to guide experimentation can be used to enhance innovative 
efforts in the marketplace. This approach is different from the traditional method of 
drug development by supporting a risk-based approach to the identification and 
evaluation of critical parameters that negatively impact product characteristics. 
Experimental design to evaluate formulation and processing parameters with 
benchmarks gained through reverse engineering (product characterization of 
marketed competitors) serves as an improved model for generic drug development. 
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Utilizing reverse engineering techniques to understand how the products are 
formulated and manufactured is not a novel concept. Generic pharmaceutical 
manufacturers use reverse engineering to understand the performance of innovator 
products in order to model their formulations to mimic the marketed product closely 
enough to gain FDA approval. While this method of deconstruction to copy the 
original product may be effective, it does not improve the product design or 
manufacturing practices. Instead of attempting to duplicate ineffective, expensive, 
or other disadvantageous methods, improvements can be made to the drug product, 
delivery system and manufacturing process to provide a well understood generic 
product. This conceptual generic product development strategy will serve as the 
intellectual basis of this work and will provide generic manufacturers with an 
understanding of the advantages of implementing these methodologies. As a result 
of improved product development, consumers of generic products will ultimately 
reap the rewards of a more competitive market with theoretically lower costs and 
decreased time to market entry. 
1.2 Objectives of the Study 
The primary aim of the study is the comparison of formulation and process 
development for two extended release water-soluble pharmaceutical compounds, 
propranolol HCl and metoprolol succinate. Propranolol HCl development will 
largely be empirical, from raw ingredients to a final sustained release capsule using a 
traditional approach. General information gained through the traditional 
development process of propranolol HCl will be used to support decisions for a QbD 
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developmental approach of metoprolol succinate extended release tablets. While the 
development of a single drug product is dependent on its chemical and physical 
properties, the traditional approach can be understood and improved to yield a 
stronger process understanding. Process understanding can be gained through the 
use of multivariate statistical approaches to support a design space. Utilizing a 
systemic approach facilitates understanding of the material attributes and process 
parameters that are linked to a drug product's critical quality attributes (CQA's). 
Figure 1 is an adapted overview of the ICH Q8 Annex strategy for Pharmaceutical 
Development, from concept through commercialization. The Q8 strategy provides a 
general framework of drug development, which will be applied to metoprolol 
succinate throughout this research. 
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Figure 1 Adapted Overview of Pharmaceutical Development Described in Q8 Annex 
(ICH 2007) 
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Throughout the development and product life cycle, changes in formulation 
and manufacturing practices offer opportunities to gain greater knowledge of product 
characteristics and performance under various conditions. Inclusion and analysis of 
relevant experimental and experiential information can be used to create, support, 
and expand the control and design spaces. While absolute operational and process 
understanding is impossible, it is important to recognize what is known and operate 
within those parameters. This project will use the sequential approach presented by 
the ICH Q8 annex to guide the enhanced product development approach to support 
elements of a conceptual design space. Scale up, development of a control strategy, 
and product life cycle management are important aspects for commercialization, but 
are beyond the scope of this work. Due to equipment and financial limitations, 
development will avoid costly high tech machinery and utilize a practically based 
QbD approach of statistical methodology and process understanding to support 
elements of the design space. 
A secondary objective is the evaluation of aqueous systems in place of 
organic solvents where feasible, as an environmentally friendlier alternative. It can 
be hypothesized that both brand and select generic products utilize organic solvents 
in selected aspects of their manufacturing. Solvent usage is not limited to sustained 
release coatings, and may be used during the production of immediate release beads. 
Therefore, both the immediate release bead preparations and the sustained release 
coatings provide areas where aqueous systems may be explored. 
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The formulation and process development aspects of the project are divided 
into four phases based on common processing steps where intermediate testing 
occurs. Figure 2. serves as an overview of the study approach for drug product 
development, with processing steps presented in squares, and potential variables as 
rounded squares. Phase I deformulates the competitor's products and uses physical, 
chemical, and published literature to support the development of product profile 
targets. Phase II evaluates the formulation and process development of an immediate 
release bead, from raw ingredients to final dried beads. Phase III is the development 
of a sustained release bead, which spray coats and cures the polymer system onto the 
immediate release beads. Phase IV topcoats the sustained release beads, before 
blending and compressing them into multiparticulate sustained release tablets. 
Identification and evaluation of intermediate metrics will facilitate a comprehensive 
system understanding in addition to the final product characterization. Evaluation 
throughout the process will bolster process understanding and a systemic approach to 
support formulation and production changes. Each stage of development has an 
impact on the final product; therefore it is essential to understand processing ranges 
and yields for each stage. 
Drug development does not occur in a vacuum, therefore it must be fluid and 
flexible in order to adapt to changes. For example, the development of spherical 
immediate release beads in a controlled particle size distribution is an important 
intermediate goal. The traditional approach would strive to optimize the batch yield 
and proceed to the next phase. Optimization of a poorly understood process is not a 
wise allocation of time and resources. In contrast, the goal for the immediate release 
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beads should be to evaluate the output over a reasonable processing range to 
understand the impacts of variability and processing conditions. Therefore, when the 
second phase of development begins, sustained release coating and curing, and the 
data suggests an adjusted particle size distribution, the necessary changes are made 
based on process understanding. 
The ICH Q8 approach for drug development is divided into four stages for 
this research: 
1. Targets will be identified utilizing deformulation/reverse-engineering 
methods of currently manufactured brand and generic competitors. 
Characterization of marketed product's vital metrics serves to support 
benchmarks for both the propranolol HCl and metoprolol succinate 
formulations. 
2. Identification and justification of CQA's for the target multiparticulate 
formulations 
3. Linking specific factors to CQA's and exploring the preliminary relationships 
utilizing "traditional" approaches. 
a. Development of an uncoated immediate release drug pellet through 
the evaluation of formulation and wet granulation processing 
parameters. 
b. Evaluation of polymer coating to the pellets developed in phase 1 to 
yield an extended release dissolution profile. 
c. Metoprolol Succinate extended release tablet formulation and process 
parameters for the final dosage form. 
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4. Evaluating the selected factors by design of experiment and other QbD 
approaches to support elements of a conceptual design space. 
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Chapter 2 Pharmaceutical Regulatory Environment 
2.0 Introduction 
Generic pharmaceuticals are a vital element of healthcare and often deliver 
quality medications at a fraction of the price of the brand product. This chapter aims 
to familiarize the reader with the current regulatory, legal landscape and competitive 
climate of the generic pharmaceutical market. 
2.1 Regulatory Background of Generic Pharmaceuticals 
The "Drug Price Competition and Patent Term Restoration Act of 1984'', 
commonly referred to as the Hatch-Waxman Act, legalized the approval of 
Abbreviated New Drug Application (ANDA) submissions for generic equivalents to 
currently marketed products (Mathias, Dole et al. 1984). This act specifically 
required generic manufacturers to demonstrate the following: 1) The innovator 
product was currently approved. 2) There were no patent infringements related to 
their product. 3) All required in vitro and in vivo bioequivalency studies met the 
Food and Drug Administration (FDA) requirements. The key advantage of this new 
avenue for drug approval was the removal of duplicate and costly clinical trials for 
generic products, since the innovator previously established safety and efficacy for 
initial market approval. Additionally, generic manufacturers must comply with 
Current Good Manufacturing Practice regulations (cGMP's), in order to market their 
products. 
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Bioequivalency studies became the clinical standard that generic products 
had to meet in order to gain FDA approval. The Code of Federal Regulations part 
320.1 defines bioavailability and bioequivalence as the following: "Bioavailability is 
the rate and extent to which the active ingredient or active moiety is absorbed from a 
drug product and becomes available at the site of action . ... " While "Bioequivalence 
is the absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical 
alternatives becomes available at the site of drug action when administered at the 
same molar dose under similar conditions in an appropriately designed study 
(CFR:320.l 2003)." Recently the FDA expressed interest in receiving feedback on 
the regulatory process and has issued the "Guidance for Industry: Bioequivalence 
Recommendations for Specific Products", which describes the agency's goal to 
streamline the process and become more efficient through improved communication 
with manufacturers and the public (FDA 2007a). 
For approval of multiple strengths of a narrow therapeutic index drug to avoid 
duplicitous bioequivalency testing the FDA's Guidance on In Vitro/ In Vivo 
correlations for extended release products must be met. In addition to the acceptance 
criteria, one of the following three situations must be satisfied: 
1. Bioequivalence has been established for all strengths of the reference-listed 
product. 
2. Dose proportionality has been established for the reference listed product, all 
reference-listed products are compositionally proportional or qualitatively the 
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same and have the same release mechanism, and the In Vitro dissolution 
profiles of all strengths are similar. 
3. Bioequivalence is established between the generic product and the reference 
listed product at the highest and lowest strengths, and for the reference listed 
product, all strengths are compositionally proportional or qualitatively the 
same and have the same release mechanism, and the In Vitro dissolution 
profiles are the same. 
Acceptance Criteria: The difference in predicted means of Cmax and AUC 
should be no more than 10% based on dissolution profiles of the highest 
strength and the lower strength product (FDA 1997a). 
The goals of the Hatch-Waxman act were to expedite and expand the 
availability of more affordable generic drugs, while simultaneously providing 
incentives for the development of innovative and novel products. This legislation 
created the framework for the birth of the generic pharmaceutical industry, which has 
grown and evolved over the past two decades. The Food and Drug Administration 
has worked with the pharmaceutical industry and outside agencies to create rules and 
regulations to govern the approval and manufacture of generic drug products. In the 
fiscal year of 2007 (ended September 30, 2007), the Office of Generic Drugs 
received a record high 877 ANDA's, and approved over 600 of those submissions 
(Wechsler 2007). 
In addition to demonstrating bioequivalency to the innovator product, new 
generic drug products must be adequately labeled, and manufactured in compliance 
with good manufacturing practices (cGMP's) for the FDA to approve the ANDA 
12 
(Holovac 2004) Generic pharmaceutical manufacturers can make minor formulation 
modifications, such as limited excipient (inactive ingredients) substitutions, and 
changes to the manufacturing method, such as processing equipment and procedure, 
as long as the final product is found to be bioequivalent to the innovator. 
Manufacturers must use caution about radical formulation changes to a reference-
listed drug when submitting an ANDA. The FDA states, "Any product variations 
because of differences in excipients (e.g. absorption enhancers or hydrophobic 
agents) or other changes in formulation that may significantly affect absorption of 
the active drug ingredient or active moiety should be submitted in separate 
applications (FDA 1998)." 
Meeting regulatory requirements and a manufacturer's desire to improve a 
product's process and/or formulation must be balanced. Advances in manufacturing 
technology, equipment, and materials should be explored in order to gain a 
competitive advantage in the marketplace. While the exclusivity associated with 
being first to the generic market is highly desirable, an efficient formulation and 
process will reap long-term profits and allow sustainability throughout the product 
lifecycle. 
2.2 Current State of Pharmaceutical Regulations for Manufacturing 
Current pharmaceutical leaders have recognized the limitations of cGMP's 
examples include dubious and repetitive product testing, validation procedures and 
extensive documentation for well-understood process changes. Within the 
pharmaceutical industry, there is apprehension over the interpretation of the new 
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regulations by the agency's field representatives. Trepidation over regulatory 
backlash has hindered process improvements in the past and became an object of 
industry and FDA focus for change (Hussain 2002). In response, the FDA released 
Guidance for Industry, which addressed the use of Process Analytical Techniques 
(PAT) (FDA 2004a) and Pharmaceutical cGMP' s for the 21st century (FDA 2004b ). 
These documents are supported by a number of GMP guidelines including: Q8 
Guideline on Pharmaceutical Development (FDA 2006a), Q9 Guideline on Quality 
Risk Management (FDA 2006b) and Q 10 Guideline on Quality Systems which is 
still under development (Joneckis 2006) to encourage innovation in the 
pharmaceutical industry. 
2.2.1 PAT Background 
The FDA defines PAT as: 
A scientific, risk-based framework intended to support innovation and efficiency in 
pharmaceutical development, manufacturing, and quality assurance. The framework is 
founded on process understanding to facilitate innovation and risk-based regulatory decisions 
by industry and the Agency. The framework has two components: (I) a set of scientific 
principles and tools supporting innovation and (2) a strategy for regulatory implementation 
that will accommodate innovation (FDA 2004a). 
The definition for PAT presented does not define the overall strategy of the 
initiative, but serves as an introduction to the regulatory practice. A practical 
definition of PAT is given as "systems for continuous analysis and control of 
manufacturing processes based on real-time measurements, or rapid measurements 
during processing, of quality and performance attributes of raw and in-process 
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materials and processes to assure acceptable end product quality at the completion of 
the process" (Hussain 2002). 
These revised guidance documents have created a new era for the 
pharmaceutical industry. The documents shift away from conventional thinking, an 
example is a current guidance document for the submission of products using on line 
process controls in place of end product sterility testing for terminally moist heat 
sterilized products. Parametric release is defined as "a sterility assurance release 
program where demonstrated control of the process enables a firm to use defined 
critical process controls in lieu of sterility testing .. . (FDA 2008c)." Traditionally, 
these sterile products were subject to end product testing, which sampled a small 
amount of material and was limited to identifying only the most serious of 
contaminants due to scientific limitations. Through greater process understanding, 
the decision was made to validate and control the process parameters to monitor the 
product bioburden. The process understanding, approach supports an environment 
of continuous improvements. 
2.2.2 Design Space-Background 
The new focus is to understand the product, the manufacturing process, and 
operations. This approach has been described as the "design space", defined by the 
FDA as: 
... the multidimensional combination and interaction of input variables and process 
parameters that have been demonstrated to provide assurance of quality. Working within the 
design space is not considered as a change. Movement out of the design space is considered 
to be a change and would normally initiate a regulatory postapproval change process. 
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Design space is proposed by the applicant and is subject to regulatory assessment and 
approval (FDA 2006c). 
Within the design space, the control space has been described as a: "Multi-
dimensional space that encompasses process operating parameters and component 
quality measurements that assure process or product quality. It is a subset of the 
design space" (Desai 2006). Exploration and understanding of these areas will lead 
to the identification of critical parameters, as well as metrics and methods to capture 
their impact on the process, enabling quality management through a risk based 
approach. A new control strategy aims to minimize risks associated with failures 
when critical and non-critical process parameters fall outside the control space but 
remain within the design space. 
2.2.3 Quality by Design (QbD) Background 
The FDA has recognized, similarly to outside industries, that quality must be 
built into the design of the product, and that it cannot be achieved through testing or 
inspection alone. In order to promote the idea of incorporating quality into product 
development, the ICH adopted "Quality by Design (QbD)." QbD is defined as, "A 
systematic approach to development that begins with predefined objectives and 
emphasizes product and process understanding and process control, based on sound 
science and quality risk management (ICH 2007)". 
By the standards of the 21st century the development and manufacturing of 
pharmaceutical products is generally considered to be inefficient when compared to 
other industries (FDA 2004a). The FDA has introduced cGMP's for the 21st century 
(FDA 2004b) to facilitate the improvement of pharmaceutical manufacturing through 
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the use of a risk-based approach. Figure 3 depicts a conceptual representation of the 
hierarchy of manufacturing control strategy. Data generated through experimental 
designs provide the framework for creating and supporting the manufacturing 
practices. Changes to the control space, within the design space, supported by 
adequate data as defined by the manufacturer would conceivably not require 
supplemental FDA approval. 
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This understanding will lead to the identification of critical parameters, as well as 
metrics and methods to capture their impact on the process, which enables quality 











minimize the risks associated with failures when the critical and non-critical process 
parameters fall outside the control space but remain within the design space. The 
ICH presents the concept of Critical Quality Attributes (CQA), defined as "A 
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physical, chemical, biological, or microbiological property or characteristic that 
should be within an appropriate limit, range, or distribution to ensure the desired 
product quality (ICH 2007)." Ideally all CQAs should be evaluated early in 
development, but the process of continuous improvement necessitates vigilance 
throughout the development and life cycle of the product as guided by the ICH QlO 
documentation. The first step is to identify all of the factors, which may impact the 
product throughout the process, and then to identify those factors with the theorized 
greatest impacts to evaluate experimentally. Changes in formulation and 
manufacturing practices offer opportunities to gain greater knowledge of product 
characteristics and performance under different conditions. Inclusion and analysis of 
relevant experimental and experiential information can be used to create, support, 
and expand the control and design spaces. Figure 4. is an example of an Ishikawa 



























Table I is an overview of the differences that can be found between the 
"minimal" (traditional), and "enhanced"(QbD) developmental approaches. The ICH 
recognizes in the Q8 Annex that manufacturers will most likely utilize tools from 
both of these approaches, with their processes' described between the two extremes. 
The emphasis is to incorporate these techniques from the initial stages throughout the 
entire product life cycle. A hybrid approach between the two extremes, would help 
to introduce new techniques to well established systems to encourage improvement. 
For many small to medium manufacturers, an incremental approach may be the only 
economically feasible option. Knowledge gained from utilizing the QbD approaches 
on a small scale or through a partial implementation can serve to guide improvement 
for future expansions and products. 
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Table 1 Different Approaches to Pharmaceutical Development (ICH 2007) 
Aspect Minimal Approach Enhanced, quality by design 
Approach 
Overall • Mainly empirical • Systematic. relating mechanistic 
Pharmaceutical 
• Developmental research often understanding of input material 
Development 
conducted one variable at a time attributes and process parameters to drug product CQAs 
• Multivariate experiments to understand 
product and process 
• Eswblishment of design space 
• PAT tools utilised 
Manufacturing • Fixed • Adjustable within design space 
Process 
• Validation primarily based on initial • Lifecycle approach to validation and, 
full-scale batches ideally. continuous process verification 
• Focus on optimisation and • Focus on control strategy and 
reproducibility robustness 
• Use of swtistical process control 
methods 
Process • In-process tests primarily for go/no • PAT tools utilised with <1ppropriate feed 
Controls go decisions forward and feedback controls 
• Off-line analysis • Process operations tracked and trended 
to support continunl improvement 
efforts post-approval 
Product • Primary means of control • Part of the overall quality control 
Specifications 
• Based on batch data available at strategy 
time of registration • Based on desired product performance 
with relevant supportive data 
Control Strategy • Drug product quality controlled • Drug product quality ensured by risk-
primarily by intermediate and end based control strategy for well 
product testing. understood product and process 
• Quality controls shifted upstream. with 
the possibility of real-time release or 
reduced end-product testing 
Lifecycle • Reactive (i .e .. problem solving and • Preventive action 
Management corrective action) 
• Continual improvement facilitated 
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The FDA has given the pharmaceutical industry an opportunity to enter the 
21st century of manufacturing by expanding the control space of their operations 
while still staying within safe operating conditions in the design space. PAT, the 
design space, and QbD has excited many in the pharmaceutical industry, who see the 
potential to continuously improve processes as they occur in other manufacturing 
industries. 
This drastic change in the regulatory mindset has raised many questions 
regarding feasibility and practicality. The FDA has promoted the adoption of these 
techniques on a general level. For example, PAT has become an industry 
"buzzword" with much of the knowledge only attainable through consultants, and/or 
is guarded closely within the industry. Current seminars and workshops address very 
specific ideas of using novel techniques for limited areas, such as specific assays 
used during processing to verify quality (Tyler 2006). Some consultants may 
propose vague "buzzword" laden approaches to improvements without scientific 
background and appear to be more oriented to selling their services. Widespread 
adoption of these new approaches has been slow due to a lack of technical 
knowledge and trepidation over the interpretation of these guidance documents by 
regulators. 
Moving toward an "enhanced" developmental approach is still in its early 
stages with skepticism and uncertainty of how the FDA will regulate this new area. 
While the long-term benefits of manufacturing improvements are clear, it may be 
difficult to make the argument for a sizable investment in innovation on a product 
currently being developed for fear of clinical failure and the uncertainties of FDA 
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product approvals. Further, if a product will be approved, companies want to avoid 
delaying or jeopardizing the approval process due to changes in manufacturing 
approaches. Additionally, there are concerns over technological limitations, which 
prevent online process monitoring and understanding for complex products such as 
protein drugs (Glaser 2006). 
2.3 Organic Solvents 
The advantages of aqueous systems over organic solvents has been widely 
accepted in the pharmaceutical industry for over the past 20 years (McGinity 1997). 
Organic solvents require specialized equipment and recovery systems for production. 
Due to the volatility of the solvents, explosion proof equipment and processing areas 
are necessary. Systems for solvent scrubbing and recovery are necessary to 
minimize the environmental impacts and contain waste materials (Olsen 1989). 
Organic waste produced in the manufacturing of pharmaceuticals including: liquids, 
volatile gasses, and solid materials, all contribute to make the pharmaceutical 
industry one of the leading producers of organic waste. It is estimated that "the 
pharmaceutical industry has the highest waste generation and the highest amount of 
organic waste used per mass of product produced for any commercial sector (Slater 
and Savelski 2007)". Beyond the environmental impacts of organic solvents, there 
are health related concerns for residual levels consumed by end product users. In 
response, the International Conference on Harmonization (ICH) has identified 
acceptable residual levels and categorizes the residual organic solvents with regard to 
their associated risks: 
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2.3.1 Class I Solvents: Solvents to be Avoided 
Known human carcinogens, strongly suspected human carcinogens, and 
environmental hazards. 
Examples: Benzene, Carbon Tetrachloride, 1,2-Trichloroethane. 
2.3.2 Class 2 Solvents: Solvents to be Limited 
Non-genotoxic animal carcinogens or possible causative agents of other 
irreversible toxicity such as neurotoxicity or teratogenicity. 
Solvents suspected of other significant but reversible toxicities. 
Examples: Methylene Chloride, Methanol, Xylene. 
2.3.3 Class 3 Solvents: Solvents with Low Toxic Potential 
Solvents with low toxic potential to man; no health-based exposure limit is 
needed. Class 3 solvents have PDEs of 50 mg or more per day. 
Examples: Acetone, Isopropyl Alcohol, Ethanol(ICH 2005). 
Specialized equipment, waste disposal, analytical testing for residuals, and 
many other considerations raise the cost of organic processing (Olsen 1989). Ideally, 
aqueous systems can be substituted for organic solvents during development. 
Unfortunately due to pharmaceutical feasibility, organic solvents are still used where 
aqueous systems are inadequate. In cases where organic solvents are necessary, the 
risk classification and environmental impacts should be minimized. 
2.4 Legal Background 
Traditionally, manufacturers in many industries would develop novel 
products and kept their methodologies secret. These "trade secrets" became targets 
of commercial espionage and could be stolen by competitors. In order to protect 
innovation, patents become an important and useful barrier that manufacturers use to 
block or slow their competitors. A general "utility" patent offers 20 years of 
protection from the date of filing, and allows multiple claims on a single patent 
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(USPTO 2006). Additionally, patents may be bought, sold, or licensed and they can 
generate new revenue streams for the owners. Patents are particularly useful in the 
pharmaceutical industry to keep competitors out of the market. The following list of 
commonly utilized types of patents are employed by the pharmaceutical industry 
(Kanfer, Walker et al. 2004): 
1) Patenting a New Chemical Entity or Active Pharmaceutical Ingredient 
(API). 
2) Patenting the processing methods or synthesis of the API and/or drug 
product. 
3) Patenting the formulation of the drug product (API and excipient 
blend). 
4) Patenting the API's use in combination with other API's to create a 
new drug product. 
5) Patenting the specific polymorphic crystals and other related chemical 
structures of the APL 
6) Use patents for specific clinical indications. 
In addition to patents, manufacturers can gain exclusivity to market a product if they 
meet requirements set by the FDA. While the US Patent and Trademark Office grant 
patents, the FDA approves market exclusivity. A New Chemical Entity (NCE) is 
granted a five-year exclusivity from the date of approval (FDA 2007b ), while an 
innovative change to an existing product by the New Drug Application holder can 
yield a three year exclusivity. A six-month pediatric exclusivity is available to 
manufacturer's who perform additional studies of their drug products on pediatric 
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populations. Patent challenge, otherwise known as 180-day exclusivity, is the most 
important type of exclusivity for generic manufacturers. Competition for this 
exclusivity has become so fierce that guidance documentation has been developed to 
address procedures for when multiple ANDA's are submitted on the same day. A 
multiple first applicant approach has been adopted and allows any of the AND A's 
submitted on that day to be reviewed and approved in order to share the exclusivity 
(FDA 2003a). This intense competition for exclusivity highlights the demand for 
efficient development and submission for generic products. 
The generic pharmaceutical industry has seen strong growth, with Teva 
Pharmaceuticals, Mylan Inc., and Watson Pharmaceuticals, three leading 
manufacturers of generic drug products, increasing gross sales in 2007 by 60%, 28%, 
and 20%, respectively (Standard and Poor's January 14, 2008). The Standard and 
Poor's reports do not separate sales due to acquisitions and mergers from in house 
pharmaceutical sales. This may result in inflated gross sales, (White and Sondhi 
2007) this may be especially true for Teva due to their recent rapid expansion via 
acquisitions(Standard and Poor's January 14, 2008). In this fast paced and 
competitive market, strong formulation and process development is key to a 
manufacturer's long-term growth and survival. 
2.5 Chapter Review 
This chapter gives a brief overview of the current legal and regulatory 
climate of the generic pharmaceutical industry, and addresses challenges associated 
with developing a generic product. Opportunities for advancement in 
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pharmaceutical product/process development are outlined in the study aims. A 
rationale for the justification of the research is presented with perceived significance 
for the pharmaceutical industry and consumers. 
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Chapter 3 Target Product Profiles 
3.0 Introduction 
The first step proposed by the ICH Q8 Annex is to establish target product 
profile, consisting of chemical and physical targets. Scanning Electron Microscopy 
(SEM) of cross-sectioned drug beads allowed visualization of polymer coating 
thickness, and general formulation and manufacturing techniques. Basic physical 
characterization of the dosage forms established particle size distributions of the 
dosage form, as well as tablet/capsule fill weights and dimensions. Dissolution 
studies evaluated the drug release profile to identify variability and trends within the 
USP acceptance criteria. These imaging, physical, and chemical tests evaluated 
propranolol HCl and metoprolol succinate to gain an understanding of the 
competition and support the establishment of a target product profile. This chapter 
provides a general overview of reverse engineering and deformulation techniques 
utilized to create targets for the drug products during development. Product 
characterization of multiple manufacturers for the two target products was performed 
to identify different approaches in drug development. 
3.1 Reverse Engineering Background 
Theoretically, the simplest method for one manufacturer to create an identical 
drug product as their competitor is to steal the formulation and a copy of the master 
batch record using corporate espionage techniques. Fortunately for manufacturers, 
there are laws to prevent such activities. The Economic Espionage Act (EEA)(l 996) 
protects trade secrets in the United States, while the Agreement on Trade-Related 
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Aspects oflntellectual Property Rights (TRIPS) (1994) protects patents globally 
among countries that are part of the World Trade Organization (WTO). Reverse 
engineering is an appealing alternative to avoid criminal and litigious consequences. 
Reverse engineering is defined as "the process of extracting the knowledge or 
design blue-prints from anything man-made (Eilman 2005)." Classically general 
manufacturers used reverse engineering techniques in order to gain insight into the 
methods of their competitors. Semiconductors, software source code, and protected 
digital media have received protection from reverse engineering techniques because 
of the efficiency of reverse engineers (Samuelson and Scotchrner 2002). Currently 
the EEA and TRIPS laws do not specifically sanction or condemn the practice of 
reverse engineering, which leaves room for enforcement interpretation. 
3.2 Deformulation Background 
The term "deformulation" is often used interchangeably with reverse 
engineering, but must be considered as a tool within the broader definition of reverse 
engineering. Business sectors related to the pharmaceutical industry such as the 
polymer and paint industries, utilize deformulation techniques. A general definition 
of deformulation is "A comparative analysis of unknown materials, utilizing product 
specific methodology to separate and identify each unknown component in the 
formula" (Chen, Tseng et al. 2001 ). In the paint industry this methodology may be 
applied for several different reasons, such as: a loss of documentation during 
formulation, to investigate a competitors product to ensure that there is no patent 
infringement, investigation of whether competitors marketing claims are supported 
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by their formulation, and the identification of advantages held by the competition 
(Bruck and Willard 2006). While the polymer industry is complex and requires 
extensive methodology to understand the molecular weights, copolymerization, and 
other necessary attributes for optimal performance (Nuwaysir, Wilkins et al. 1990), 
deformulation can provide critical information. 
3.3 Pharmaceutical Deformulation 
In the pharmaceutical industry, the term deformulation is often used when 
referring to understanding the genetic structures of existing bacteria and viruses in 
order to reengineer the function to meet their objectives. Two examples of current 
published research are: the reverse engineering of bacteria to create highly efficient 
antibiotic producing organisms (Lum, Huang et al. 2004), while vaccine discovery 
has been expedited and improved by applying these strategies to genomics (Zagursky 
2003). 
Pharmaceutical development groups must perform a thorough analysis of 
chemical and physical properties during the development of a generic product, which 
could be viewed as deformulation. Generic drug manufacturers have an advantage 
over other industries because both active and most inactive ingredients that appear in 
the final product are listed on the labeling. Inactive ingredients of oral dosage forms 
are not required to be listed on the label, while all other routes must list inactive 
ingredients and concentrations found in the final dosage form (CFR:201.100 2007). 
While it is not required, it is customary for the manufacturer of oral dosage forms to 
list inactive ingredients used in the final product. The inactive ingredients listed are 
30 
useful for the formulation scientist, but information about quantities, molecular 
weights or grades of materials, and methods must be determined in order to fully 
understand the target product. This aspect is most important when a branded product 
is no longer available and there are only generic equivalents on the market. 
The process of product characterization is product specific, but general 
techniques utilized for the dosage form are useful. For solid oral dosage forms such 
as tablets and capsules, an important characteristic is the dissolution profile of the 
product. While this information may be available through research journals or other 
references, it is important to understand that manufacturers do experience variability 
within their approved specification ranges. This can be especially true for controlled 
release products, with acceptable but significant batch-to-batch dissolution 
variations. Therefore, looking at multiple lots and/or multiple manufacturers is an 
important step in understanding fluctuations which may occur (Kanfer, Walker et al. 
2004). Additional areas for consideration are the formulation ' s structural 
characteristics, chemical and physical parameters. 
3.4 Techniques 
3.4.1 SEM 
SEM is a quantitative method for identifying physical and structural 
parameters of controlled released oral dosage forms. Images obtained using SEM 
are of high resolution and have a three dimensional appearance attributed to the 
instrument's large depth field, which allows a large amount of the sample to be in 
focus at one time (Crowder, Hickey et al. 2003). Multiparticulate systems can be 
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analyzed to gain a stronger understanding of the manufacturing techniques utilized. 
By separating the internal components of active and inert ingredients of the 
multiparticulate system, the formulation scientist can use SEM to focus on the active 
system in the formulation. Images of the surface morphology can be useful to 
understand the film integrity and the impact of damage during processing. Cross 
sectional imaging can give valuable information on polymer coating thickness and 
core structure characteristics (Metha and Jones 1985). 
3.4.2 Particle Size Analysis 
Sieving is a useful method for determining the particle size distribution of the 
discharged product. Sieves are usually cylindrical open containers with 
predetermined and calibrated mesh sizes stacked upon each other with increasing 
aperture size, with the largest openings on top to catch agglomerated particles, and 
the smallest screen on the bottom to remove the fines (Crowder, Hickey et al. 2003). 
3. 4. 3 Dissolution 
Dissolution testing has been used extensively for drug development and the 
four approved apparatuses are described in detail in the USP chapter <711> (USP 
2007a). This research focused on Apparatus 1 (basket) and Apparatus 2 (paddle), to 
follow the appropriate compendia! dissolution procedures for the developed 
products. The Reference Listed Drug (RLD) is defined as "the listed drug identified 
by FDA as the drug product upon which an applicant relies in seeking approval of its 
ANDA (CFR:314.94 2008)." The dissolution profiles for the RLD strength serve as 
an important target during drug development. 
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3.5 Propranolol Hydrochloride Extended Release Capsules 
Propranolol Hydrochloride acts as a non-selective beta-blocker, and is 
indicated for the treatment of hypertension, angina pectoris, migraine, and 
hypertrophic subaortic stenosis. The drug has a pKa of about 9.45, is readily soluble 
in water (lg/20ml) and ethanol (lg/20mL), practically insoluble in ether (Troy 
2005). Propranolol is nearly completely absorbed from the gastrointestinal tract, and 
is >90% protein bound throughout the body with a half-life of 3.4 to 6 hours. After 
administration, constant blood concentrations of drug for approximately 12 hours are 
apparent before an exponential decline over the following 12 hours of the extended 
release period (American Society of Health-System Pharmacists 2008b). 
Propranolol HCl extended release capsules (Inderal LA, Wyeth) is available in 
60mg, 80mg, 120mg, and 160mg. The Reference Listed Drug product is the 160mg 
extended release capsule (FDA 2008b). All of the capsule strengths comply with the 
USP dissolution test I. Propranolol has a molecular weight of 295.80 Da, a chemical 
























J..M..)'.!an 200?2_ J_Actavis-Elizabeth 200~ 
Ammonio Metha~ate C~o!i'.!!!_er Black Iron Oxide 
Black Iron Oxide D&C Yellow # 10 Aluminum Lake 
D&C Red #28 Aluminum lake Et~cellulose 
D&C Yellow # 10 Aluminum Lake FD&C Blue # 1 Aluminum Lake 
Dibu_!l! Sebecate FD&C Blue #2 Aluminum Lake 
Ethylcellulose FD&C Red #40 Aluminum Lake 
FD&C Blue #I Aluminum Lake Gelatin 
FD&C Blue #2 Aluminum Lake H..2:'_dro~o_E)'l Cellulose 
FD&C Red #40 Aluminum Lake 0_E._acode S-1-8114/81 15 
Gelatin Pharmaceutical Glaze 
H_y_dro~~ cellulose Povidone 
H_2'.E"omellose Pr~ene_g!l.col 
Microqy_stalline cellulose Sug_ar S_J>_heres 
Po~et~ene _g!r.col Talc 
Pr~Jene Gly_col Titanium Dioxide 
Shellac Glaze 
Sodium L~ Sulfate 
Talc 
Titanium Dioxide 
3. 5. J Current Manufacturer's of Propranolol HCl Extended Release Capsules 
Table 2. provides an overview of the currently marketed propranolol HCl 
extended release capsules. Formulation and processing strategies are discussed in 
conjunction with the SEM imaging in the results section. 
3.5.2 Recent Research/or Propranolol HCI Extended Release 
Propranolol HCl has been used extensively as a model drug for many 
applications due to its availability and relative low cost. Recently patented 
formulations for extended release Propranolol HCl is found in Table 3. 
T bl 3 P a e 1 1 HCl E t d d R 1 ro_Q_rano o x en e e ease F 1 t' (Ch 2006) ormu a 10n en 
Formulation 1 Quantity Formulation 2 Quantity Function 
(%) (%) 
Core Core 
Propranolol HCL, USP (<75 Propranolol HCL, USP (<75 Active Ingredient 
Microns) 51.17 Microns) 49.56 
S~ar SJJheres, NF 30/35 18.73 Sl!_g_ar ~heres, NF 35/40 9.75 Inert Core 
Microcrystalline Cellulose, Microcrystalline Cellulose, Filler 
(PH 105) NF 21.76 (Vivapur Ty_l)_e 99) 27.84 
Eth_.l!cellulose I 0 C..E_s 5.04 Et~lcellulose l 0 ~ 4.11 Binder 
Sustained Release Coatin_g_ Sustained Release Coatin_g_ 
Sustained Release 
Et~cellulose, NF 45 C_l)_s 2.48 Et~cellulose, NF 10 C_l)_s 6.42 Polymer 
Ac~ Tribu~ Citrate 0.25 Ac~ Trib~I Citrate 0.419 Plasticizer 
Pore 
Hydroxypropyl Hydroxypropyl Former/Water 
Met~cellulose,J_E5) USP 0.25 Met~lcellulose,i_E5) USP l.028 soluble Pob'._mer 
Talc, USP 0.33 Talc, USP 0.824 Antisticking 
*Cps is Centipoise, a measure of viscosity. 
The formulation uses a blend of isopropyl alcohol and ethanol to create an 
organic solvent slurry with the ethylcellulose, Propranolol HCl and the 
microcrystalline cellulose. The slurry is applied to the inert cores (Sugar Spheres®) 
in a fluid bed processor. The active drug layered beads are then sustained release 
coated with an ethylcellulose, acetyl tributyl citrate, HPMC ES, and talc solution 
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dissolved in isopropyl alcohol and acetone. Chen's patent for Propranolol extended 
release capsules demonstrates strong correlation to Inderal for in vitro dissolution 
and the in vivo fasting condition, but failed the fed state condition due to a spike at 
the first time point. 
3.6 Metoprolol Succinate Extended Release Tablets 
Metoprolol Succinate is a beta-1 selective blocker indicated for the treatment 
of hypertension, angina pectoris, and heart failure. The drug is freely soluble in 
water and sparingly soluble in ethanol, with a molecular weight 652.8 Da (Astra-
Zeneca 2007). The RLD strengths ofToprol XL are 50mg and 200mg (FDA 2008a), 
which interestingly creates two similar but distinct product targets. The 25mg and 
50mg strengths, and the 1 OOmg and 200mg strengths are dose proportional to each 
other. Figure 6 is the chemical structure of Metoprolol Succinate. 
OH 
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Figure 6 Metoprolol Succinate Chemical Structure (Astra-Zeneca 2007) 
The drug has a pKa of9.68, is 11-12% bound to albumin, the half-life ranges 
from 3-7 hours, and is predominately metabolized in the liver by CYP2D6 with a 
50% first pass effect. Interestingly, the oral steady state bioavailability of the 
extended release tablets is approximately 77% of the immediate release equivalent 
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metoprolol tartrate. Peak plasma concentrations are 25-50% of the levels attained by 
equivalent Metoprolol tartrate dosing, time to plasma concentration max (CPmax) is 7 
hours (American Society of Health-System Pharmacists 2008a). 
3.7 Metoprolol Succinate Formulations 
Table 4 is an overview of the excipient formulations used by manufacturers 
of Metoprolol Succinate extended release tablets. Each formulation and the 
theorized function of each excipient ingredient are presented in the results section, 
except the Watson formulation found in the "Recent Research for Metoprolol 
Succinate" section. 
T bl 4 In a e active In d. t fM t 1 1 s gre 1en so e O..Q!O o t F uccma e 1 f ormu a 10ns 
Astra-Zeneca (Brand) Eth ex Watson*(Sriwongjanya, 
J_Astra-Zeneca 20on_ J..Ethex 2007_2. Sandoz Yuk et al. 200~ 
Cellulose Acetate Butyrate, 
Cellulose Com..E_ounds Calcium Stearate Colloidal Silicon Dioxide CAB 171-15 
Carboxymethylcellulos 
Paraffin e Sodium Cro~ovidone Cro~ovidone 
Po_!teth_2'.!ene G.!l_col Carnuba Wax l-!1'£_rom e II ose Eudr~t SlOO 
Silicon Dioxide Croscarmellose Sodium Magnesium Stearate G.!l_c~ Monostearate 
Sodium Stearyl Methacrylic Acid Hydroxypropylcellulose (E-
Fumarate Glyceral Behenate Co..E_o.!l_mer 5) 
Hydrogenated Lutrol F68 
Titanium Dioxide V~etable Oil Micro~talline Cellulose (Poloxamer 188 NF) 
H~omellose Po!yet~ene G.!l_col Micro~talline Cellulose 
Maltodextrin Polysorbate 80 Ojl_ad_ry_ White/HPMC 
Methacrylic Acid 
COf>_o!Y_mer Sl!_g_ar S..E_heres Po!Y_sorbate 80 
Microcrystal I ine 
Cellulose Talc Silicon Dioxid/Talc 
Po!Y_dextrose Titanium Dioxide S~ar S..E_heres/Ce!E_here 










*The Watson brand is not yet commercially available (Watson-Pharmaceuticals 
2007), therefore, the ingredients list is theoretically based on the company's patent. 
3.8 Recent Research for Metoprolol Succinate 
3.8.1 Watson 
Table 5 Watson Metoprolol Succinate Formulation and Function (Sriwongjanya, 
Yuk et al. 2008) 
Estimated 
Content % per 
Formulation St~ formulation st~ Function 
Phase I Develo_p_ment of an IR Bead 
Core 
S~ar SIJheres 60/80 NF/Ce!E._here CP-203 Inert core for drl!&_ l~eriTlg_ 
IR Dr'!&_ L~erin_g_ 
Meto_Qrolol Succinate 70-99 Active I~edient 
HPMC_{E-5) 1-25 Binder 
Po~orbate 80 0-0.5 Surfactant 
IR Beads 
Silicon Dioxide/Talc Anti-StickiTlg_ A__g_ents 
Phase II Develo_p_ment of an SR Bead 
SR Polymer Coating_ 
IR Ori!&_ loaded beads Active ln~edient 
Cellulose Acetate BU!)'_Iate, CAB 171-15 75-90 Poh'._meric Membrane 
5-15 Polymeric Membrane/Channeling 
Eudragit SI 00 Agent 
Lutrol F68 (Poloxamer 188 NF_l 2-10 Plasticizer/Emulsifier 
Development of a Multiparticulate 
Phase III Tablet 
Tablettin_g_ In_g_redients 
SR Dru__g_ Loaded Beads 25-45 Active In_g_redient 
IR Ori!&_ Loaded Beads** 2-8 Active ln_g_redient 
G !I'_c{!ryl Monostearate 5-30 Lubricant 
30-50 Flow/Disintegrant/ 
Micro~talline Cellulose Filler 
Crosi:>_ovidone Disintegrant 
Tablet Coatin_g_ 
O_p_ac!!2'_ White/HPMC Sealant/P!_g_ment 
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**Note that the patent entails either SR beads alone or a combination ofIR and SR 
beads. For SR beads only, the IR bead content is substituted with SR beads. 
Watson is currently licensing its exclusivity rights for the 50mg strength of 
Metoprolol Succinate, and intends to pursue their submitted ANDA after March 18, 
2008 when Astra-Zeneca's extended exclusivity period for pediatric studies expires 
(Watson-Pharmaceuticals 2007). Table 5. is an overview of the metoprolol 
succinate formulation patent developed by (Sriwongjanya, Yuk et al. 2008), which is 
the property of Watson Pharmaceuticals via the acquisition of AND RX 
Pharmaceuticals. This formulation utilizes a water/acetone solvent system for the 
sustained release polymer coating and follows a similar process as the innovator. 
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Table 6 Metoprolol Succinate Sustained Release Formulation (Ravishankar, Patil et 
al 2006) 
Function Quantities 
Sodium Core (Any of the 
followin_g:l Base for drug/polymer (425-850 Um) Sodium Citrate 





Eudragit NE30D Polymeric Modulater 20% 
Polysorbate 80 Plasticizer 2% ofNE30D Weight 
Glyceryl Monostearate Glident 5% ofNE30D Weight 
IR Dru_g_ L~erin_g_ 
Metoprolol Succinate Active Ingredient 28% 
Polyvinyl Pyrolidine Binder 1.36 
Colloidal Silicon Dioxide Anti-Caking 0.27 
Sustained Release Coatin_g_ 
Eudragit RS30D Polymer Membrane 35% 
Talc Glident 50% ofRS30D 
Triethyl Citrate Plasticizer 20% ofRS300 
Curil!_g 
Colloidal Silicon Dioxide Anti-Caking 1% 
Table 6. is the patented formulation by Ravishankar, Patil et. al. 2006, with ut 
a two-polymer system approach for their dosage form. The Eudragit® NE30D 
polymer acts to quench the ionic charges of the salt cores and create a suitable 
surface for drug layering. While the Eudragit® RS30D acts to slow the release of the 
Metoprolol Succinate from the drug loaded cores. The authors targeted a 
"chronopharmaceutical" profile, which attempts to control the release of drug based 
on the circadian rhythm to optimize the therapeutic dosing regimen. The in vitro and 
in vivo release of the drug was designed to slowly release the drug initially and then 
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more rapidly release the drug after the 7-hour period. A traditional zero order release 
profile would require optimization of both polymeric layers to adequately match the 
brand product and sustain the release over a 20 hour period. Additionally, the 
research focused on the sustained release pellets, which were not tabletted into a 
final dosage form. Compression of the coated pellets cannot be overlooked, as there 
can be a significant impact on the release profile. 
Table 7 Metoprolol Succinate Extended Release Formulation (Dias 2007) 
Function Quanti!Y_ (g) 
Core 
CelE_here CP-203 (150-300 µm) Dru_g_ L~erin_g_ Core 100 
Dr'!&:"binder solution 
Met~olol Succinate Active l~edient 300 
O~® 03F59040 Film Coatif!.g_ ~stem 15 
Po!l_vinJJ J2rolidine Binder 9 
Purified Water Solvent 1412 
Seal coat I% Weig_ht Gain 
O_l)_aciry® 03F59040 Film Coating_ system 4.2 
Purified Water Solvent 137 
Barrier Coat 26% We!_g_ht Gain 
Sure lease E-7-19040 PolY!fl_eric Membrane 445 
Purified Water Solvent 297 
To_p Coat 3% Weig_ht Gain 
0_E_aciry® 03F59040 Film Coatin_g_ ~tern 16.8 
Purified Water 523 
Tablet Additives 
Cush ionin_g_ A_g_ent* Coated bead _E_rotection (70% w/w) 23 I 
Tablet Final weig_ht 330_g_ 
Table 7. is Dias 2007 formulation, which utilized a multi step formulation on 
the inactive microcrystalline (Celphere®) cores. Opadry is a film coating system 
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composed of polymer, plasticizer, and pigment to form an adhesive film with high 
tensile strength (Colorcon 2008a). The seal coat acts as a barrier between the 
Metoprolol drug layer and the sustained release layer. The Surelease polymeric 
suspension system acts to sustain the drug's release over the dosing interval. The 
topcoat is necessary to prevent "blocking," a static buildup that prevents material 
flow at the end of processing of the Surelease polymer (Colorcon 2006). The topcoat 
can also act to aid in the cushioning of the polymer-coated beads to protect the 
barrier coating from damage. Tablet cushioning agents (*in the table) explored 
were: Pre-gelatinized maize starch (Starch® 1500), rnicrocrystalline cellulose 
(Avicel® PH102) and spray-dried lactose (Lactopress®). The agents were studied as 
dry blends and hot melt extruded granules. Additionally, the effect of compression 
force on the pellets was studied. The research concluded that low compression force 
coupled with a high level of either hot melt extruded microcrystalline cellulose or 
starch granules provided the greatest protection. 
T bl 8 Mt llS . t Et ddRl a e e O_£_ro o uccma e x en e e ease F 1 f (N" . 2004) ormu a ion iaz1 
Function _Quanti~ 1000 Tablet (g) 
Core 
Meto_Q!"olol Succinate Active lnNedient 95.0 
Polyoxol 40 hydrogenated 
castor oil Po!t_meric Membrane 25.0 
Hydroxypropyl Methyl 
Cellulose Carrier material 230.0 
Aluminum Silicate Carrier material 94.0 
Alcohol Solvent QS 
Tablet Additives 
Sodium St~ Fumurate Lubricant As needed 
Table 8. is Niazi, 2004's formulation that gives a simplified granulation 
procedure where metoprolol is mixed with the castor oil, and then mixed with the 
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HPMC and aluminum silicate. The components are then granulated with alcohol and 
dried. The dried granules are lubricated and compressed. This method of 
formulation is significantly different from the previous examples because of the use 
of an organic solvent and wet granulation, as oppose to drug layering. The drug 
release properties of a granulated formulation may experience different diffusional 
release characteristics than a drug-layered core. Binder selection and concentration, 
drug layering thickness and density, and other variables can impact the dissolution 
profiles. The author does not give dissolution profile and tablet characteristics; 
therefore it is difficult to hypothesize the performance of this delivery system. 
3.9 Materials 
3. 9.1 SEM Studies 
Inderal LA 160mg capsules (Wyeth), propranolol HCl ER caps 160 mg (Actavis 
Elizabeth), propranolol HCl ER caps 160 mg (Par Pharmaceuticals), Toprol XL 
25mg (Astra-Zeneca), metoprolol succinate 1 OOmg tablets (Ethex), and metoprolol 
succinate 25mg tablets (Sandoz) were used. 
3.9.2 Physical Characterization and Particle Size Evaluations 
Inderal LA 160mg capsules (Wyeth), propranolol HCl ER caps 160 mg (Actavis 
Elizabeth), propranolol HCl ER capsules 160 mg (Par Pharmaceuticals), and Toprol 
XL Tablets 1 OOmg and 200mg (Astra-Zeneca). 
3. 9. 3 Dissolution Studies 
Inderal LA (Propranolol HCl) ER 160 mg capsules (Wyeth), propranolol HCl ER 
caps 160 mg (Par Pharmaceuticals), hydrochloric acid, deionized water (in house), 
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sodium phosphate monobasic, phosphoric acid, anhydrous dibasic sodium phosphate, 
citric acid monohydrate, and acetonitrile were all of analytical grade. 
Toprol XL (Metoprolol Succinate) extended release 1 OOmg, and 200 mg tablets 
(Astra-Zeneca), potassium phosphate monobasic, sodium phosphate monobasic, 
phosphoric acid, sodium hydroxide, and analytical grade deionized water prepared in 
house. The water system consists of Millipore® pre filters for municipal water to 
feed a Waters® Elix 5 reverse osmosis system, and is stored in a 60-L Waters® 
Reservoir equipped with a UV Automatic Sanitation Module® (ASM), which feeds 
the Waters® A-10 Gradient reverse osmosis system equipped with a terminal 0.22 
µm filter, where the analytical water is dispensed. 
3.10 Methods 
3.10.1 SEM Sample Preparation Methods 
The contents of sample capsules were emptied while tablet samples were 
placed in approximately 1 OOml of purified water, USP and manually agitated until 
the drug and water-soluble components were in solution. The remaining insoluble 
material was screened and the active beads were separated from the other excipients. 
Samples were air dried, cross-sectioned with a razor blade, and analyzed by scanning 
electron microscopy (SEM) on a JSM-5900 JEOL (Japan). Magnification and 
background settings were adjusted based on the sample type. Whole pellet and cross 
sectional samples were imaged and measured using the instrument's software. One 
set of Inderal LA 160mg beads were studied after completion of the USP dissolution 
procedure. 
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3.J0.2 Physical Characterization and Particle Size Evaluations 
Propranolol HCl capsules were weighed, emptied, and the beads were sieved 
through screens #16-30 mesh. U.S. Standard Test Sieves (Newark, Clifton, NJ), 
which meet ASTM E-11 (Formerly the American Society for Testing and Materials) 
specification were used to screen the material. The quantity retained on each screen 
was weighed and calculated as a percent of the total weight. 
Toprol XL Tablets were weighed and measured with a Mitutoyo® CD-8"CSX 
digital caliper. The tablets were gently broken apart and screened through sieves 
#25-60 mesh. U.S Standard Test Sieves (Newark, Clifton, NJ), which meet ASTM 
E-11 Specification were used to screen the material. The quantity retained on each 
screen was weighed and calculated as a percent of the total weight. 
3.11 Analytical Methods 
3.11.1 Dissolution-Propranolol HCl 
A Hanson® SR-8 dissolution apparatus was used in accordance with the USP 
test method 1 for propranolol hydrochloride extended release capsules. Key settings: 
apparatus 1, basket speed 100 rpm, 2 phase media, 900 mL of dissolution media. 
0. lN hydrochloric acid buffer with a pH of 1.2 for the first 1.5 hours and a sodium 
phosphate monobasic pH 6.8 buffer from 1.5 hours to 24 hours. The bath 
temperature was maintained at 37 ± 0.5°C throughout the dissolution. lOmL 
samples were taken at the sampling time points, with the acceptance criteria found in 
Table 9. Concentration was primarily determined following the USP method using a 
Hewlett Packard® 8453 UV spectrophotometer at 320 nm absorbance. The general 
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method was confirmed by high performance liquid chromatography following the 
USP method. 
Table 9 USP Dissolution Test 1 Acceptance Criteria (USP 2007b) 
Dissolution Test I 
Time (hours) Amount Dissolved 
1.5 Not more than 30% 
4 Between 35% and 60% 
8 Between 55% and 80% 
14 Between 70% and 95% 
24 Between 81 % and 110% 
3.11.2 Dissolution-Metoprolol Succinate 
A Hanson SR-8 Dissolution apparatus was used for the USP test method for 
Metoprolol Succinate extended-release tablets. The key settings are: Apparatus 2, 
Paddle speed 50 rpm, pH 6.8 phosphate buffer, 500mL dissolution media volume. 
The sample volume was 5mL with sampling time points and acceptance criteria in 
Table 10, additional and alternative time points may be sampled where appropriate. 
Concentration was primarily determined using high performance liquid 
chromatography. 
Table 10 Metoprolol S · t USP D" 1 f A uccma e lSSO U 10n cc~tance C iteria (USP 2007c) r 
Time (Hours) Amount Dissolved 
I Not more than 25% 
4 Between 20% and 40% 
8 Between 40% and 60% 
20 Not less than 80% 
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3.11. 3 Analytical Calculations of Concentration for Dissolution 
ru DVO 100 
% Dissolved at first sample point, A = - x Cstd x P x x --
rs #Units LC 
Equation 1. Calculation for% Dissolved at the First Sample Point 
Where: 
ru Absorbance or Peak area of drug in the sample preparation 
rs Average absorbance or peak area of the drug in the working standard 
Csrd Concentration of Metoprolol Succinate in the Working Standard, in mg/mL. 
p Purity factor of drug Reference Standard in decimal form. 
DVO Initial dissolution volume, in mL 
#Units # of dosage units 
I 00 Conversion factor for percent. 
LC Label Claim (concentration) 
% Dissolved at n hours, A1 = B + F1 
Equation 2. Calculating % Drug Dissolved at n Hours 
Where, 
SV ru DVn 100 F1 =Ax - andB = -xCstdxPx -- x -
ovo rs Uni ts LC 
Equation 3. Calculating Fl Value for a Given Time Point 
Where: 
SY Sampled volume, amount removed at the previous time points 
DVn Dissolution volume at n hours, in mL 
This calculation method was used to determine the concentration of the drugs 
throughout the dissolution period to account for concentration lost due to sampling. 
3.11.4 Concentration Determined by High Performance Liquid Chromatography 
Propranolol HCl and Metoprolol Succinate were assayed for concentration on 
a Waters® 2695 separation module equipped with a column heater, an auto sampler, 
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and degasser. The system was equipped with a Waters® 2487 dual/.., absorbance 
detector for UV Nis detection. All methods had to meet system suitability criteria of 
less than a 2.0 % relative standard deviation (RSD) of five injections of the reference 
solution. Additionally, an in process standard was injected after every six injections 
of sample solution and with a reference standard which must be less than 3. 0 % 
RSD. The concentration was determined using equation 4. 
% Content of Drug= AT x WR x PF x 100 x MW 
AC x WTxLC 
Equation 4. Formula for Calculating Percent Content of Drug by HPLC Assay 
Where: 
AT Area of the drug peak from the sample solution. 
AC Area of the drug peak from the reference solution. 
WR Weight (mg) of reference substance taken. 
WT Weight of the sample in mg. 
MW Average mass of the capsule or tablet content in mg. 
PF Purity factor % Purity of working standard on an as needed basis. 
LC Label claim for content of drug per unit. 
I 00 Percent conversion factor 
3. I I. 5 Propranolol Hydrochloride Assay Method 
The Propranolol Hydrochloride USP monograph assay method was used, an 
overview of the method is given here. The system was equipped with a Symmetry 
shield®, RP18, 150 mm x 4.6 mm 5µm and the UV detector was set to 220 nm. An 
isocratic method was employed, with a flow rate of 2.0 ml/min, a sample injection 
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volume of 1 O µL, an average retention time of 2-4 minutes, and a sample run time of 
6 minutes. A Phosphate Buffer with a pH of 3.0, and a mobile phase of blended 
buffer at and acetonitrile (75:25 respectively). 
J.11 . 6 Metoprolol Succinate Assay Method 
The Metoprolol Succinate USP monograph assay method was used, an 
overview of the method is given here. The system was equipped with a Nova-Pack®, 
Cl8, 150 mm x 3.9 mm 4µ column, and the UV detector was set to 280 nm. An 
isocratic method was employed, with a flow rate of l .5ml/min, a sample injection 
volume of 25 µL, an average retention time of 2-4 minutes, and a sample run time of 
7 minutes. A phosphate buffer with a pH of 3.0, and a mobile phase of blended 
buffer and acetonitrile (75:25 respectively) were used in the method. 
3.12 Results/Discussion 
3.12.1 SEM and Deformulation of Competitors 
The deformulation of the competitors provided formulation and 
manufacturing strategies to guide developmental targets for metoprolol succinate and 
propranolol HCl. This section is divided by product and manufacturer to examine 
the SEM results and the inactive ingredients. Manufacturing techniques and 
formulation approaches are supported by patents, literature, and the experimental 
SEM images. For cases where concrete information was unavailable, formulation 
function and utilization are based on traditional methodology and a hypothetical 
"best guess." Due to a lack of sample availability, the Mylan formulation of 
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Propranolol HCl was not investigated, fortunately the formulation is similar to the 
Actavis product, which can be used to understand the general development approach. 
3. J 2. 2 Results- Wyeth Inderal LA Extended Release Capsules 
Based on early patents and the current list of inactive ingredients in Table 11, 
the brand product consists of a simplistic formulation utilizing organic solvents. 
Drug loaded cores are prepared via wet granulation with microcrystalline cellulose 
using alcohol, and/or methylene chloride, or an alcohol/water mix as the granulating 
agent (Guley, DeMeals et al. 1981) The sustained release coating is comprised of an 
ethylcellulose and Hypromellose blend in a methylene chloride/methanol solvent 
mix in a range from 1.5-5% (Guley and Farina 1992). 
Table 11 Inderal LA Propranolol HCl Extended Release Capsule Formulation and 
Hypothesized Function. 
Formulation Ste_J>_ Function 
Phase I Development of an IR Bead 
Dru_g_ Loaded Core 
Cellulose (MCC) Core material 
PrO!""anolol HCl Active Ingredient 
Phase II 
SR Polymer Coating Development of an SR Bead 
IR Dru_g_ Loaded Beads Active Ingredient 
Et1!l!cellulose SR Polymeric membrane 
Hypromellose Pore Forming agent 
Phase III Top Coat/ Aesthetics 
Titanium Dioxide Pigment 
HJ'.Eromellose Binder 
Phase IV Encapsulation 
Gelatin C~sules Dosage Form 
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Figure 7 lnderal LA 160mg Whole Pellet 
Figure 7, the whole particle imaged showed sphericity near 1.0, which cannot 
be generalized to all of the beads in the dosage form, but is a good example of the 
desired bead. The surface morphology was smooth and free of cracks or defects. 
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Figure 8 Inderal LA 160mg Cross Section 
Figure 9 Inderal LA Cross Sectional Polymer Coating 
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Figures 8 and 9 of Inderal LA display the thin coating level of polymer used to 
achieve the sustained release profile, and support the theorized organic polymer 
system for the sustained release profile. 
Figure 10 Propranolol HCl ER Caps 160mg- Cross Section after Dissolution 
The porous core after dissolution, seen in Figure 10, indicates that the 
production method utilized a wet granulation with extrusion/spheronization approach 
to create pellets of the desired size. The material remaining after dissolution are 
water insoluble excipients, such as microcrystalline cellulose, ethylcellulose, etc . . .. 
3.12. 3 Results-Par Propranolol HCl Extended Release Capsules 
The Par formulation is similar to lnderal LA, based on the inactive ingredient 
list in Table 12.and the SEM figures. The Par formulation appears to have followed 
a similar formulation approach to the brand product. 
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Table 12 Par Propranolol HCl Extended Release Capsule Formulation and 
Hypothesized Function. 
Formulation Stt!Jl_ Function 
Phase I Develo_l)_ment of an IR Bead 
Drl!_g_ Loaded Core 
Micro~talline Cellulose Core material 
Pr~anolol HCI Active Ingredient 
Phase II 
SR Po!I_mer Coatil!&_ Development of an SR Bead 
IR Drl!_g_ Loaded Beads Active Ingredient 
Eth_ylcellulose SR Polymeric membrane 
Meth_ylcellulose Pore Forming agent 
Phase III Top Coat/Aesthetics 
Titanium Dioxide Pigment 
Meth_2:'.!cellulose Binder 
Phase IV Encapsulation 
Gelatin C!!.E_sules Dosage Form 
Figure 11 is the whole bead image for the Par formulation of propranolol HCl 
at a magnification of 1 OOx. The bead appears to have a smooth defect free surface 
morphology, and a bead sphericity near 1.0. 
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Figure 11 Par Propranolol 160mg 
Figure 12 is alOOx magnification of the cross-sectioned bead, with the drug 
loaded core and the sustained release polymer coating visible. Figure 13 is a 2500x 
magnification of the edge of a cross sectioned bead, which shows a thicker coating of 
polymer than the brand product. More polymers are likely necessary due to the 
smaller particle size distribution yielding a greater surface area. 
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Figure 12 Par Propranolol 160mg Cross-Section 
Figure 13 Par Propranolol 160mg- Cross Sectional Polymer Coating 
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3.12. 4 Results- Actavis Propranolol HCl Extended Release Capsules 
The Actavis formulation in Table 13 is markedly different than the 
extrusion/spheronization techniques used by the other manufacturers, using a drug 
layering approach on sugar spheres. 
Table 13 Actavis Propranolol Formulation 
Com_p_onent Function 
Phase I Development of an IR Bead 
S~ar S_E_heres Inert core for drug layeririg_ 
Povidone Binder 
MetOJ'.l!"olol Succinate API 
Phase II Development of an SR Bead 
Pr~ene _g!y_col Plasticizer 
Ethylcellulose SR Polymer 
Hy_droxypropyl Cellulose Pore Former 
Phase III To_£_ Coatin_g_ 
Titanium Dioxide Pigment 
Talc Lubricant 
Hl'._drOx...iEo_N! Cellulose Binder 
Phase IV EncaJJSulation 
Gelatin Encapsulation 
Phase V Ci1£sule Identification 
0_E_acode S-1-81 14/81 15 Ink System 
Pharmaceutical Glaze Moisture barrier/O_])_acode Com_])_onent 
Propylene glycol Plasticizer/Opacode Component 
Black Iron Oxide Ci1£sule Pigment 
D&C Yellow #10 Aluminum Lake Capsule Pigment 
FD&C Blue #1 Aluminum Lake Ci1£sule Pigment 
FD&C Blue #2 Aluminum Lake Capsule Pigment 
FD&C Red #40 Aluminum Lake Ci1£sule Pigment 
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The solubility of Propranolol HCl in water would likely result in an 
extremely long processing time, and may employ an aqueous polymer coating. The 
Actavis formulation utilizes a drug layering approach, which may utilize an organic, 
aqueous or organic/aqueous solvent system. Research has effectively used 
ethanol/water (60:40 respectively) to load the required drug amount (Dashevsky and 
Mohamad 2006). Aqueous systems alone have been used to layer the drug (Percel, 
Vishnupad et al. 2002). Either approach would conceivably be a time consuming 
process due to the drug's solubility and the quantity necessary to achieve the target 
potency (Jones 1989). 
Figure 14 Actavis Propranolol 160mg Whole Pellet 
Figure 14 is the whole bead of the Actavis formulation of propranolol HCl, 
which contains a speckled appearance. The SEM software determined the speckles 
to be titanium dioxide from the topcoat. 
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Figure 15 shows the inert core (Sugar Sphere®), the drug layer, and the 
sustained release-coating layer. The magnified sustained release layer in Figure 16 
indicates a thick polymeric coating level and may indicate the use of an aqueous 
polymer. A topcoat is applied after the sustained release polymer to give an 
aesthetically pleasing bead and provide a protective coating for the sustained release 
system. Interestingly, both the Mylan and Actavis formulations utilize 
pharmaceutical glaze (shellac) which historically has been used as a seal coat to 
provide an adequate moisture barrier (Kottke and Rudnic 2002). The Opacode S 
product family of pharmaceutical ink utilizes pharmaceutical glaze (Shellac) and 
requires a solvent system, such as IPA (Colorcon 2008c). Due to the dual colored 
capsule (pink and gray) and information printed on the capsule, a large amount of 
pigments and other excipients are required. 
Figure 15 Actavis Propranolol 160mg Cross-Section 
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Figure 16 Actavis Propranolol 160mg Cross Sectional Polymer Coating 
3.13 Metoprolol Succinate 
Metoprolol succinate brand and generic marketed products were 
deformulated using SEM imaging, physical and chemical techniques. The list of 
ingredients is presented with their theorized function to describe the formulation 
approach. SEM imaging was performed on the whole bead to identify surface 
morphology and sphericity. Cross-sectioned imaging was used to identify drug 
and/or polymer coating thicknesses and manufacturing strategies, such as drug 
layering vs. extrusion/spheronization. 
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3. J 3. I Astra-Zeneca (Brand) 
Table 14 is an overview of the formulation and theorized function for Toprol 
XL. Based on a formulation and process patent (Jonsson 1990), sustained release 
Metoprolol Succinate tablets are prepared by the following steps: 1) Metoprolol 
Succinate is dissolved in ethanol 95% and sprayed onto the inert silicon dioxide 
cores in a fluidized bed granulator. 2) The drug-loaded cores are spray coated in the 
fluidized bed granulator with the sustained release polymer coating with methylene 
chloride and isopropylic alcohol as the organic solvents. 3) Inactive microcrystalline 
cellulose based granules are prepared through wet granulation. 4) The inactive 
granules, the drug loaded beads, and a lubricant are mixed and compressed into 
tablets. 5) The tablets are coated with a coating solution in a coating pan. 
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Table 14 Astra-z eneca M 1 1 s etO_E!O 0 uccmate F 1 . ormu at1on an d Th eonze dF unctl on 
Formulation Ste_!!_ Function 
Phase I Develo...2_ment of an IR Bead 
Core 
Silicon Dioxide 0.15-0.3 mm _[diameter) Inert core for drug layering 
IR Drl!_g_ Ll!Y_erin_g_ 
Meto_Q!olol Succinate Active ln~edient 
Phase II 
SR Po!Y_mer Coatin_g_ Development of an SR Bead 
Po!Y_mer Coatin_g_ 
IR Dru_g_ Loaded Beads Active Ingredient 
Cellulose Compounds Polymeric membrane 
(Et~cellulose 10-50 C...2_s!HPMC Blend) 
Poly_eth_ylene Glycol Plasticizer 
Development of a Multi particulate 
Phase III Tablet 
Tablet Additives 
Microc_rystalline Cellulose (Avicel®) Disintegrant/Tabletting Agent 
Sodium Ste'!!}'._I Furnarate Lubricant 
Tablet Coatin_g_ 
H_ydro~~ Meth_.i'!cellulose Binder 
Po.!x._et~ene G.!x._col Plasticizer 
Titanium Dioxide Pigment 
Paraffin Sealant/Coating Agent 
The sustained release coated pellets are 0.4-0.6mm in diameter with a 
density of 1.2-1 .3 g.cm3 (Abrahamsson, Alpsten et al. 1996). The small inert cores 
have a large surface area and utilize a combination of the following organic solvents: 
isopropylic alcohol, ethanol 95%, and/or methylene chloride in order to avoid 
agglomeration during drug layering and sustained release coating to ensure a uniform 
distribution of the material. 
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The beads appear to be spherical, based on the SEM image in Figure 17, with 
a sphericity of the beads near 1.0. The surface is relatively smooth and without 
visual cracking or defect. 
Figure 17 Astra-Zeneca 25mg- Whole Pellet 
Figure 18 is a cross-sectioned bead at 1 OOx magnification; the bead is 
comprised of the silicon dioxide core, a drug layer, and a sustained release layer. 
Figure 19 is a 250x magnification focused on the sustained release layer of the bead. 
Sizing was calculated by the system software and gives an approximate range 
between 32-45µm. 
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Figure 18 Astra-Zeneca 25mg- Cross Section 
Figure 19 Astra-Zeneca 25mg- Cross Sectional Polymer Coating 
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3.13. 2 Ethex 
Table 15 is a list of the ingredients in the formulation and the theorized 
function for each component 
Table 1 th M SE ex I I S eto__Q_ro o uccmate F I . ormu at10n an d Th eonze dF unct10n 
Formulation Step_ Function 
Phase I 
Core Devel~ment of an IR Pellet 
Met~olol Succinate Active I~edient 
Micro~talline Cellulose Core Material 
Carbox_i'!!!_eth_llcellulose Sodium Binder 
Phase II 
SR Po!r_mer Coati'!&_ Development of an SR Bead 
Po!r_mer Coati'!&_ 
Metha~ic Acid Co_E_o!i'._mer Polymeric Membrane 
Vi1!i'.} Acetate Cq£_o_!i'._mer Polymeric Membrane 
Triacetin Plasticizer 
Trieth_ll Citrate Plasticizer 
Development of a Multiparticulate 
Phase Ill Tablet 
Tablet Additives 
Sodium Ste~ Fumarate Lubricant 
Maltodextrin Cushioning agent 
Polydextrose Cushioning agent 
H_}'21'omellose Cushioning agent 
Povidone Pore former 
Carbo~meth_.1'.!cellulose Sodium Disintegrant 
G_!i'._ceral Behenate Lubricant 
Calcium Stearate Lubricant 
Tablet Coatin_g_ 
Po_!i'._eth~ene G!i'._col Binder/Plasticizer 
Titanium Dioxide Color 
Carnuba Wax Sealant 
Hl:'._drqg_enated V~etable Oil Sealant/Lubricant 
This formulation appears to use the greatest amount of different inactive 
ingredients to create a viable dosage form. The impact and cost of each excipient 
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should be well understood when creating a generic product. While the individual 
excipient may not be particularly expensive to purchase, it is important to consider 
the costs associated with maintaining cGMP material for production and the 
extensive handling and documentation required for use. Additionally, all of the 
inactive ingredients must be examined to ensure that there are no compatibility 
issues or long-term stability implications. Based on the processing methodology and 
magnitude of excipients, this formulation is theoretically the most expensive and 
identifying specific excipients with their functions is challenging. 
Figure 20 is a whole pellet and displays a dumbbell like shape, which may be 
attributed to the immediate release bead processing during extrusion/ spheronization. 
The bead is not as spherical as the brand product, and visual observations indicated a 
significantly larger particle size distribution. 
Figure 20 Ethex 1 OOmg- Whole Pellet 
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Figure 21 is a 75x magnification of a cross-sectioned bead, which does not 
contain an inert core or separate drug layering. Figure 22 is a 1 OOx magnification of 
the sustained release polymer level with approximately 9-11 µm thickness. Based on 
the ingredient list and the SEM images, the Ethex® formulation is the only currently 
marketed product theorized to be manufactured using a wet granulation process. 
Figure 21 Ethex lOOmg- Cross Section 
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Figure 22 Ethex 1 OOmg- Cross Sectional Polymer Coating 
3.13. 3 Sandoz 
Table 16 contains the Sandoz formulation for metoprolol succinate, with the 
theorized function for each ingredient. This formulation is unique in the approach to 
sustained release coating by employing Methacrylic acid copolymer alone. 
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Table 16 Sandoz Metoprolol Succinate Formulation 
Formulation Ste_£_ Function 
Phase I Develo...£_ment of an IR Bead 
Core 
Si:g_ar S_e_heres Inert core for drug layering 
IR Drl!&_ Ll!.Y_eril!&_ 
Meto_£_rolol Succinate Active In_gredient 
Polyeth_2'1ene Glycol Binder 
Phase II Development of an SR Bead 
SR Po!Y_mer Coating_ 
Po!Y_mer Coatin_g_ Active Ingredient 
Metha~ic Acid C~o!r_mer Polymeric membrane 
Colloidal Silicon Dioxide _i~oid)_ Anti-Sticking agent 
Po!r_sorbate 80 Plasticizer 
Development of a Multi particulate 
Phase III Tablet 
Tablet Additives 
M~nesium Stearate Lubricant 
Micro~talline Cellulose Flow/Filler/Cushioning agent 
Methacrylic acid copolymer, USP is a general name describing a number of 
different systems, commercially available examples of this polymer can be seen in 
Table 17. 
Tabl 17 M th e e r A ·de acry 1c Cl o_£o~er T J'.£_eS (D egussa 2007b) 
Methacrylic acid 
Trade Name Copolymer USP/NF Solubility Release Site 
Grade 
LIOO A 2: pH 6.0 Jejunum 
Ll2.5 




2: pH 5.5 Duodenum 
While all three grades of Methacrylic acid copolymer are used for enteric 
coating, each has a specific pH solubility, which allows for targeted colonic delivery. 
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All of the polymers in Table 17 may utilize organic solvent systems, while grade C 
polymers have the option for dispersion in an aqueous system. An aqueous 
dispersion, Eudragit L30-55D, is commercially available and Eudragit Ll00-55 can 
be redispersed in water from a powder. If a grade C polymer were used, a sustained 
release profile would be difficult to achieve due to rapid dissolution of the polymer 
in the small intestines resulting in immediate drug release. Additionally, the two 
grade C polymers contain polysorbate 80 and sodium lauryl sulfate for aqueous 
dispersion. Polysorbate 80 is utilized in the formulation but sodium lauryl sulfate is 
not, which would indicate this grade of polymer was not used. Therefore, it can be 
hypothesized that a thick coat of a grade B polymer or a blend of A and B grade 
Methacrylic acid copolymer are employed in order to yield a zero order kinetic 
release throughout the gastrointestinal tract (Degussa 2007b ). 
Figure 23 is a whole pellet of the Sandoz metoprolol succinate 25mg at 75x 
magnification. The beads appear relatively spherical and dumbbells were not found. 
Figure 24 is a 75x magnification of the cross-sectioned bead with a drug layering 
approach is similar to the branded product, and the sugar sphere, drug layer, and 
sustained release layer are clearly visible. Figure 25 is a 500x magnification of the 
cross-sectioned bead, focused on the sustained release layer. The image shows a 
range of polymer thickness from approximately 37-52 µm. 
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Figure 23 Sandoz 25mg- Whole Pellet 
Figure 24 Sandoz 25 mg- Cross Section 
71 
Figure 25 Sandoz 25 mg- Cross Sectional Polymer Coating 














Particle size distribution Propranolol Extended 





20 I I • 0 #16 #18 #20 #25 #30 





Figure 26 Particle Size Distribution of Propranolol HCl Extended Release Beads 
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Figure 26 depicts the unique particle size distributions for branded and 
generic Propranolol HCI. Interestingly, the Actavis and Par Propranolol HCl 
extended release beads are shifted to smaller particle size distributions. The shift to 
smaller particles indicates a larger amount of polymer was needed to compensate for 
the increased bead surface area to match the dissolution profile of the other 
competitors. A marginal increase in the polymer level can be seen by the SEM of 
the cross section of the Par in Figure 27. Additionally, the cross section of Actavis 
Propranolol HCl in Figure 27 shows a significantly larger amount of polymer 
applied, which may indicate that an aqueous polymer was employed for the 
intermediately distributed beads. 
3.15 Metoprolol Succinate Particle Size Distribution Results 
Table 18 Approximate Particle Size Distribution of 1 OOmg Metoprolol Succinate 
Tablets (N=3) 
Mesh Cut We!.g_hti_m_& % Retained Observations 
#25 15.2 1.47 Granules 
#30 66.1 6.41 Granules 
#35 356 34.53 80% SR Beads/ 20% Granules 
#45 190.6 18.49 Most!Y_ SR Beads 
#60 23 2.23 Granules 
Pan 180 17.46 Fine ExciE_ients 
Shell Coati'!&_ 200 19.40 Mix ofTo_IJ_ Coat and comj)ressed exciQients 
Total 1030.9 
This small sampling of branded tablets yields an estimate of the target end 
process particle size for the SR beads prior to tabletting. Excipient granules and 
beads could be differentiated and estimated with the naked eye. Table 18 shows that 
qualitatively the bulk of the active beads are retained on sieve sizes #35 and #45. 
The excipient granules are spread out over the range of the sieves, with a significant 
73 
amount of fine excipients comprised of crushed excipient granules during tabletting 
and fine excipients (i.e. lubricant). 
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3.15.1 Results- Propranolol HCl Extended Release Capsules- Fill Weight 
Table 19 Average Fill Weights for Propranolol HCl 160mg Capsules 
Average Gross Average Capsule Average Net Fill 
Brand We~ht (m_g) (n=lO) Weight (m_g) (n=lO) weight (mgl (n=lO) 
Wyeth 341.0 73.0 268.0 
Par 349.4 73.0 276.4 
Actavis 343 .5 73 .1 270.4 
Table 19 shows that all of the marketed products have similar fill weights, and provide a reasonable fill weight to target. 
~ All of the products used size 1 capsules to encapsulate the extended release beads. The Mylan brand was unavailable for 
evaluation. 
3.15. 2 Results-Metoprolol Succinate Extended Release Tablets-Dimensions/Fill Weight 
Table 20 Metoprolol Succinate SR Tablet Dimensions/Fill Weight 
Tablet Length Length Width Width Thickness Thickness Average Tablet Standard 
Strength (in) (mm) (in) (mm) (in) (mm) Weight Deviation RSD (%) 
(m~ Tablet Sh<l£_e (n=lO) 
100 Scored Round 0.401 10.18 NA NA 0.1595 4.05 366.76 7.90277 2.15 
200 Scored Oval 0.6785 17.23 0.2585 6.56 0.3425 8.7 703.9 5.03918 0.72 
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The Metoprolol Succinate 1 OOmg tablets are slightly more than half of the 
weight of the 200mg tablets, which supports the dose proportionally of the RLD. 
The high dose tablets were selected for initial development, 25mg and 50mg tablets 
were not evaluated. Table 20 provides information about target weights and tablet 
dimensions for tooling selection. 
3.15. 3 Results- Dissolution Profile- Propranolol HCl Extended Release Capsules 
Figure 27 is a comparison of Inderal LA 160mg and Par pharmaceutical's 
generic Propranolol extended release 160mg capsule dissolution profiles. Due to an 
initial erroneous run and limited sample availability the Par brand and Inderal LA 
were run in the same bath to examine the product trends. Appendix 1. displays the 
complete experimentation performed to determine the mean Inderal LA profile used 
during the development of this product. The Par generic follows the same trend as 
the brand product but has a quicker initial release before matching the innovator at 
the 22-hour time point. The error bars represent the calculated standard deviation of 
the samples at that point, and indicate a difference in the profiles. Previous 
exploratory work (not shown) determined that the Actavis formulation exhibited a 
slower dissolution than the branded product. Mylan's Propranolol extended release 
capsule formulation was unavailable at the time and therefore not studied. Variation 
between the manufacturers was expected, but all FDA approved generics met the 
USP I dissolution criteria. 
Propranolol HCl extended release capsules are comprised of sustained release 
coated beads; each strength is adjusted by fill weight and are proportional dosage 
forms. The FD A's approval of lower strengths of the dosage form without an In 
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vitro/In vivo correlation is possible if the bioavailability data are available for the 
highest strength (FDA 1997a). The USP monograph acceptance criteria and the 
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Figure 27 Comparison of Dissolution oflnderal LA 160mg Capsules and Par Propranolol Extended Release 160mg Capsules Using 
USP I Method 
3.15. 4 Results-Dissolution of Metoprolol Succinate Extended Release Tablets 
Figure 28 is the USP II dissolution profiles of Astra-Zeneca's Toprol XL-
1 OOmg and 200mg dosage forms, with the USP low and high levels of acceptance 
criteria. The standard error bars for the dissolution profiles overlap and the profiles 
can be considered equivalent. The Toprol XL 1 OOmg and 200mg strength 
dissolution profiles are considered dose similar, and the formulation is dose 
proportional. The Ethex Metoprolol Succinate Tablets do not comply with the USP 
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3.16 Chapter Review 
SEM imaging was used in conjunction with published formulation ingredient 
lists to facilitate the identification of component activity. The imaging supported a 
bead sphericity target of~ 1.0 for Propranolol HCl. The identification of dumbbells 
in the Ethex formulation of metoprolol succinate supported a more flexible sphericity 
target in anticipation of potential formulation or processing difficulties. The sieving 
studies identified a controlled particle size distribution for both Propranolol HCl and 
metoprolol succinate. The Propranolol HCl competitors each had a tailored particle 
size distribution but varied in their tailored approach, with the brand product having 
the largest mean particle sizes. The Metoprolol Succinate beads were significantly 
smaller than the Propranolol HCl beads, and also showed a tailored approach to 
particle size distribution. The dissolution profiles of both Propranolol Hcl and 
Metoprolol Succinate brand products were within the USP acceptance criteria, and 
served as the targets for drug release for the target products. 
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Chapter 4 Critical Quality Attributes 
4.0 Introduction 
This chapter gives an overview of current techniques used to formulate and 
process multi particulate sustained release in order to support the selection of Critical 
Quality Attributes (CQA's). Wet granulation, extrusion/spheronization and fluid bed 
drying are the primary processing techniques explored for immediate release pellets, 
which were utilized in the development of the experimental dosage forms in order to 
provide a viable platform for the water-soluble drugs. The second area of interest is 
in polymeric membrane formulations and processing conditions required to create a 
viable controlled release. Finally, a basic overview oftop coating and tabletting are 
discussed to support the selection of the CQA's. 
4.1 Stress-Strain Relationship 
Throughout the manufacturing process ingredients are subject to stress and 
strain, which can impact product properties. Tensile strength testing is used to 
calculate stress ( cr ), where the force applied to the material is divided by the cross-
section of the sample and strain (i::) where; the resulting length of the sample is 
divided by the initial length (With 2006). Figure 29. is a simplified example of a 
stress-strain relationship, where the material begins by experiencing reversible 
elastic deformation, then moves to viscoelastic deformation. The elastic region 
displays extension length proportional to the load applied and is reversible upon 
removal of the load, while viscoelastic material can experience any of the following 
when a load is applied: immediate elastic deformation, slow elastic deformation, or 
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a plastic deformation (McArthur and Spalding 2004). Viscoelastic behavior is seen 
for many amorphous materials used throughout pharmaceutical manufacturing, 
including tabletting (Hoag, Vivek et al. 2008). Beyond the "yield" (elastic limit), the 
material is experiencing irreversible plastic deformation, until it reaches a final 
"rupture" point where fracture occurs. Fracture is a disruption of the continuous 
connective nature throughout the system, which can result in a weakened unit (With 
2006). 
Plastic Rupture 
,,,J........................... ~ 4\~ yield I"' . 
Viscoelastic 
Elastic 
Figure 29 Example Stress-Strain Curve for Uniaxial Tension (Hoag, Vivek et al. 
2008) 
4.2 IR Bead Processing 
4.2. J Granulation 
Common reasons for granulating pharmaceutical material described by 
(Parikh 2005) include: Increased drug distribution uniformity, densification of 
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material, enhanced flow rates and rate uniformity, easier metering or volumetric 
dispensing, dust reduction, and improved product appearance. 
Extensive research has been conducted on difficulties associated with the 
granulation process, examples include studies focused on: high shear granulation 
(Devay, Mayer et al. 2006), extrusion/spheronization (Chatchawalsaisin, Podczeck et 
al. 2005) (Sriamomsak, Nunthanid et al. 2007), and fluid bed processing (Lipsanen, 
Antikainen et al. 2007) (Rajniak, Mancinelli et al. 2007). Common general 
equipment used in wet granulation processes are: high shear mixers, low shear 
mixers and fluid bed granulators. While each method has its distinct advantages and 
disadvantages, high shear granulation will be explored in this research. 
4.2.2 Wet Granulation 
Wet granulation uses liquid to wet the seed particles to create controlled 
conditions of agglomeration. Liquid binding forces are responsible for the particle 
size generation, while solid bridging is the key factor for granule strength (Crowder, 
Hickey et al. 2003). Figure 30. gives an overview of the rate processes of agitative 
agglomeration that includes: wetting, growth, consolidation, and breakage. The 
figure also describes the critical formulation and process variables, which are 
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Figure 30 Overview of Critical Factors During Granule Formation (Ennis 2005) 
The general steps of the wet granulation process are: 1. Weighing and 
blending all active and inactive ingredients. 2. Preparing a damp mass. 3. Screening 
the damp mass into granules. 4. Drying the granulation. 5. Sizing the granules 
through dry screening (Ansel, Allen et al. 1999). The sized particles can then be 
further processed with sustained release coating or blended with excipients for 
tab letting. 
Water-soluble drugs are well suited to wet granulation methods which can 
use water as the granulating liquid to provide adhesion of the particles to one 
another. Water acts to raise the contact angle of water soluble materials at the solid 
liquid interface to enhance the distribution of the drug throughout the mass (Cantor, 
Augsburger et al. 2008). Challenges associated with this approach are found during 
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the establishment of a compatible uniform formulation due to possible drug 
migration and robust processing parameters to create a pharmaceutically viable 
product (Allen, Popovich et al. 2005). 
4.2.3 High Shear Wet Granulation 
Figure 31 Schematic of a Bottom-Driven Vertical High Shear Granulator with 
Horizontal Chopper Shaft (NiroPharma 2003) 
Figure 31 is a schematic of a typical vertical high shear granulator for wet 
granulation. Dry material is introduced to the granulator through the load port and 
can be mixed with the main impeller to achieve a uniform dry blend. Dust created 
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from dry materials is captured in the product filter to prevent external contamination. 
Granulating liquids, such as water or organic solvents, are introduced through the 
spray port during main impeller and/or chopper mixing. When an acceptable granule 
is formed, the wet mass exits the system through the discharge port. 
Granule growth in a high shear granulator is largely dominated by 
coalescence or layering. Coalescence is the agglomeration of materials based on 
collision and binding of granules to one another. Binders facilitates fine particle 
adherence to larger particles, to achieve layering (Gokhale, Sun et al. 2005). 
Adequate water is essential for success for both of these methods of granule growth. 
Two types of water are inherent in the system: internal water, which is captured 
within the particles during agglomeration, and "free" surface water remaining from 
the addition of granulating liquids. Both forms of water are necessary to create 
bonding strength and plasticity to allow coalescence and layering (Ghebre-Sellassie 
1989). 
High shear granulation has been shown to create denser particles with lower 
porosity to slow disintegration times compared to alternative methods of single step 
extrusion granulation (Keleb, Vermeire et al. 2004b) and fluid bed granulation (Gao, 
Jain et al. 2002) approaches. This method's unique physical properties are 
associated with the high shear granulation's adhesion of material with water before 
repeated cutting and compaction to yield a denser and harder material (Gao, Jain et 
al. 2002). 
Research has shown the importance of shear on a granule's growth and its 
final properties. (Oulahna, Cordier et al. 2003) found that higher impeller speeds 
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during processing result in lower granule porosity and friability, with a narrower 
particle size distribution overall. This research also found that granule size is a 
critical factor for a granule's properties regardless of the impeller speed and 
increasing shear alone does not result in more homogenous granules. 
4. 2. 4 Extrusion 
Extrusion can be defined as "a method of applying pressure to a mass until it 
flows through an orifice or defined opening. It is a technique that determines two 
dimensions of an agglomeration of particles (Hicks and Freese 1989)." The two 
dimensions of the particles defined by extrusion are: 1) the cross sectional diameter 
which is a function of the screen size the material passes through. 2) The length of 
the extrudate, which is dependent on the formulation and processing parameters. 
There are a number of different types of extruders, but all achieve the same 
objective of converting a wet mass into cylindrical particles. A wet mass can be 
created using high or low shear granulation, and is forced through a screen with 
holes of uniform diameter to create spaghetti like rods. The extrudate hangs down 
and breaks under its own weight into similar lengths. The critical formulation 
parameter during extrusion is the material's plasticity, which must break but avoid 
adherence to other particles during spheronization (Mehta, Singh Rekhi et al. 2005). 
Water in the formulation, added during granulation, aids the extrusion process by 
increasing the plasticity of the material, and provides lubrication to the die during 
processing (Tomer and Newton 1999). The final extrudate should be a cohesive unit, 
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with suitable firmness and plasticity to withstand the remaining downstream 
processes(O'Connor and Schwartz 1989). 
Extrusion is typically viewed as an intermediate processing step, with 
formulation adjustments made in the previous granulation step. Current research in 
extrusion focuses on formulation properties and different types of extruders used. 
Examples include: examining different base excipients (Almeida-Prieto, Blanco-
Mendez et al. 2007), use of twin screw extruders (Keleb, Vermeire et al. 2004a), and 
hot melt extrusion (Andrews, Jones et al. 2008). Equipment modifications and 
operational parameters have been studied to evaluate non-formulation based 
variables. The study of water distribution and loss during extrusion is important for 
aqueous wet granulation formulations. Research has demonstrated water migration 
during slower speeds of extrusion resulting in wetter extrudates early in the process 
(Tomer and Newton 1999). The authors associated this phenomenon with slow 
extrusion speeds allowing water greater time to travel through void spaces to the die. 
Additionally, the loss of surface water has been associated with evaporation due to a 
rise in temperature of the extruder and die during processing (Vervaet, Baert et al. 
1995). 
4. 2. 5 Spheronization 
The spheronizer was patented over 40 years ago to rapidly create small (<2.0 
mm diameter) uniform spherical granules using crossing grooves to cut and rub the 
material (Nakahara 1966). Figure 32 is comprised of A) Motor to drive the system. 
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B) A cross-hatched friction plate, which spins to shape the material. C) A sidewall 




Figure 32 An Adapted Schematic of an Early Spheronizer (Nakahara 1966) 
Spheronization occurs after extrusion, where the cylindrical particles are 
broken into short lengths by contact with the rotating frictional plate, and collisions 
at the particle/particle level and the particle/wall interface to create spherical shapes 
with nearly uniform diameters. The centrifugal force generated by the rotating plate 
throws the material to outside of the plate where it climbs up the sidewall before 
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gravity results in a tumbling ("rope like") motion back to the friction plate, where it 
repeats the same cycle (Nakahara 1966). The cross hatch angle, pattern, and groove 
distance (space between edges) can all be adjusted to improve the efficiency of 
spheronization for different sized beads (Hicks and Freese 1989). 
(Reitz and Kleinebudde 2008) evaluated jacketed vessels for temperature 
control during processing to alter product viscosity, plasticity and sticking more 
basic spheronizer research focuses on spheronization speed and duration. 
Spheronization speeds are generally evaluated to yield an optimal rope like 
movement of the material (Dukie-Ott, Remon et al. 2007) and adequately densify 
the material (Vervaet, Baert et al. 1995). Spheronization cycle times directly impact 
the sphericity of a particle by increasing the number of collisions the material 
undergoes during a cycle, and serves as an important area for research (Pinto, 
Lameiro et al. 2001). In general, the longer the cycle is run the greater chance the 
material will be round, but there is also an increased chance for unintended particle 
size growth. 
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4. 2. 6 Fluid Bed Drying 
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Figure 33 Schematic of Fluid Bed Drying of Wet Material (Olsen 1989) 
Figure 33 depicts how a wet mass can be dried using a fluid bed dryer instead 
of a traditional oven (tray) dryer. Granules, pellets or other wet materials are first 
loaded into the product container of fluid bed dryer. The air inlet introduces air into 
the system through the lower plenum; the air is heated, cooled, and humidified 
depending on the equipment configuration (Olsen 1989). 
The air passes through a lower screen (distribution plate); screen mesh sizes 
are changed for different products to accommodate varying loads and to alter the 
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flow pattern and restriction of airflow to lift the product. Heated air will lift and dry 
the wet mass; the drying rate is described by Equation 5: 
dw 
dt 
Equation 5. Drying Rate (Parikh 1992) 
Where aw is the mass transfer rate (drying rate), h is the heat transfer 
dt 
coefficient, A is the surface area, His the latent heat of evaporation, and !1T is the 
temperature difference between the air and the material surface. Heat transfers to the 
material during drying to supply latent heat to evaporate the liquid, while 
simultaneously mass transfers as the internal liquid/vapor diffuses and evaporates 
from the surface (Parikh 1992). 
Physical interactions with other particles, chamber walls, and the air 
distribution plate will aid in the breakage of agglomerated particles that may have 
formed during earlier stages of processing. A critical balance must be maintained 
during fluidization for drying; over fluidization will break the particles and create 
excess dust resulting in concentration or excipient loss, while under fluidization can 
leave particles wet, agglomerated and unsuitable for further processing (Olsen 1989). 
The air then passes through the expansion chamber, where cooling occurs, and to the 
filter housings. 
Filters may consist of bags, cartridges, or a drying screen similar in design to 
the air distribution plate on the bottom of the chamber. Filter pore size must be 
selected carefully to balance adequate airflow to sustain fluidization, and prevent the 
escape of API or excipients. Generally, a smaller pore size is chosen when drying 
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become clogged during processing, thereby limiting the airflow. The filters are 
shaken or "blown back" using compressed air to reintroduce the drug or excipients to 
the immediate release pellets to prevent concentration loss during processing. While 
every effort is made to keep the material off the filters and on the product, filters may 
gradually become clogged and decrease the fluidization level. It is critical to 
monitor the filter pressure and product pressure for machinery equipped with these 
gauges. Adjustments to the fan speed during processing may be required to maintain 
an optimal fluidization height and must be evaluated to understand and control the 
process parameters (Parikh 1991). 
An "air blast" or a "bed blast" can be utilized to lift the product off the air 
distribution plate during the process if necessary. This technique closes the valves 
above the filters on the top of the chamber to allow vacuum pressure to build just 
above the product chamber. The valves are rapidly opened and a large amount of 
vacuum pressure pulls the material off of the air distribution plate. The abrupt 
movement can lift and break up wet materials that may have formed large 
agglomerates. Standard operating parameters designed to avoid over agitation of the 
product and may not sufficiently lift the wet materials early in the drying stages 
when it is heaviest. After the fluid bed is discharged, it is important to separate 
process generated agglomerates and fine particles (also referred to as "fines") from 
the usable material (Olsen 1989). 
Sieving is performed to remove agglomerated particles, fines, and 
undesirable particle sizes that may be generated during processing. This controls the 
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particle size of the immediate release pellets that will be subsequently coated for 
sustained release. 
4.3 Controlled Release Background 
4.3.1 Fluid Bed Spray Coating 
Product Container 
Expanded View 
A - Coating Chamber D - Spray Nozz le 
B -Partit ion E - Expansion Ch amber 
C -Air Di•tribution Plafe 
Figure 34 Cross Sectional Schematic of a Standard Bottom Spraying Configuration 
with a Wurster Column (Olsen 1989). 
Figure 34 depicts the schematic of the product container where spray coating 
using a bottom spray nozzle with a Wurster column is used for the addition of liquid 
materials to the fluidizing solid materials. Within the coating chamber, (A), 
temperature controlled air is drawn through the air distribution plate, (C), via a motor 
drawing vacuum to lift and fluidize the solid material. The Wurster column, (B), 
acts to create capillary action and create an ideal spray zone, where the spray nozzle, 
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(D), can introduce liquid coating materials to the fluidizing solid material. The spray 
nozzle, (D), is also capable of introducing atomizing air to the system to aid in the 
lift, and capillary action of the Wurster column, in addition to controlling the droplet 
size of the materials being sprayed. After the air passes the fluidized material it 
enters the expansion chamber, (E), and is filtered prior to exiting the system (Olsen 
1989). 
Drug layering on inactive cores, the addition of polymeric membranes and 
other excipients to drug loaded pellets for sustained release or protection are 
common uses for this configuration. The formulation and operating conditions 
during spraying are critical for the successful production of a product. 
When spraying polymeric membranes onto drug loaded beads, it is important 
to understand the impact of the starting material. Figure 3 5 is a useful estimator of 
particle surface area based on diameter, in order to estimate the required polymer 
quantity. As the particle size increases, the surface area and the amount of polymer 
required for 1 mg/cm2 decreases. This is important when considering the target 
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Figure 35 Adaptation of Blaine's ASTM Des. C 205-55 for Estimating the Surface 
Area of Small Particles and Polymer Coating Requirements (Degussa 2007a). 
4.4 Curing 
After completion of the aqueous sustained release coating process, the film 
applied may not completely coat the immediate release bead. This is due to the 
incomplete coalescence of the polymer particles into a homogenous film, resulting in 
variable drug release from the beads (Bodmeier, Guo et al. 1997). Curing is a 
processing step that may use heat and/or humidity to facilitate the rapid coalescence 
of the polymer into a uniform coating to protect the beads to create a uniform drug 
release profile. The extreme conditions of curing, such as: high temperature, high 
humidity, and long durations of curing have been studied. The results are highly 
dependent on the polymer coating material used and cannot be generalized among 
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polymer systems(Siepmann, Muschert et al. 2008). Curing polymers has also been 
found to reduce the brittleness when compared to uncured beads, which is 
advantageous during tabletting to minimize bead crushing (Abbaspour, Sadeghi et al. 
2007). For Aquacoat ECD aqueous dispersion, the manufacturer recommends a 
curing cycle of two hours at 60°C (FMC-BioPolymer 2006). Curing approximately 
10-12°C above the Tg allows relaxation of polymer chains and an alteration of the 
film wetting properties reduces instability during storage for beads coated with an 
Aquacoat ECD and DBS (Wheatley and Steuemagel 1997). 
4.5 Bead Top Coating 
A protective excipient blend is of primary importance to minimize bead 
crushing during tabletting, top coating aqueous ethylcellulose beads may offer an 
additional level of protection during processing (Dias 2007). Mannitol, polyethylene 
oxide, polyethylene glycol and microcrystalline cellulose have also been explored as 
protective excipients to provide cushioning, especially for high potency beads in 
poorly uniform blends (Torrado and Augsburger 2008). Opadry II Y-30-18037, 
contains a proprietary blend of triacetin (plasticizer), Hypromellose, Lactose 
monohydrate, and titanium dioxide, triethyl citrate (Spectrum, Gardenia, California) 
was used as a plasticizer to provide additional flexibility. The Opadry II top coating 
suspension is advertised to act as an environmental moisture protection for water 
sensitive drugs to enhance product stability and shelf life. Additionally, strong film 
mechanics for protection against peeling and cracking support the use predominantly 
for tablets (Colorcon 2008b ). 
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4.6 Tablet Background 
Compressed oral tablets for immediate release applications are a well-
established pharmaceutical dosage form for the generic market, with formulation and 
manufacturing practices studied extensively. Materials experience volume reduction 
until consolidated into a solid unit; tabletting traditionally places material into a die 
and then uses a set of punches to reduce the volume under pressure (Hoag, Vivek et 
al. 2008). Advantages of tablets over other dosage forms include: ease of 
administration, low cost to manufacture, ease of packaging and shipping, and 
product stability and tamper resistance (Kottke and Rudnic 2002). The tabletting of 
multiparticulate modified release systems offers additional advantages over standard 
tablets. The primary advantage of a multi particulate system is the enhanced surface 
area and distribution in the gastrointestinal tract as compared to a traditional single 
unit system. This can yield decreased inter/intrapatient drug release variability, 
potentially diminish food effects, avoid "dose dumping" if the system is damaged, 
and facilitate the combination of multiple incompatible drugs (Torrado and 
Augsburger 2008). 
Compaction acts to transform the raw ingredients into a final dosage form 
through the following mechanisms: Initial volume reduction rearranges particles 
closer together until interparticulate friction prevents movement. Further volume 
reduction is achieved through reversible (visco )elastic deformation, and proceeds to 
irreversible plastic deformation which contributes to the tablet's strength, or 
undergoes brittle fracture which yield crumbling tablets of poor quality (Kottke and 
Rudnic 2002). This compaction results in the formation of chemical (i.e. 
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electrostatic, Van der Waal forces) and physical (i.e. mechanical interlocking, solid 
bridges formed via melting) interparticulate bonds to create a viable tablet (Hoag, 
Vivek et al. 2008) 
Direct compaction may be a viable approach to a limited number of products 
as an effective tabletting method. These products do not require adjustments to their 
flow properties, density, and/or particle size distribution, to yield appropriate 
physical parameters for an acceptable dissolution profile (Parikh 2005). For many 
drugs, wet granulation is used to create viable drug granules for compression. 
Creating an appropriate size distribution and shape/morphology of intermediate 
pellets for tabletting into a multiparticulate dosage form, with proper physical 
parameters such as compressibility attributes bulk/tap density and flow properties are 
complicated. Varying granule properties such as: particle size, sphericity, and 
porosity can all influence the granular deformation during tabletting. Plastic 
deformation is primarily seen during tabletting, but porous and irregular granules 
may experience fragmentation and breakage (attrition) resulting in rapid drug release 
(Hoag, Vivek et al. 2008). 
One common tabletting technique matches the active and excipient particle 
sizes in order to gain better homogeneity to minimize segregation due to the flow 
properties of the powders during the blending steps. If homogeneity and adequate 
flow is not achieved, the dissolution properties, tablet weight, hardness, and 
manufacturability may all be adversely effected (Crowder, Hickey et al. 2003). 
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4. 7 Key Excipients for Formulation 
4. 7.1 Fillers/Bulking Agents 
There are a number of fillers and bulking agents used to create a core 
structure for the active ingredient. Examples include: lactose, sugars, dicalcium 
phosphate, starch (pregelatinized), and microcrystalline cellulose (MCC) (Chan and 
Heng 2005). The choice of core material is dependent on the active ingredient and 
dissolution profile target. Two examples: 1) For water soluble drugs within a 
sustained release product, an insoluble core (i.e. mcc) will slowly release the drug 
via diffusion through the insoluble structure. 2) For poorly water soluble drugs, it is 
necessary to use a soluble filler (i.e. starch) to facilitate the release of the drug from 
the inert matrix (Dukie-Ott, Remon et al. 2007). 
MCC is ubiquitously found throughout pharmaceutical manufacturing in a 
multitude of functions, available in a range of mean particle sizes and grades. It is 
primarily used for oral capsules/tablets as a binder and diluent in wet granulation and 
direct compression (Weller 2003). MCC primarily undergoes plastic deformation 
during compression, in contrast to crystalline lactose and sucrose which may be more 
prone to experience fracturing (Hoag, Vivek et al. 2008). MCC's addition to an 
excipient blend improve the plastic characteristics during compression and lubricant 
efficiency to protect sustained release coatings on the beads during compression 
(Torrado and Augsburger 2008). 
Smaller mean particle sized grades ofMCC (e.g. Avicel PH-101 -50µm 
(FMC-BioPolymer 2008) are utilized in wet granulation, due to their beneficial 
rheological properties as a wet mass during extrusion and spheronization (Faure, 
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York et al. 2001). Avicel PH-102 (-100 µm) (FMC-BioPolymer 2008) may be used 
during tabletting to provide excipient protection for smaller coated beads, but 
potential formulation dependent segregation issues must be understood (Torrado and 
Augsburger 2008). Larger sized grades of MCC (e.g. Avicel PH 200 -200 µm) have 
been found to yield lower tablet weight variations, while maintaining compactibility 
similar to smaller sized materials (Doelker, Massuelle et al. 1995). In addition to 
MCC's enhanced compactibility, wetting and drying occur at a rapid and even pace 
to prevent variable distribution of soluble ingredients in the granule (Cantor, 
Augsburger et al. 2008). 
4. 7.2 Granulating Agent 
A variety of granulating agents can be employed depending on the 
physicochemical properties of the dry mass of excipients and active ingredient(s). 
Water, ethanol, acacia, alginate, pectin, HPMC, sodium carboxy methylcellulose 
(CMC), polyvinylpyrrolridone (PVP), citric acid and calcium chloride solution (in 
water) were studied as granulating agents for the wet granulation process 
(Sriamornsak, Nunthanid et al. 2007). This research found that the higher viscosity 
agents resulted in dumbbell formation, while low viscosity watery agents with 
calcium chloride, which reduced the swelling potential of the excipient blend and 
yielded desirable spheres 
Water has become the primary granulating agent of choice, with organic or 
hydro alcoholic solvent blends employed when hydrolysis of the active ingredient or 
other concerns are apparent (Cantor, Augsburger et al. 2008). The amount of water 
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used during granulation will dictate the properties of the intermediate materials 
throughout process. If the mass is over wetted during granulation agglomerates may 
form during the spheronization process and yield an undesirable particle size 
distribution and shape (Vervaet, Baert et al. 1995). Conversely, ifthe mass is not 
sufficiently wet to lubricate the extrusion die, excessive die pressure and heat due to 
frication can result in a failed process (Tomer and Newton 1999). 
4. 7. 3 Binding Agents 
Binders provide cohesion for bonding of solid particles to promote size 
enlargement to produce granules and improve the blend flow during processing 
(Harned, Moe et al. 2005). Binder selection is critical and can impact the 
formulation 's friability, hardness, disintegration time, and dissolution rate. Binders 
are not required if the formulation can yield a evenly distributed granule, hard 
enough to withstand processing conditions with acceptable flow and compaction 
properties. There are a number of binders which are commonly used and can be 
divided into three categories, see Table 21 . 
Table 21 Common Categories and Examples of Binders, Adapted from (Cantor, 
Augsburger et al. 2008) 
Binder Cat~ory Exam_Q_les Comments 
Primarily used for Chewable 
Sugars Sucrose, Glucose, Sorbital Tablet 
Pregelatinized Starch, Acacia, Gelatin, Pregelatinized Starch is 
Natural Po~mers/Gums Sodium Alginate most common 
Polyvinyl Pyrrolidine (PVP), Poly Ethylene 
~nthetic Po.b'_mers G.b'_col (PEG), 
Hydroxypropylmethylcellulose (HPMC), 
methylcellulose, Hydroxypropylcellulose Most popular choice for 
(HPC), Sodium Carboxymethylcellulose wet/dry mixing, to avoid 
(CMC), Ethylcellulose, and Methacrylates health concerns over 
Semi ~thetic Po!ymers (Eudrctgits) naturally sourced binders 
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4.8 Polymers 
Polymers can be made from a variety of natural or synthetic materials, and 
are used throughout the pharmaceutical industry to conquer challenging 
formulations. Cellulose is a natural polymer found in the fibrous tissues of cotton 
and wood, which pass unchanged through the human digestive tract (Kim 2004). 
Many unique derivatives of this natural polymer have been created for diverse 
formulation applications. Alternatives to cellulose based polymers include 
derivatives of acrylic acid, synthetics: such as poly vinyl acetate (PV A), polyvinyl 
pyrrolidine (PVP), and natural ingredients such as waxes and shellac (Kottke and 
Rudnic 2002). 
4. 8.1 Methylcellulose 
Hydroxypropylmethyl cellulose (HPMC) is soluble in water, isopropyl 
alcohol (IP A), and hydro alcoholic mixtures depending on the grade of material 
(Harwood 2002). The polymer is used in many areas of the pharmaceutical industry, 
including film coating and sustained release matrix tablets. The HPMC acts to form 
viscous gels to control the diffusion of water and drug release and when it is 
combined with a water insoluble polymer, such as ethylcellulose, it facilitates the 
creation of a "non-continuous film" (Dow 2008), or commonly referred to as a pore 
former. HPMC can be used as an effective pore former when combined with 
ethylcellulose for both organic and aqueous systems. Upon hydration HPMC acts to 
open channels within the polymeric matrix and facilitates drug release (Bodmeier, 
Guo et al. 1997). Research has indicated that the use of HPMC can result in 
flocculation and unstable coating systems when used with aqueous dispersions of 
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ethylcellulose (Ong 2006b) The flocculation was overcome when the dispersion was 
adequately mixed, which is consistent with standard processing parameters (Ong 
2006a). High concentrations (30-40% of Polymer weight) of HPMC can result in the 
dissociation of carboxylic groups of the ethyl cellulose resulting in cracks and a loss 
of membrane controlled drug release (Gunder, Lippold et al. 1995). Overall the 
challenges of coating with HPMC in aqueous systems are considered greater than in 
organic systems, due to stricter processing controls to prevent undesirable results 
(Nagai, Ohara et al. 1997). 
4. 8. 2 Ethyl cellulose 
Ethylcellulose is a hydrophobic polymer, used to coat granules and/or tablets 
to create a sustained release profile (Dahl 2002). Ethylcellulose is brittle due to inter 
chain hydrogen bonding and bulky glucose subunits and requires plasticization 
(Bodmeier and Paeratakul 1994). The hydrophobicity of the polymer necessitates 
that it be dissolved in an organic solvent or be dispersed in an aqueous system. 
While aqueous or organic systems may be employed for ethylcellulose, the film 
formation mechanism is different. Organic solvents dissolve the ethylcellulose and 
other components to form a film when the organic solvent evaporates leaving the 
individual polymer molecules in contact (Osterwald 1984 ). 
In contrast, aqueous systems undergo the following film forming process: 1) 
Individual polymer spheres containing hundreds of polymer chains dispersed in 
water coat the surface. 2) As water evaporates, the interfacial tension between the 
remaining water and polymer spheres increases and results in an ordered 
arrangement of polymer spheres. 3) Capillarity resulting from the increased 
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interfacial tension provides a driving force to overcome the repelling forces and 
cause deformation to fuse and coalesce the particles together (Wheatley and 
Steuemagel 1997). 
In addition to avoiding the negatives of organic solvents, highlighted in 
chapter 1; aqueous systems offer several additional advantages: the lower viscosity 
dispersion allows a greater amount of polymer to be applied per unit of volume, and 
lower water vapor transmission rates due to the coalescence of small latex spheres 
(Wheatley and Steuemagel 1997). 
Aquacoat® ECD and Surelease® are commercially available ethylcellulose 
aqueous dispersions. The Surelease® system is ready for use after the addition 
agitation of water to the desired solids concentration, and a 15 minute mixing time 
(Colorcon 2006). A disadvantage of the Surelease® system is the need for additional 
barrier coating, adding processing time and material expenses. In addition to 
ethylcellulose, the Aquacoat® ECD system contains, cetyl alcohol, and sodium lauryl 
sulfate which act as an emulsifier and stabilizer, respectively. The Aquacoat® ECD 
system requires the addition of a plasticizer, and a 30 minute mixing time before it is 
ready for application (FMC-BioPolymer 2006). 
4.8.3 Plasticizers 
Organic and aqueous ethylcellulose dispersions require plasticizers due to 
their brittle nature to prevent cracking, improve flexibility, reduce the polymer's 
glass transition (Tg) temperature to promote uniform film (Bodmeier, Guo et al. 
1997). Plasticizers provide flexibility to the polymer by increasing the free space 
between the polymer chains and decrease rigid polymer-polymer binding (Aulton, 
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Abdul-Razzak et al. 1981). Additionally, plasticizers facilitate water uptake into the 
film to improve the coating's permeability to drugs (Lippold, Gunder et al. 1999). 
Common plasticizers used are hydrophobic, such as Dibutyl Sebecate, Polyvinyl 
Acetate Phthalate, and mineral oil, or hydrophilic, such as: Polyethylene Glycol 
(PEG), Triethyl Citrate (TEC), and Triacetin (Rowe, Shesky et al. 2002). TEC and 
DBS (15-30%) are both capable of decreasing the Tg and subsequently reducing the 
minimum film formation temperature (MFT) for Aquacoat dispersions to improve 
coalescence and film formation (Ohara and McGinity 1995). Research has shown a 
greater association between the hydrophobic DBS than the hydrophilic TEC with 
Aquacoat (Tarvainen, Sutinen et al. 2003). DBS is initially emulsified in the water 
phase of the system, prior to incorporation into the polymer phase within 30 minutes 
of mixing (Bodmeier, Guo et al. 1997). DBS at approximately 24% of the polymer 
weight has been demonstrated to adequately plasticize and soften the ethylcellulose 
spheres to facilitate continuous film formation by reducing the glass transition 
temperature of Aquacoat from 89°C to 42-44°C (Wheatley and Steuemagel 1997). 
4.8.4 Other Inactive Ingredients for Tabletting 
Other inactive ingredients that are used in the formulation of tablets are 
lubricants and disintegrants. Lubricants act to overcome the increased friction 
generated during compression between the tablet and die walls (Armstrong 2008). 
Examples of lubricants used in tabletting include: Stearic acid and its salts (calcium, 
magnesium, zinc), hydrogenated vegetable oil, waxes, and mineral oils (Kottke and 
Rudnic 2002). 
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Tablet disintegrants are defined as, "Any solid, pharmaceutically acceptable 
material included in the formulation that acts to cause the tablet matrix to break up 
when the tablet comes into contact with aqueous media (Moreton 2008)." This 
broad definition encompasses many excipients, examples include: 
Carboxymethylcellulose Sodium, Povidones, starches, and alginates (Rowe, Shesky 
et al. 2002). 
4.9 Identifying Critical Quality Attributes (CQA's) 
CQA' s are factors that affect a final product's potency, stability, and drug 
release (ICH 2007). Numerous factors would satisfy the requirements for 
consideration as a CQA, but attempting to study all of them would be unfeasible. 
Identification of the CQAs for this developmental process was selected based on the 
ICH Q8 guidelines, product deformulation characterization, current literature and 
available equipment. 
4.9.1 Particle Size Distribution 
The particle size distribution generated at the completion of the granulation 
process is identified as a potential CQA in the ICH Q8 Annex. The importance of 
the particle size distribution on down stream processes is widely recognized and 
must be monitored (ICH 2007). Products with tailored particle size distributions 
have narrower specifications for acceptance criteria, with poor process control 
resulting in highly variable and poor yields (Dukie-Ott, Remon et al. 2007). The 
yield can have a significant impact on the profitability and sustainability of a product 
throughout its life cycle. For sustained release products, understanding how the 
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formulation and process effect the immediate release bead particle size distribution is 
critical. Variable particle size distribution will yield varying surface areas for 
coating and can drastically affect the dissolution profile of the system. Figure 36. 
depicts research comparing particle sizes when coating and tabletting, on the 
extended release dissolution profile. 
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Figure 36 Effect of Particle Size on Dissolution Profile (Dashevsky, Kolter et al. 
2004) 
In Dashevsky's research, both pellets were coated to 20% w/w gain with a 
polymer for modified release. It is clear from Figure 36. that the smaller sized 
pellets release the drug faster due to an increased surface area and consequently a 
thinner polymer coating than the larger particles. While smaller pellets in general 
undergo less mechanical stress during compression and improved distribution into 
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the void space, pellet rupturing appears similar for both sizes for this research 
(Dashevsky, Kolter et al. 2004) 
4. 9. 2 Sphericity 
The sphericity of a pellet indicates the roundness of material, by direct 
comparison of perpendicular lengths of the material or by how well the material rolls 
(Vervaet, Baert et al. 1995). The closer the measured ratio is to 1.0, the rounder the 
material. Rounder sustained release coated pellets have been associated with a more 
uniform drug release, than irregularly shaped material (Chopra, Alderbom et al. 
2002). This research concluded that rounder pellets had more uniform polymeric 
coating, while dumbbell shaped pellets experienced disproportionate coating at the 
body and edges resulting in variable drug release. Mathematically, rounder pellets 
will increase the surface area for hydration and drug release. 
The pellet sphericity can also impact down stream processes. Spherical 
pellets will move through the manufacturing process easier and create a more 
uniform dosage form. Conversely, pellets with an aspect ratio of> 1.2 have been 
found to cause variability during filling operations for capsules (Chopra, Podczeck et 
al. 2002). 
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4.9.3 Moisture Content 
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Figure 37 Example of a Design Space for a Drying Operation (ICH 2007). 
Figure 3 7 is given by the Q8 annex as an example of a drying operation 
design space. The target endpoint was set between 1-2% moisture content, and the 
drying is dependent upon the temperature path. If the material is dried too rapidly 
there can be excessive particle attrition and damage, conversely if the drying is 
performed too slowly the additional moisture in the product can result in an impurity 
formation (ICH 2007). From a practical stand point, over drying will generate a 
greater amount of dust, which may be composed of active ingredients and result in 
potency loss. High levels of moisture content can have adverse effects during 
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compression, causing changes in the mechanical strength of tablets due to excess 
lubrication (Kottke and Rudnic 2002). Excessive moisture in the final product can 
result in concerns over microbial growth, and an long term instability of the drug 
product (Petereit and Weisbrod 1999). 
4. 9. 4 Dissolution Profile 
A simplistic definition of the dissolution rate is "the amount of active 
ingredient in a solid-dosage form dissolved in unit time under standardized 
conditions of liquid-solid, interface, temperature, and media composition (Hanson 
1991 ). " The dissolution profile provides information about critical factors and can 
guide scientists towards understanding their effects when changes occur. It is 
important to identify and understand the process and formulation factors , which must 
be controlled to yield a useful dissolution profile and a viable pharmaceutical 
product. Post approval, dissolution testing most often serves as a quality control 
function to determine acceptable variability and monitor variations during 
manufacturing, determine stable release profiles over time, and support regulatory 
changes (FDA 1997a). 
The FDA provides three levels of in vivo/ in vitro correlations as detailed in 
the guidance document: Extended Release Oral Dosage Forms: Development, 
Evaluation, and Application ofln Vitro/In Vivo Correlations (FDA 1997a). In 
general the level assigned to the correlation is based on the following (Shah and 
Williams 1994) : 
Level A: Superimposable in vitro/in vivo profiles, "point-to-point" 
correlation. 
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Level B: Comparable mean in vitro/ in vivo dissolution time using statistical 
moment analysis, considered a single point correlation. 
Level C : Mean In vitro dissolution time correlated to one pharmacokinetic 
parameter, considered a one-point correlation. 
Ideally the formulation provides a Level A correlation, but often the anticipated 
bioavailability cannot be adequately projected through dissolution alone prior to 
performing the in vivo studies. While it is an imperfect method, it is widely 
considered as the most sensitive predictor of in vivo performance (Banakar 1991 ). 
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Chapter 5 Linking Materials and Processes to CQA's- Risk Assessment 
5.0 Introduction 
This chapter outlines the general approach for each phase of drug 
development to initially link the materials and processes to CQA's. The Risk 
Assessment approach used Ishikawa diagrams to help identify potential factors for 
study. The materials and methodology used for this section and throughout the rest 
of the study are given. The results of the traditional/exploratory batches are given to 
guide the design of experiments. 
5. 0.1 Phase JI: Formulation and Process Development of an Immediate Release 
Drug Pellet 
Phase II- The De-.elopment of an Immediate Release Pellet 
1 
.--· 
ion __.. High Shear __.. Extrusion ... Spheroniz ... Mixing ... 
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Figure 38 Processing Steps for the Immediate Release Pellet 
Propranolol HCl will serve as the drug for the "traditional" approach to the 
formulation of a generic marketed product. The formulation parameters are guided 
by the desire to closely mimic the marketed product's dissolution profile. The bulk 
of the research for phase II manufacturing process serves as an opportunity to 
identify variables to understand the Critical Quality Attributes (CQA's). The results 
found during the development of Propranolol HCl guided the factor selection for the 
formulation and processing of Metoprolol Succinate. The selected factors will 
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initially be evaluated for Metoprolol Succinate using exploratory batches to 
determine feasible operating parameters. The factors will be narrowed down and the 
operating levels will be fixed for a factorial experiment to support the QbD 
approach. 
Figure 3 8 is an overview of the process from raw ingredient to dry immediate 
release bead. There are a number of processing steps involved in converting the raw 
materials into a viable drug pellet, which could then be coated with a polymer and 
ultimately encapsulated or compressed into a tablet. Critical parameters were 
identified during the process for investigation. The process begins with a dry mixing 
of the excipients and active ingredients, using only the impeller blade. After the dry 
ingredients are adequately mixed, purified water, USP, is added as the granulating 
agent. During water addition, the impeller blade and the chopper mixes and shear 
the material in a Jaygo-1 OL high shear mixer, to create a wet mass. The mass is then 
extruded using a Nica®El40 extruder with a screen size adequate to yield the desired 
particle size distribution. The extrudates are then spheronized with an Aeromatic 
Fielder® S450 spheronizer into moist round pellets. The moist pellets are then dried 
using a Mendel® MFB-1 fluid bed processor to the desired moisture level, as 
determined by loss on drying(%) by an Ohaus® MB200. 
Experiments comparing the effects of the duration of shearing (kneading), 
spheronization parameters, and the amount of liquid added for granulation are areas 
of interest to identify the variables that link to the Critical Quality Attributes 
(CQA's). An Ishikawa diagram, Figure 39 was first prepared to determine variables 
of interest for the IR bead formulation and process. The key metrics of the pellets 
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will include the particle size distribution and sphericity of the produced IR beads. 
The final pellet product will then serve as the basis for polymer coating and 
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Figure 39 Ishikawa Diagram-Immediate Release Beads 
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S.0.2 Phase III: The Creation and Evaluation of Coated Controlled Release Pellets 
Phase Ill- The De\elopment of a Sustained Release Pelle-t - - - --i 
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Figure 40 Phase III-General Methodology for a SR Pellet 
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Figure 40 is an overview of the processing steps and potential variables for 
the development of a sustained release bead. In addition to difficulties associated 
with standard formulation and processing techniques, creating oral compressed 
tablets capable of delivering extended release profiles introduces a new dimension of 
challenges. The selection of an appropriate polymer system for targeted delivery and 
the desired release profile requires investigation and formulation studies. 
Traditionally, non-aqueous and organic solvent systems were utilized to enhance the 
solubilization of polymers. A clear polymeric solution will form uniform coatings on 
substrates with reproducible film characteristics to create an extended release 
product. Solvent processing can be seen in product patents (Dhalinder 1993), but are 
generally not described in depth in literature, because it is viewed as an intermediate 
processing step; a classic example can be seen in the formulation of Metoprolol 
Succinate (Ragnarsson, Sandberg et al. 1987) (Sandberg, Rangarsson et al. 1988). 
Due to environmental hazards, pollution, and costs associated with handling, 
processing, and disposal of solvents, some manufacturers may prefer aqueous 
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polymeric coating systems to solve their needs for polymer application. However, 
more environmentally friendly and theoretically cost effective over the long term, 
aqueous polymer coatings can be difficult to process due to their delicate nature. 
The coating process is highly dependent on processing conditions, with inconsistent 
results often due to a lack of process control or inappropriate processing parameters. 
Additionally, aqueous polymer dispersions may experience variability or 
inappropriate physicochemical properties dependent on the polymer(s) selection 
(Porter and Bruno 1990). Figure 41 is an Ishikawa diagram for the development of 















Figure 41 Ishikawa Diagram-Sustained Release Beads 
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The immediate release pellets developed in Phase III will be coated with 
aqueous polymers first to evaluate the feasibility of the system against benchmarks 
set by the marketed product. For products, which cannot reasonably use aqueous 
systems, an organic solvent system will be employed. Each polymer system required 
the development of individual processing parameters in order to ensure a quality 
outcome. Functional polymer selection, coating thickness, curing conditions and 
curing duration are vital factors in the creation of a controlled release pellet. The 
primary metric was the pellets' dissolution profiles over their controlled release 
periods. The USP monographs for Propranolol Hydrochloride Extended Release 
Capsules (USP 2007b) and Metoprolol Succinate Extended Release Tablet (USP 
2007c) dissolution methodology will be followed to evaluate the release profiles. 
For Propranolol HCl, Ultra Violet (UV) Spectroscopy was used for concentration 
determination, and the method was verified by high performance liquid 
chromatographic (HPLC). Metoprolol Succinate did not use UV spectroscopy due to 
interference and concentration was determined via HPLC. Scanning electron 
microscopy (SEM) or other visual imaging methods will be used to evaluate the 
surface morphology and coating patterns on the pellets. Pellets will be sieved to 
determine the particle size distribution. Additional physical characterization will be 
performed as needed. 
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5.0.3 Phase JV: The Creation and Evaluation of a Multiparticulate Compressed 
Oral Tablet 
.- -- Phase IV- The De-.elopment of a Multiparticulate Sustained Release Tablet 
Top Coating 
SR Beads Tabletting 






J Tablet Top/ 
~eal Coating _J 
Figure 42 is an overview of the development steps for the creation of a 
multiparticulate sustained release tablet. Top-coated sustained release beads were 
combined with different excipient blends to act as fillers, cushioning agents, and 
binders. The blend is compressed to form a multiparticulate tablet, which is 
ultimately top-coated to prevent damage and water incursion. Experimental 
evaluations of the sustained release polymer content, excipient blend, and 
compaction force, measured as hardness will be evaluated to create a robust tablet 
dosage form. Figure 43 is an Ishikawa diagram of potential factors that could be 
explored for the formulation of a sustained release multiparticulate tablet. The final 
experimental dosage form's dissolution profile will be compared with the marketed 
product to compare the performance of the product over the extended release period. 
Additionally, the an objective is to demonstrate process understanding to show 
improvement towards meeting the USP monograph for the drug product, to support 
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Figure 43 Ishikawa Diagram-Multiparticulate Tabletting 
5.1 JR Bead Formulation Materials 
5. I. I Propranolol 
Propranolol hydrochloride, USP (SIMS, Italy), Microcrystaline Cellulose 
(A vicel PH 101) (FMC Biopolymer, Philadelphia, Pennsylvania) ( d90 <106 µm), 
and Purified Water, USP (in house). 
5.1. 2 Metoprolol Succinate 
Metoprolol Succinate, USP (Esteve Quimica, Barcelona, Spain) (98.1 % <200 
µm), Microcrystalline Cellulose (Avicel PH 101) (FMC Biopolymer, Philadelphia, 
Pennsylvania), and Purified Water, USP (in house). 
5.2 SR Bead Formulation Materials 
5.2.1 Propranolol HC! 
Formulated drug loaded immediate release pellets from Phase II, 
Aqueous Coatings: Purified Water, USP (in house), Aquacoat ECD (FMC 
Biopolymer, Philadelphia, Pennsylvania), Dibutyl Sebecate, NF (Spectrum, Gardena, 
California), HPMC E6 (Dow, Midland, Michigan). 
Organic Coatings: Ethocel 10 cp (Colorcon, West Point Pennsylvania), HPMC E15 
(Dow, Midland, Michigan), Dibutyl Sebecate, NF (Spectrum, Gardena, California), 
Talc (Spectrum, Gardena, California), Isopropyl Alcohol, USP (100%) (Spectrum, 
Gardena, California), and Purified Water, USP (in house). 
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5.2.2 Metoprolol Succinate 
Formulated drug loaded immediate release pellets from Phase II, Syloid 244 
FP, NF (Grace Davidson, Columbia, Maryland), Aquacoat ECD (FMC Biopolymer, 
Philadelphia, Pennsylvania), Dibutyl Sebecate, NF (Spectrum, Gardena, California), 
and Purified Water, USP (in house). 
5.2.3 Materials- Sustained Release Bead Top Coating 
Metoprolol Succinate Sustained Release coated and cured beads from Phase 
III of the study, Opadry II Y-30-18037 (Colorcon, West Point, Pennsylvania), 
Triethyl Citrate, NF (Spectrum Chemicals, Gardenia, California), Purified Water, 
USP (in house). 
5.2.4 Materials- Tabletting 
Metoprolol Succinate top coated beads, Microcrystalline Cellulose, NF 
(A vicel PH 102®) (FMC Biopolymer, Philadelphia, Pennsylvania), Microcrystalline 
Cellulose, NF (A vicel PH 200®) (FMC Biopolymer, Philadelphia, Pennsylvania), 
Crospovidone, NF (Polyplasdone® XL-10) (International Specialty Products, Wayne, 
New Jersey), Povidone, USP (Plasdone® K29/32) (International Specialty Products, 
Wayne, New Jersey), Lactose Monohydrate (80m) (Kerry Bio-Science, Tralee, 
Ireland), Starch 1500, NF (Colorcon, West Point, Pennsylvania), Hydrogenated 
Vegetable Oil, NF (Lubritab®) (J. Rettenmaier & Sohne, Rosenberg, Germany). 
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5.2.5 Excipient Granule (Formulation #1) for Metoprolol Succinate SR Tabs 
Microcrystalline Cellulose NF (PH102), Crospovidone NF K29/32, 
Pregelatinized Starch (1500) NF, Lactose Monohydrate NF, and Purified Water, USP 
were granulated. All dry ingredients were first screened through a #25 sieve to 
remove large particles, prior to processing. Low shear wet granulation was 
performed on the Jaygo 10-L mixer, at a low impeller speed without the chopper 
blade. The granules were dried in a Freas® Scientific 625 oven, until an LOD of less 
than 5% was achieved. The granules were milled in a Fitzpatrick® Comminutor, 
with a screen size of 60 and knives facing forward. 
5. 2. 6 Excipient Dry Blend (Formulation #2) for Metoprolol Succinate SR Tabs 
Microcrystalline Cellulose, NF (PHI 02) Crospovidone, NF K29/32 
Pregelatinized Starch (1500), NF Lactose Monohydrate, NF were screened through a 
#25 sieve and Hydrogenated Vegetable Oil, (Lubritab®) was screened through a #30 
sieve to remove large particles prior to blending. 
5.2. 7 Excipient Dry Blend (Formulation #3) for Metoprolol Succinate SR Tabs 
Microcrystalline Cellulose, NF (PHI 02), Microcrystalline Cellulose, NF 
(PH200), Crospovidone, NF XL-I 0, were screened through a #25 sieve and 
Hydrogenated Vegetable Oil, (Lubritab) was screened through a #30 sieve to remove 
large particles prior to blending. 
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S.3 Processing Methods 
5.3.1 Propranolol HC! IR Bead Processing 
The approach to development was to evaluate a selected factor while holding 
the other parameters constant to determine their effects, and to use visual 
observations to make adjustments. Early development utilized 400g batch sizes, 
while the final three lots RB005054, RB005055 , and RB005056 were 800g batches 
to evaluate the process parameters effects of doubling the batch size. Propranolol 
HCl followed the general processing procedure described above. During wet 
granulation, impeller blade speed and chopper speeds were fixed throughout water 
addition and kneading. A l .Omm stainless steel screen was used during extrusion to 
yield larger extrudates. The experimental process parameters can be seen for 
Propranolol immediate release bead production in Table 22. An example of the fluid 
bed drying cycle and processing parameters for the spheronized moist pellets can be 
seen in Figure 44. The moisture content specification was set to not more than 2.5%, 
based on the initial moisture content of the active ingredient and the excipient to 





















Figure 44 Example of Propranolol IR Bead Drying Cycle 
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Table 22 Propranolol IR Experimental Overview 
Raw and Coded Process Parameters 
H20 H20 H20 Addition H20 Addition Kneading Spheronization Spheronizatio Spheronization Spheronization Trial Amount Amount g/min/500g Coded Time RPM (Avg) n RPM Coded Time (min) Time Coded (g) Coded batch Coded 
91907 200 Low 25 Low Low 600 High 2.5 Low 
92007 265 Low 30 Low Low 550 High 2.5 Low 
RB005008 275 Medium 83 .33 High Low 600 High 3 Low 
RB005009 325 High 55 High Low 366.66 Low 3 Low 
RB005010 300 High 55 High Low 475 High 4 Low 
RB005013 290 High 50 Low Low 300 Low 2 Low 
RB005021 275 Medium 50 Low Low 520 High 5 High 
RB005022 290 
........ 
High 50 Low Low 336 Low 4.75 High 
N 
"° 
RB005023 275 Medium 50 Low High 450 Low 6 High 
RB005048 275 Medium 75 High Low 460 High 5 High 
RB005049 275 Medium 68.75 High High 460 High 5 High 
RB005054 275 Medium 62.5 High High 440 Low 5 High 
RB005055 275 Medium 50 Low High 450 Low 6 High 
RB005056 275 Medium 62 .5 High High 450 Low 6 High 
5.3.2 General Metoprolol Succinate JR Bead Processing 
Metoprolol Succinate followed the general processing procedure described 
above. During wet granulation, impeller blade speed and chopper speeds were fixed 
throughout water addition and kneading. A 0.6 mm stainless steel screen was used 
during extrusion to yield finer extrudates. An example of the fluid bed drying 
parameters for the spheronized moist pellets can be seen in Figure 45. The moisture 
content specification was set to not more than 2.5%, based on the initial moisture 
content of the active ingredient and the excipient to ensure an adequately dry 
product. 
5. 3. 3 Exploratory Metoprolol Succinate JR Bead Processing 
Initial exploratory batches were run based loosely on the processing 
parameters observed during the development of the Propranolol HCI IR beads. The 
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200 Hig_h 80 
180 H!_g_h 90 
190 Hig_h 95 
170 Low 85 
180 High 180 
140 Low 120 
150 Low 150 
160 Low 160 
ter for Met lol IR Beads E torv Batch 
-
Raw and Coded Process Parameters 
H20 Kneading 
Addition Kneading Time Spheronizer Spheronizer Spheronizer Spheronizer 
Coded Time__{_ mil!}_ Coded RPM _{_Av_g}_ RPM Coded Time _(_mil!}_ Time Coded 
Low I Hig!l 628 Low 7 H!_g_h 
Low 1 Hig_h 680 Low 5 Low 
Low 2 Hig!l 800 H!_g_h 4 Low 
Low 1 Hig_h 600 Low 2 Low 
Hig_h 0 Low 767 Low 6 Low 
Hig_h 0.66 Hig_h 800 H~ 7 H!_g_h 
H!_g_h 0.25 Low 800 Hig_h 5 Low 
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5.3.4 Sustained Release Coating and Curing Methods 
5. 3. 5 General Spray Coating Methods 
Drug loaded immediate release pellets produced in phase II were spray 
coated in the Mendel Fluid Bed® processor. For aqueous trials, the inlet temperature 
was set to 65°C, the product temperature was maintained between 35°C-45°C. 
Organic trials operated at an inlet temperature of 50°C, and maintained the product 
temperature between 32°C-42°C. The fan speed was adjusted during processing to 
maintain adequate fluidization. The Wurster column height was fixed at a setting of 
6, the spray nozzle had an internal bore size diameter of 0.8mm, the spray rate was 
between 2-5g/min with an atomizing air range between 0.2-1.2 bar and Tygon® 3350 
tubing used to deliver the coating material via an external peristaltic pump. The 
machine was adequately purged during organic solvent processing to prevent an 
explosion. 
5. 3. 6 Aquacoat ECD Trials- Propranolol HCl 
Immediate release beads were coated with an Aquacoat ECD aqueous 
dispersion. Dibutyl Sebecate, NF acted as a plasticizer, and Hydroxypropylmethyl 
Cellulose E6, was used as a pore former, both were added as fixed percentage of 
polymer weight throughout experimentation. Varying polymer concentrations were 
evaluated at 6 different levels from 4-15% polymer level. Screening studies will 
utilize subsampling to determine the effects of polymer levels within a batch. 
Subsamples and final samples were cured where appropriate. 
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5. 3. 7 Aquacoat ECD Solids Concentration Trials- Propranolol HCZ 
Immediate release Propranolol HCl beads were coated to the same polymer 
weight gain(% w/w) using two different concentrations of polymer in the coating 
suspension. The low concentration coating suspension formula had 40% less solids 
than the high concentration coating suspension. The coating suspensions were 
prepared and administered following the same procedures in the coating level trials. 
5.3.8 Organic Ethylcellulose Coating Trials 
Immediate release Propranolol HCl beads were coated to two different levels 
of polymer weight gain, but contained the same solids content. The polymer levels 
were significantly lower than the aqueous polymer levels applied. Curing was 
performed at various conditions and durations in the VWR® 9005 Stability Chamber. 
5.3.9 Aquacoat ECD Trials- Metoprolol Succinate 
Immediate release beads were coated with an Aquacoat ECD aqueous 
dispersion. Di butyl Sebecate, NF acted as a plasticizer, and was added as fixed 
percentage of polymer weight throughout experimentation. Varying polymer 
concentrations were evaluated from 3-30% polymer level. Screening studies utilized 
sub sampling to determine the effects of polymer levels within a batch. Subsamples 
and final samples were cured where appropriate. 
5. 3.10 Curing Trials Overview 
Uncured and cured material will be compared to understand the effects of 
curing. Non-humidified curing was performed in either the VWR® 1415 Vacuum 
oven (without pulling vacuum), or the Freas® Scientific 625 convection oven. While 
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both humidified and dry curing trials will be performed in a VWR® 9005 Stability 
Chamber. The baseline curing for all batches was performed in dry heat at 60°C for 
2 hours. Curing studies compared dry heat, humidification, and duration were 
performed to understand the effects on the sustained release beads. 
5.3.11 Methods-Sustained Release Bead Top Coating 
Cured sustained release beads were charged into the Mendel Fluid Bed 
(MFB-1) processor. Inlet temperature was set to 65°C, product temperature was 
maintained between 40-45°C, the fan frequency was adjusted during the coating 
process to sustain adequate fluidization, the coating suspension was sprayed at 
approximately 3g/min, through a nozzle with an inner bore diameter of 0.8mm, and 
Tygon 3350 tubing was used. After the top coating suspension was applied, the 
beads continued to fluidize for 5-15 minutes to allow the beads to dry. A wide range 
of top coating quantities was studied, from low (<3%) to high (>15%) to evaluate the 
cushioning and protective effects of the topcoat. 
5. 3.12 Tabletting Methods-Blending 
A 1: 1 ratio of excipient blend to active top coated beads were blended, with 
the exception of Lubritab® which was added at 3-8% tablet weight at the final stage 
of blending. A Patterson Kelley® V-Blender, equipped with a 4-qt shell, and a shell 
speed of 25 rpm was used for blending. All excipients except the Lubritab® were 
blended for 4 minutes, top coated Metoprolol succinate beads were then added and 
blended for 4 minutes, and finally Lubritab® was added and blended for 5 minutes. 
The final blend was tested for LOD to ensure an acceptable level of moisture in the 
tablet. 
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5. 3.13 Methods-Tabletting 
A Natoli® Type BB bilayer tablet press, with a 13/32" (.4062) diameter 
standard cup with Natoli® tooling was used: The tooling dimensions are: cup 
volume 0.0025 in3, cup area 0.1341 in2, perimeter 1.2761 in. , Upper tip size 0.4043 
in., lower tip size 0.4050 in., die size 0.4062. The metoprolol succinate blended 
with excipients was loaded directly into the feed frame and compressed on the tablet 
press by manually rotating the turret. The theoretical tablet fill weight was 
calculated and tablets prepared within 3-5% of the desired target were accepted for 
sampling. Pre compression was set low, resulting in 1-2kp hardness depending on 
the blend. Low hardness and high hardness samples were prepared by adjusting the 
compression force on the main compression cam, and analyzed by a DR. Schleuniger 
Pharmatron 6D hardness tester. Samples were tested during the beginning, middle, 
and end of the run to ensure that hardness was maintained within± 1 Kp. 
5.4 Analytical Methods 
5. 4.1 Dissolution and Concentration 
USP methodology described in Chapter 3 was used. 
5. 4. 2 Comparison of Dissolution Profiles 
100 
f 2 = 50 log -;:::===== 
D. 
L:CTi - Ri) 2 
l+-'-;...i ___ _ 
n 
Equation 6. f2 Equation 
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Equation 6 is the f2 equation, where Ti is the concentration of the sample at a 
time point, Ri concentration of the reference product at that time point, and n is the 
number of sample points. This equation is a tool to aid in comparing dissolution 
profiles for sustained release drug products. The comparison of the profiles is 
critical for supporting changes to products currently on the market (FDA 1997b ). An 
fi values greater than 50 suggest that the formulations are sufficiently similar (FDA 
1995). Additionally, this method is used during development to compare novel 
formulations against currently marketed products (Dias 2007). 
5.5 General Statistical Methodology 
Minitab and Microsoft Excel software was employed for the design and 
analysis of the experiments. Exploratory data was fit into appropriate general linear 
models to study the significance of their main effects. A Full factorial design was 
employed for phase II and while a box benhken design was used for phase III. The 
analysis of variance (ANOVA) and DOE will be used to determine main effects and 
interactions between independent and dependent factors. Dissolution profiles will be 
the primary metric by which sustained release bead and final product formulations 
and processing parameters will be evaluated. Each method, statistical, mathematical 
or graphical interpretation of dissolution profiles has drawbacks, (O'Hara, Dunne et 
al. 1998); therefore, appropriate methodology will be chosen on an individual basis. 
5. 5.1 Statistical Methods-Exploratory Batches 
Table 25 gives the coded trial parameters and the percentage of material 
yielded on each sieve size. The coded variables and the yields from each of the trials 
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were fitted into a general linear model and the ANOVA using the Tukey's method 
For complete results for the general linear model using the Tukey's method for all of 
the sieve sizes, see Appendix 2. The Tukey's method was used to compare multiple 
processes to simultaneously evaluate ifthe means are equal (NIST/SEMATECH 
2006b). The Tukey's method is useful for making comparisons across multiple 
factors and is an extension of the ANOVA method (Cobb 1998). The model's R2 
value indicates the fraction of the total variability in the responses that the model can 
account for (NIST /SEMA TECH 2006a); The adjusted R 2 value corrects the R2 for 
the sample size and for the number of terms in the model, with low values indicating 
a potential pooling error (Gardiner and Gettinby 1998). 
Tables 22 and 23 previously presented in the process methods section gives 
the specific and coded process parameters for Propranolol and Metoprolol, which 
were investigated during the exploratory batches to create the general linear model 
and represents unbalance nested retrospective design. This design was used because 
the trials were not a balanced or a crossed design, where each variable is evenly 
tested. The results for the full general linear model for the ANOVAs is presented in 
Appendices 2 and 4, the results section presents the reduced general linear models. 
Model reduction was performed in accordance with statistically valid methods. 
Variables were evaluated in the full model and removed in a step wise approach with 
careful consideration of the impacts on the R2 and adjusted R2 (Colton 2004). 
The main effects plots indicate the major changes in the response value. 
Evaluation of the slope is the critical parameter for the main effects plot; with a steep 
slope indicating a strong effect, and a near 0 slope indicating little effect (Gardiner 
138 
and Gettinby 1998). The plots do not indicate significance, but aid in visualizing 
which factors have the greatest impacts. 
5.6 Physical Characterization Methods 
5. 6.1 Particle Size Distribution Analysis 
U.S.A. Standard Test Sieves (Newark, Clifton, NJ), which meet ASTM E-11 
Specification were used to screen the material. Sieve sizes and their dimensional 
conversions used for both Metoprolol Succinate and Propranolol HCl are listed in 
Table 24. Deblinding of screens was performed as needed when sample particles 
size and shape resulted in screen blinding. 
Table 24 Sieve screen size conversion to microns and inches 
Sieve# Microns lnches 
14 1400 0.0555 
16 1180 0.0469 
18 1000 0.0394 
20 850 0.0331 
25 710 0.0278 
30 600 0.0234 
35 500 0.0197 
45 355 0.0139 
60 250 0.0098 
5.6.2 Loss on Drying (LOD) 
An Ohaus MB200 was used to determine the LOD of the immediate release 
beads. All samples were at least 5.0g, and the LOD was calculated as the percentage 
of weight lost after 10 minutes at 105°C. 
5.6.3 Sphericity 
The immediate release pellet sphericity was determined on a Nikon TE2000-
E inverted research microscope set to 4X magnification. The width and length were 
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calculated with the NIS-Elements AR software for at least 20 beads per sample and 
used to calculate the aspect ratio, see Figure 46. for a screenshot of the sphericity 
measurements. 
Figure 46 Screenshot of Sphericity Measurements 
::JJ- •• 
a 
The larger value of each bead was considered the length (!) and the shorter value was 
treated as the width (w), where: 
~ Sphericity (Aspect Ratio) 
w 
Equation 7. Aspect Ratio for Pellet Sphericity Measurements 
Early experimentation using 50 bead readings yielded only ~3.5% reduction in 
RSD and <0.05 difference between the calculated mean sphericity. Additionally the 
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small sample space on the microscope made large sample sizes infeasible, especially 
with larger sized beads. 5.6.4 Tablet Friability 
Tablet friability was performed on a Yank.el® Friabilator, in accordance with 
the USP <1216>, on the compressed multiparticulate tablets without a top coating. 
The sample weight taken was as close to 6.5g of whole tablets for each test, and run 
for 100 rotations. A maximum mean loss of 1.0% was considered acceptable. 
5.7 Exploratoryffraditional Results 
The traditional immediate release approach is presented in this section for 
Propranolol HCl and Metoprolol Succinate. The development of the final 
exploratory drug products is presented separately. Results from these studies will be 







Table 25 P lol IR Bead Particle Size Distrib · 
Coded Process Parameters % Retained Sieve# 
Spheron Spheroniz 
H20 H20 Kneading ization ation 
Amount Addition Time RPM Time 14 16 18 20 25 
Trial Coded Coded Coded Coded Coded J_l 40Q.!!_m _l J_l 18Q.!!_m _l J_lOOOl!_ml_ J_85Q.!!_m _l _{710j!_m _l 
91907 Low Low Low Hi.B_h Low 0 0 0.36 31.57 20.67 
92007 Low Low Low Hi.B_h Low 0 0 8.8 59.3 19.4 
RB005008 Medium H!g!i Low H!g!i Low 1.12 8.21 56.3 30.09 4.27 
RB005009 Hi.B_h H_!g!i Low Low Low 3.2 8.4 47 37.7 3.4 
RB005010 High H!g!i Low H!g!l Low 0.34 1.5 26.2 59.1 8.2 
RB005013 Hi.B_h Low Low Low Low 0.8 5.42 42.2 41.22 9.8 
RB005021 Medium Low Low Hig!l Hi.B_h 0.14 1.6 49.5 41.45 6.3 
RB005022 Hi.B_h Low Low Low Hi.B_h 13 .79 15.87 57.91 11.4 I 
RB005023 Medium Low Hi.B_h Low H!g!l 0.97 4.82 58.78 30.85 4.32 
RB005048 Medium Hig_h Low Hig_h Hi.B_h I 3.36 67.44 22.96 4.86 
RB005049 Medium Hig_h Hi.B_h Hig_h Hi.B_h 4.6 13 .5 60.79 17.48 3.37 
RB005054* Medium Hi.B_h H!g!l Low Hi.B_h 15.77 30.21 45.79 7.32 0.84 
RB005055* Medium Low Hi.B_h Low Hi.B_h 1.32 10.31 60.28 24.43 3.52 
RB005056* Medium Hig_h H!g!i Low H!g!i 0.66 7. 11 58.79 27.91 5.31 
* Represents 800g batches 
**The mean sphericity and RSD (%)was determined for the blended beads 
Sphericity 
Mean 
% Sphericity Std. Dev. Sphericity 







1.01 90.95 1.12 0.09 8.31 
0.02 69.31 1.15 0.19 16.28 
0.26 89.63 1.16 0.11 9.75 
0.38 90.4 I.I 0.12 10.96 
0.18 78.27 1.15 0.15 13.16 
0.07 53.11 
0.14 84.71 
0.23 86.7 1.23* 0.22 17.78* 
5. 8.1 Propranolol IR Statistical Results 
The ANOV A from the general linear model for the material retained on all of 
the sieve sizes and the overall target(%) yield are in Appendix 4. Due to its greatest 
importance for yield, only sieve size 18 results are presented in this section. The 
only factor that can be considered to be statistically significant from this data is the 
amount of water added during the wet granulation of the material. The R 2 value of 
88.74% and the adjusted R2 of78.59% is a good indicator of fit for the data. 
Appendix 2 presents the full general linear models for all of the sieve sizes used. 
Figure 47 is the mean effects plot which indicates that the medium level 
(275g) of water amount added yields the greatest amount of particles retained on 
sieve # 18. The high level of water yielded a lower amount of size # 18 beads, but 
was better than the low level of water. The other factors are not statistically 
significant, but the means are useful in supporting processing decisions. 
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Target RB005021 RB005022 RB005023 RB005048 RB005049 RB005055/56 
Lot# 
Figure 48 Propranolol IR Bead Yield vs. Mean Sphericity 
-, 
o % Retained on Sieve #18 
• % Retained on Sieve #20 
o Mean Sphericity 
Figure 48 compares the batches with regard to the amount (adjusted to a 1 % 
scale) versus the mean sphericity ratio. Note that not all batches were analyzed for 
sphericity; due to availability and undesirable characteristics (failed batches), which 
may give the appearance that, all mean sphericities are relatively uniform (1.1-1.23). 
Early batches did not produce spherical beads, but served to guide development to 
improve the shape. A "Target" column was placed on the left side, to indicate the 
theoretical targets for each value. Due to particle size growth anticipated in the 
sustained release coating phase a tailored particle size distribution of -65% retained 
on sieve size# 18 and-35% retained on sieve size #20, and a sphericity near 1.0 was 
set. The batches can be divided into separate phases throughout the development: 
Initial processing information, identifying critical processing parameters, 
confirmation/optimization of those parameters, doubled batch size to understand the 
impacts of batch size. 
5.8.2 Initial Processing Information 
The early batches 091907-RB005013 were essential to determining general 
processing parameters and their effects. Batch RB005008 had the best yield for 
sieve sizes #18, #20, and overall yield(%). The first consideration during 
development was to identify the appropriate amount of water during the high shear 
granulation. Kneading time and spheronization can both impact the particle sizes 
generated but the granulating liquid will dictate all of the downstream processes 
(Ghebre-Sellassie 1989) and should be identified and evaluated early on. The batch 
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used a medium amount of water (275g) and was selected as the model for the next 
developmental phase. 
5.8.3 Identifying the Critical Parameters 
Lots RB005021, RB005022, and RB005023, were the pivotal batches for the 
selection of the water level amount added during high shear granulation. Lots 
RB005021 and RB005023 both used medium (275g) amounts of water, while 
RB005022 used a high (290g) amount. The particle size distributions were relatively 
similar between the two lots with a medium amount of water, but the high water 
batch yielded an unacceptably high level of material retained on sieve #16, and an 
insufficient yield on sieve #20. Some of the process parameters were varied for each 
lot to explore their impacts, and RB005023 yielded the most promising results and 
guided the remainder of the development process. 
5.8.4 Confirmation/Optimization of Critical Parameters 
In order to optimize the yield of the process, RB005048 was modeled after 
RB005023 , but varied a number of the process parameters. The granulation water 
was added at a faster rate (50g/ml to 75g/ml), the kneading time was reduced, and 
the spheronization speed was increased slightly ( 450 to 460 rpm). These parameters 
increased the amount of surface water available (Gokhale, Sun et al. 2005) and may 
have resulted in greater particle size grow during spheronization due to greater 
adhesive forces in the formulation (O'Connor and Schwartz 1989). These parameters 
also yielded the best sphericity ratio and supported the decision to move to a larger 
batch size of 800g. Note: RB005049 was a failed batch that was attempted to 
optimize the process parameters. 
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5.8.5 Doubling the Batch Size 
The process parameters were then evaluated at twice the batch size to explore 
the impacts of the increased load. RB005054 was first prepared according to the 
parameters developed in RB005048, with minor adjustments; the water was added at 
a slower rate (75 to 62.5 g/min) and slightly slower spheronization speed (460 to 440 
rpm) in anticipation of the larger batch size. The batch yielded larger particles than 
had been anticipated, with unacceptable retention of sieve sizes # 14 and # 16. In 
response to the failed batch, the addition rate water was reduced (62.5 to 50 g/min), 
the spheronizer rpm was raised slightly ( 440 to 450 rpm) and the spheronization time 
was increased (5 to 6 min) to RB005055. This improved the yield to an acceptable 
level of 84. 7% within the desired target. Finally, RB005056 was run following the 
same parameters as the previous batch, RB005055, with the exception of an 
increased water addition rate back to the RB005054 level (50 to 62.5g/min) and 
yielded the best results of the three batches. The small changes between RB005054 
and RB005055 in process parameters may be responsible for a portion of the 
improvement, but an uncharacteristically erroneous batch cannot be ruled out. This 
incremental improvement approach was successful in generating basic process 
parameters and demonstrated reproducibility between the final two batches. 
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Figure 49 Propranolol IR Bead-Round (RB005055/56 Blend) 
Batches RB005055 and RB005056 were blended together and an example of 
a spherical bead is seen in Figure 49. The pellets are reasonably round, and the 
surface morphology contained smoothed bumps and appears consistent with 
acceptable bead formations (Mehta 1989). This blend was subsequently used for 





5.9 Results Propranolol HCI SR 
Table 26 Propranolol Aqueous SR Results Organized by Coating Level 
% Propranolol Released Over Time (hrs) 
Coating Coating 
Level Cone. Curing 
Batch# (Coded) (Coded) Method 1.5 3.5 5.5 7.5 10 22 24 F2 Value 
2hrs@60c 
RB005053 2 Low IV acuum OvenJ 14 35.5 50.5 61.1 69.9 87.8 87.7 96.3 
RB005053 2hrs@60c 
4 Low IV acuum OvenJ 16.5 33.6 45 53.7 62.3 77.9 80 58.2 
2hrs@60c 
RB005026 5 High IV acuum Oven 10.1 26.4 41.1 51.9 63.9 82.4 82.4 56.3 
Table 26 is an overview of the Propranolol HCl sustained release coatings which displayed an acceptable f2 values over 50. 
The coating levels, concentration, curing methods, and dissolution data for all of the batches is found in Appendix 6. An fi value of 
96.3 is nearly point-to-point, and indicates that the coded coating level 2 and low solids content for the coating suspension yield the 
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Figure 50 Comparison of High and Low Polymeric Coating Suspension Solids 
Figure 50 compares the differences in the dissolution profiles of beads coated 
with a low and high polymeric concentrated formula applied to the same final 
percentage (% w/w). The dissolution profile slows considerably when the 
concentration of the solids within the coating suspension is decreased. The 
decreased solids in the coating suspension results in a greater amount of water being 
applied the system, which increases the humidity in the chamber and will reduce the 
product temperature if the inlet temperature and fan frequency is not adjusted. The 
benefits of increased processing time and humidity will result in a longer mean 
residence time for the polymer to adhere to the bead surface. A lower polymeric 
solid's concentration will result in a longer overall coating period to reach the 
desired polymer concentration, which must be balanced to ensure a feasibly cost 
effective process. For example: To apply a 10% (w/w) polymer coating to a l .OKg 
batch of IR beads at a spray rate of 5 g/min, the required processing time for a coating 
suspension with a polymeric concentration of 10%, would be 20 min. If the coating 
suspension were diluted to 5% polymer, the processing time would double to 40 
minutes. While the spray rate increases with the batch size, the doubling of the 






5. 9.1 Results- Effects of Curing Oven 
Vacuum Oven vs. Humidity Chamber Curing 2hrs @60c 
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Figure 51 Curing Propranolol Aqueous SR Beads in a Vacuum Oven vs. Humidity Chamber 
~ RB005053 Vacuum Oven 
RB005061 HumidityChamber 
----- Mean lnderal 160mg 
Figure 51 compares two batches where the same polymer content was applied 
but cured with different ovens. The VWR 1415 vacuum oven was compared against 
curing in the VWR 9005 humidity chamber. A marked difference can be seen when 
comparing the two sets of data. Additional studies, not shown here, depict that 
curing in the Freas convection oven appears to slow down the release of the drug 
overall, while curing in the VWR 9005 stability chamber shows a sharp increase in 
drug release at the first sampling point. All of the chambers were set to 60°C and the 
materials were cured for 2 hours. Interestingly, the VWR 9005 chamber and the 
VWR 1415 vacuum oven are both closed systems, which may prevent the escape of 
moisture from the system. The VWR 9005 chamber operated at ambient humidity; 
with 18-25% RH observed during curing and is dependent on the humidity of the 
day. The VWR 1415 vacuum oven visibly condensed the moisture from the coated 
beads on the front door which had a glass viewing plate, the system humidity was 
measured to be <10% RH when curing at 60°C. The Freas 625 convection oven is 
an open system, which sweeps across the heater in a single pass of air before exiting 
the system, this system operates at a lower relative humidity (5-8% RH) because it 
can effectively wick away moisture. 
When moisture remains in the polymeric coating the pores created by the 
HPMC E6 remain hydrated and act to channel the drug through the sustained release 
coating (Bodmeier, Guo et al. 1997). An adequate amount of moisture is necessary 
to maintain polymer flexibility and prevent cracking, but saturating pores with 
moisture must be avoided. (Gunder, Lippold et al. 1995) explored an Aquacoat, 
DBS, and HPMC coating system for a water-soluble compound and determined that 
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in an acidic medium (pH 1.2) the HPMC pores open and will irreversibly close 
within 1-2hrs. Subsequently, a change to the alkaline media will not reopen the 
pores, and diffusion proceeds slowly. Additionally, HPMC has been shown to 
potentially cause flocculation when combined with ethylcellulose and result in an 
unstable dosage form (Wong and Bodmeier 1996). 
Further complicating the balance of moisture in the system is the need to pass 
long term accelerated stability studies. ICH guidelines dictate that a product must 
not have appreciable degradation (>5%) in their dissolution profile throughout the 
stability study. The two acceptable accelerated conditions are 30°C and 60% (RH) 
for 6 months, or 40°C and 75% (RH) for three months (ICH 2003). Additionally, 
room temperature must be maintained as a control to confirm normal storage 
conditions seen by the patients. Preliminary stability data of 10 days at 40c/75% RH 
confirm that even the vacuum cured beads show an unacceptably sharp increase in 
drug release. Aqueous ethylcellulose systems with HPMC based pore formers have 
shown increased drug release over time due to physical changes in the coating layer 
such as hydrolysis and changes in coalescence, as well as drug migration into the 
coatings (Siepmann, Siepmann et al. 2005). This instability resulted in the 





Table 27 P lol 0 . SR Coating: A ccep table Dissolution R1 
Pr~anolol HCI Released l_o/~ 
Coating 
Level 
Batch # Coded Curin_g_ Method l.S 3.S S.S 7.S JO 22 24 F2 Value 
RBOOS072 I 6 hrs_@ SOC Chamber 2 9.0 3S.4 S2.9 64.3 7S.O 92.2 92.7 72.0 
RBOOS064 2 6hrs _@soc Chamber 2 7.8 29.S 4S . l S6.9 70.J 92.7 9S.3 6S.S 
RBOOS064 2 2 hrs @ SOC Freas 6.9 28 .8 46.7 60.4 72.0 94.3 9S .8 64.8 
RBOOS064 2 18 hrs @ SOC Freas 7.8 30.4 44.8 SS.6 6S.4 83 . 1 8S.6 64.3 
RBOOS064 2 6 hrs_@_ 60c Freas I 1.0 37.4 S4.5 67.S 79.0 97.1 99.9 61.S 
RBOOS064 2 24 hrs @ SOC Freas 8.3 36.2 S4.8 67.S 80. l 99.8 100.3 S7.7 
RBOOS072 I 2 hrs_@ 4SC Chamber 2 7.6 36.5 SS.I 68 .7 79.9 99.9 103.7 S6.8 
RBOOS064 2 24hrs @ SOc Chamber 2 16.8 41.2 S8 .0 69.5 82.2 100.S 102.6 S4.2 
RBOOS072 I 18 hrs @ 4SC Chamber 2 7.9 39.5 S7.7 69.9 82.J 100.4 JOI.I S3 .8 
RBOOS072 I 24 hrs @4SC Chamber 2 8.1 38.J S7.6 70.4 83.9 100.6 103.0 S2.9 
RBOOS072 I 24 hrs_@ SOC Freas 9.7 37.6 S7.2 72.1 84.4 JOO. I JOI.I S2.8 
RBOOS064 2 18 hrs_@ 60C Freas 12.3 46.4 64.0 73.8 83.8 93 .2 94.3 S0.6 
RBOOS064 I Uncured S.6 22.7 37.3 49.2 61.S 83 .6 8S.3 S0.4 
Table 27 is an overview of all of the formulations which could be considered similar to the reference dissolution profile, 
where f2 is greater than 50. The complete experimental results for the organic sustained release coating of Propranolol HCl are in 
Appendix 7. 
The organic ethylcellulose coatings are not as markedly adversely affected by curing in the humidity chamber as the 
aqueous dispersions. This would indicate a more uniform coating of the sustained release layer, able to seal the particle and protect 




1997). Batch RB005072, with a low coating level and a curing condition of 6 hours @ 50°C was selected as the final formulation 
for long-term stability studies, (not included in this study)S.9.2 Immediate Release Beads- Metoprolol Succinate Exploratory 
Table 28 E t Batches-P p t d Results 0 
- -
Processing Parameters Yields Sphericity 
Final 
Trial H20Amount H20 Addition Kneading Time Spheronizer Spheronizer Time Prod. LOD Target% Comments Observed Mean Standard (g) g/min batch (min) RPM (Avg)** (min) Temp (%) Shape Sphericity Deviation 
oc 
RB005077* 153 50 2 680/550 2.5 45.2 1.2 63.36 300g Reshaped/ Rods/dumbbells 1.36 0.28 Re~heronized 
RB005081 200 80 I 300/628 I I 7 51.6 1.2 91.77 Reextruded/ More dumbbells 1.31 0.28 Re~heronized 
RB005107 More 
180 90 l 680 5 51.3 1.3 86.47 Straight run Rods/Some 1.35 0.29 
dumbbells 
RB005108 190 95 2 800 4 51.6 1.3 53.53 Straight run Too big 1.39 0.30 
RB005109 170 85 l 600 2 51.l l 94.26 Straight run Rods formed 1.76 0.40 
Fast addition- Agglomerated 
RB005119 180 180 0 5001767 016 50.5 1.9 73.81 Reextruded/ Then l.18 0.23 Respheronized then good Round/few 
sh~ dumbbells 
Fast Addition-Straight More RB005120 140 120 40 sec 800 7 50.2 1.6 82.7 Dumbbells than l.52 0.28 Batch-Dry side Rods 
RB005122 150 150 15 Sec 800 5 50 l.4 90.4 Fast Addition- Straight Dumbbell l.58 0.33 Batch shaped 
RB005123 160 160 30 sec 800 9 48.6 1.7 85.78 Fast Addition- Straight Dumbbells 1.32 0.20 Batch 
*RB005077 was not included in the general linear model because the batch size was only 300g. 
**Average spheronization speed does not include the standardized first minute, and is a time weighted average. If two values are present a respheronization 
process was necessary and reflects the original and respheronized values respectively. 
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Figure 52 Metoprolol Succinate IR Beads Exploratory Batch Overview of Mean Sphericity vs. Yield(%). 
o Mean Sphericity Ratio 
•Yield(%) 
To adequately assess the effects of the processing parameters, the material generated 
within the target particle size distribution and the mean sphericity ratio must be well 
understood. Figure 52. depicts both the mean sphericity and the target yield 
(adjusted to a 1 % Scale for easier viewing) of the metoprolol succinate IR beads. It 
is the goal for the two values to be as close to 1 as possible, and can be considered 
inversely related for the interpretation of this graph. The processing parameters 
found in Table 26. must be considered when evaluating the output data. 
The best target yield was produced for lot RB005109, with greater than 94% 
of the particles within the desired target particle size distribution. Unfortunately, this 
batch also yielded the worst mean sphericity ratio with the formation of rods. The 
formation of the rods may have caused a skewed distribution to appear, specifically 
with large narrow particles retained on #30 instead of on #25, which was more 
commonly seen in the other batches. 
The best sphericity ratio was found in RB005119, which had initially formed 
large agglomerates after the completed process and required a re-extrusion and re-
spheronization to achieve a desirable shape. This suggests that the additional 
processing of extrusion and spheronization facilitated the distribution and removal of 
water from the system. The water level, l 80g in this batch was in an intermediate 
range of 140-200g as compared to the other batches but was added extremely rapidly 
(180 g/min) and did not undergo kneading. Excess water during extrusion can over 
saturate the material and make the extrudates difficult to process in the spheronizer. 
Conversely, insufficient water can create a high viscous mass that is difficult to cut 
and can result in machine blockage (Keleb, Vermeire et al. 2004b ). These process 
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parameters imply that the water added remained as surface water and due to the lack 
of kneading did not get fully incorporated into the wetted mass. The primary 
extrusion and spheronization contained a large amount of surface water, which 
resulted in the initial agglomeration of the materials. The initial processing also 
acted to remove a portion of the water from the damp mass. While some water was 
removed during extrusion via heat transfer and friction, water migration in the 
formulation was most likely prevalent yielding disproportionately wet extrudates 
similarly to research conducted by (Vervaet, Baert et al. 1995). 
The wet extrudates were then spheronized and visible condensation was 
formed on the cover during processing due to centrifugal force driving the surface 
liquid off of the beads, and squeezing out the internal water to the bead surface 
(O'Connor and Schwartz 1989). The spheronizer's purge air supplies compressed air 
to the system to facilitate the lift of the wet material during processing, which 
subsequently dries the formulation further. After the initial process was completed 
the re-extrusion served to redistribute the remaining water into the formulation. The 
re-spheronization cycle was able to shape the extrudates into a desirable shape, 
because they contained sufficient water incorporated into the core material and 
surface water. As the extrudates undergo the spheronization cycle, adequate water 
must be present at the surface to allow adhesion of smaller particles to reduce the 
formation of fine particles, but must be balanced with internal water to allow 
uniform extrusion and particle size growth (Gokhale, Sun et al. 2005). Reprocessing 
steps should be considered as a last resort to create a viable formulation; only after 
all other approaches have been exhausted 
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5. 9. 3 Metoprolol Succinate IR Exploratory Statistical Results 
5. 9. 4 Particle Size Distribution 
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Fi gure 53 Main Effects Plot for the Reduced Model of Particle Size Target % Yield 
r Metoprolol Succinate IR Exploratory fo 
The reduced model ANOV A found that the amount of water used during 
gr anulation and the speed of the spheronizer (rpm's) are both statistically significant. 
160 
While spheronization time was found not to be statistically significant, it remains in 
the reduced model in order to follow the proper reduction approach. Figure 53. 
shows that lower spheronization speed and lower water amount had greater yields 
within the target. Lower amount of water will tend to yield smaller particles, while 
slower spheronization will prevent excessive particle agglomeration. The particle 
size distribution within the target% yield is important but must be considered with 
the sphericity data, prior to making any processing decisions. 
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While spheronization time was found not to be statistically significant, it remains in 
the reduced model in order to follow the proper reduction approach. Figure 53. 
shows that lower spheronization speed and lower water amount had greater yields 
within the target. Lower amount of water will tend to yield smaller particles, while 
slower spheronization will prevent excessive particle agglomeration. The particle 
size distribution within the target% yield is important but must be considered with 
the sphericity data, prior to making any processing decisions. 
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5. 9. 5 Metoprolol Succinate IR Exploratory Statistical Results- Sphericity 
Table 30 Analysis of Variance for Mean Sphericity, Using Adjusted SS for Tests 
r Source DF s~ss Adj SS Adj MS F 
H20 Coded 1 0.112813 0.188576 0.188576 47.32 
Kneading 1 0.057604 0.072630 0.072630 18.22 
Time Coded 
Spheronizer 1 0.050030 0.050030 0.050030 12.55 
Time Coded 
Error 4 0.004975 0.004975 0.001244 
Total 7 0.025688 
S == 0.0631302 R-Sq = 93.26% R-Sq (adj)= 88.20% 
1.5 
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Figure 54 Main Effects Plot for Mean Sphericity for Metoprolol Succinate IR 
Exploratory Batches 
162 
The amount of water added, the kneading time, and the spheronization time 
were all found to be significant factors for the mean sphericity of the beads. These 
findings are in agreement with (Baert, Vermeersch et al. 1993) which found that the 
amount of granulation water added, the spheronization speed, and the spheronization 
time are the most important factors that determine pellet sphericity. Figure 54. 
shows that higher levels of water, lower kneading times, and higher spheronization 
time all contribute to the improvement (closer to 1.0 is the goal) of the mean 
sphericity. The sphericity is improved by having more available surface water, 
which occurs due to the higher level of water added and the diminished kneading 
time, and longer spheronization time which increases the bead contact with the 
spheronizer walls and friction plate to improve the roundness. These conditions may 
negatively effect the particle size distribution and yield larger particles. 
T bl 31 An l . f V . £Sh . . SdD a e a ys1s o ariance or ~ enc1ty t . ev., U. Ad. smg JUSte d SS£ T or es ts 
Source DF s~ss Adj SS Adj MS F p 
H20 Coded 1 0.001513 0.007811 0.007811 6.28 0.066 
Kneading 1 0.008229 0.010971 0.010971 8.82 0.041 
Time Coded 
Spheronizer 1 0.010971 0.010971 0.010971 8.82 0.041 
Time Coded 
Error 4 0.004975 0.004975 0.001244 
Total 7 0.025688 
S = 0.0352668 R-Sq = 80.63% R-Sq (adj)= 66.11 % 
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Main Effects Plot (data means) for Std. Dev. Sphericity 















Figure 55 Main Effects Plot for Sphericity Standard Deviation for Metoprolol 
Succinate IR Exploratory Batches 
The ANOV A for the sphericity standard deviation determined kneading time 
and spheronization time to be statistically significant. Low kneading time and high 
spheronization time both decrease the standard deviation of the bead sphericity, 
while the amount of water does not play a significant role. Higher time in the 
spheronizer allows the material more time to contact the surfaces for rounding and 
approach or reach their maximal roundness (Baert, Vermeersch et al. 1993). Lower 
kneading times will disperse less water through the mass and leave more available 
surface water during extrusion and spheronization. 
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5.9.6 Results-Metoprolol Succinate Exploratory Batches-New Approach 
Based on the raw data and the statistical interpretations, the greatest 
challenge is generating a spherical bead, while maintaining adequately sized 
particles. Table 32 is an overview of the significant variables and the levels, which 
yield the desired results. 
Tabl 32 0 e verv1ew o fS' 'fi tCddV 'bl fr E 1gru 1can o e aria es om t B t h x_I>Jora ory a c es 
H20 
H20 Addition Kneading Spheronization Spheronization 
Re5.[l_onse Amount Rate Time S_E_eed Time 
% Ta!:_g_et Yield Low NS NS Low NS 
Mean S_E_heric~ H!g_h NS Low NS H!_g_h 
Std. Dev. S_E_heric~ NS NS Low NS H!_g_h 
It is apparent from the table that the water amount necessary is not in 
agreement. Interestingly, the water addition rate was not found to be significant for 
any of the responses. Research has indicated that slow addition of the granulating 
water coupled with kneading would incorporate the granulating liquid into the 
system and improve the sphericity, the negative impacts of this approach was that the 
particle size distribution would skew to the larger size (Devay, Mayer et al. 2006). 
Conversely, rapid addition of water resulted in smaller particles due to the process of 
faster agglomeration but may yield poorly shaped pellets (Mehta, Singh Rekhi et al. 
2005). 
To achieve the correct balance of internal and surface water in the 
formulation, a new approach was implemented during the high shear granulation 
stage. An initial slow water addition phase was performed, followed by a rapid 
addition of water. Previous research had used this technique of slow addition 
(50g/min) followed by faster addition (lOOg/min) to successfully create dense beads 
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(Gao, Jain et al. 2002). This method theoretically allowed more time for initial 
agglomeration by forming liquid bridges, and supports particle growth during 
compaction and cutting to promote bead hardening and densification. The remaining 
processes followed the results seen in Table 32, low kneading time, low 
spheronization speed, and high spheronization time. The new process parameters 





Table 33 Processing Parameters and Results for 2 Phase Water Addition for Metoprolol Succinate IR Beads 
Processif!g_ Para meters Yields ~heric_i_!y_ 
Trial Final 
H20 Prod. 
Amount H20 Addition Kneading Spheronizer Spheronizer Temp LOD Target Observed Mean 
(g) G/min batch Time J..mil!lJ RPMJ_Avg}_ Time J_min}_ J_o/tl_ •1. Sha_l)_e S_l)_herici!Y_ Std Dev 
80 for 1.5 min, 
RB005124 170 200 for 15 sec 15 sec 772 8 48.2 1.6 92.41 ~heres 1.2 0.15 
160 for 1.5 
min, 
RB005128 340 400 for 15 sec . 15 sec 772 8 50 2.3 86. 15 ~heres 1.16 0.15 





The two-phase water addition coupled with the process parameters derived 
via statistical methodology successfully yielded a sufficiently round bead within the 
desired particle size distribution. The water amount and addition rate were doubled 
for the 800g batches, while the remaining process parameters remained the same. 
The larger batch yielded a slightly more spherical bead but lost some of the target % 
yield. The improved sphericity may be attributed to the increased load in the 
spheronizer, which results in more inter particle interactions, and a greater mass 
cascading onto the friction plate at the end of the rope like cycle to improve shaping. 
Research has shown that load can have both negative and positive impacts on shape 
and particle size distribution (V ervaet, Baert et al. 1995). The water added during 
granulation may have been distributed more evenly when kneading due to more 
advantageous surface to volume ratios than smaller loads. Additionally, variability 
within the process is expected, and doubling the batch size may not have identical 
yields if linear parameters are employed. 
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Exploratory Bead Polymer Levels 
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Figure 56 Exploratory Metoprolol Succinate SR Beads 
Figure 56 is a graph depicting early exploratory coating levels; the medium 
and high level of polymer bracket the brand profile. This batch was performed to 
give a minimum starting point for bead coating experiments. The range of polymer 
concentration's used is approximately half the range that were ultimately used. The 
development strategy must account for a level of bead crushing, which will be highly 
dependent on the amount of protection provided by the excipient granule blends and 
top coating during tabletting (Abbaspour, Sadeghi et al. 2005). 
To hedge against damage to the beads during compression, Figure 57 is a 
coating trial, which examined a range of polymer levels two to three times of that 
seen in Figure 56. A significant decrease in drug release is present from the previous 
data present. The early points of 1 and 4 hour shows that the rate of initial hydration 
is similar for all of the beads. A divergence in the profiles from the lowest and 
highest profiles appears at 8 hours due to slower diffusion rates associated with the 
thicker polymer levels. Polymer levels 2 and 3 are similar and can be attributed to 
only a 2% coating thickness difference, which may not significantly impact the 
coating thickness for the standard curing cycle but may have an impact when cured 
under extreme conditions. Therefore, polymer levels 2 through 4 served as the 
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Figure 57 Exploratory Metoprolol Succinate SR Beads for Tabletting Studies 
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5.9. 7 Results- Top Coating 
Top coating with Opadry II suspension was found to have no negative or 
positive effects on the sustained release beads, data not shown. Overall, top coating 
at any level provided an improvement to the sustained release profile of any of the 
experimental tablets. Top coating the beads up to 15% w/w was studied, and the 
particle size distributions were found to grow too large and negatively affect the 
product yield. A final top coating level less than 10% was selected and fixed based 
on the exploratory studies for the future DOE. Figure 58 and 59 show cross sections 
of the finalized sustained release coating with a top coating. The topcoat can be seen 
to be significantly thinner than the sustained release, as it was applied at 
approximately 25% of the sustained release coating level. In addition to providing 
added protection, the topcoat imparts an aesthetic white finish to the beads. 
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Figure 58 Metoprolol Succinate SR Low Polymer Coating Level with Topcoat 






5.10 Results-Exploratory Tabletting Study 
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Figure 60 Overview of Dissolution Profiles for the Metoprolol Succinate Exploratory Tab letting Study 
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Figure 60 is an overview of the dissolution data for the exploratory tab letting 
study to screen three potential excipient blends. The granulated excipient blend 
provided very little protection during compression. This failure may be a result of 
the granules being too dense and/or brittle. Granules can lose some of the beneficial 
compactibility properties that they exhibit as raw materials after undergoing the 
granulation and drying processes (Abbaspour, Sadeghi et al. 2005). Particle size 
control of the granules was limited by the available mesh screens for the 
communitor, which ultimately discouraged further evaluation of wet granulation 
techniques for excipient granules. 
The dry blend contained MCC 102, crospovidone, pregelatinized starch 1500, 
and lactose monohydrate. On initial inspection the high hardness tablets appear to 
exhibit slow drug release, but at the four-hour time point the release is consistent 
with unprotected beads experiencing crushing. The initial time point demonstrated 
poor tablet disintegration, and artificially prevented drug release by limiting the 
contact between the drug beads and the dissolution media (Moreton 2008). The poor 
disintegration may be caused by the grade of Crospovidone, and the binding ability 
of the other excipients. 
The second dry blend used A vicel 102 and 200 in a 1 : 1 ratio, and 
polyplasdone XL-10 (30-50µm) to improve the disintegration of the tablets. This 
blend provided the best protection out of the three-excipient options. The addition of 
A vicel 200 raised the mean particle size of the excipient granulation and offered 
greater protection. This blend was chosen as the final formulation to examine during 
the design of experiment studies. 
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Chapter 6 Design Space 
6.0 Introduction 
Current research for granulation utilizing PAT and QbD approaches 
incorporate both on line monitoring and statistical design methodologies to 
characterize their formulations to support a design space. On line methodologies 
focus on monitoring the power consumed, torque produced by the blades, and near 
infrared spectroscopy for moisture content. Much of the on line monitoring is 
focused on parameters which are related to the flow properties and drug distribution, 
which have not yet been fully investigated in the literature (Cantor, Augsburger et al. 
2008). 
It is important to consider that not all recent research correlates these 
techniques to feasible end points. One example, utilized formulation and simulation 
to test the power consumption monitoring method for high shear granulation 
(Leuenberger, Puchkov et al. 2008). The author's found that a true granule "end 
point" during processing could not be derived and that a tailored individualized 
formulation approach was necessary. QbD is a general approach with many tools 
that can aid process understanding, an exploration of some of those approaches are 
described in this section. 
6.1 Statistical Methods-DOE Batches 
The 23 factorial design were analyzed for the estimated effects and 
coefficients, and an ANOV A of main effects and 2-way interactions to determine 
significant factors and interactions. All of the full model outputs can be seen in the 
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Appendices. Proper model reduction techniques were followed where necessary. 
Main effects and interaction plots are given for significant factors. Both main effects 
and Interaction plots with intersecting lines are indicative of factor interactions for 
that response, but do not indicate statistical significance. 
6.1. l Full Factorial Design for Metoprolol Succinate IR Bead Processing 
The experimental process parameters can be seen for the full factorial design 
for Metoprolol Succinate immediate release bead production in Table 34. The 
factors and levels were chosen based on the findings from the exploratory batches. 
The spheronizer was run at 600 rpm for one minute, and checked for excessive 
balling for all experiments. The spheronizer was then set to 775rpm, run for two 
minutes, and checked again. Then the spheronizer was run for the remaining time, 
either three minutes (low) or 6 minutes (high). 
Table 34. Ove · rv1ew o f th F ll F t . 1 M t 1 1 S . t IR B d DOE e u ac ona e o_Ero o uccma e ea 
Randomized H20 Amount Kneading Spheronization 
Order (g) TimeJ_Sec:l_ Time JM_in_l 
I 175 30 5 
2 175 30 8 
3 165 15 5 
4 165 30 5 
5 165 30 8 
6 175 15 5 
7 175 15 8 
8 165 15 8 
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6.1 .2 Box-Behnken Designs 
The ICH Q8 annex recommends the use of response surface techniques to 
visualize factor effects and interactions to support the design space (ICH 2007). 
Two prominent methods of response surface techniques are the central composite 
and Box-Behnken designs. The Box-Behnken approach has the advantage of 
requiring fewer total runs because it only requires three levels for each factor instead 
of five, while remaining a balanced incomplete block design (Wu and Hamada 
2000). The surface plots and contour plots that can be generated by this method are 
useful tools to aid in the visualization of the design space. The Box-Behnken 
designs have been used in pharmaceutical research such as (Zidan, Sarnmour et al. 
2007) and (Shah, Zidan et al. 2007) to characterize critical factors for a novel 
delivery system. 
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6.1.3. Statistical Methods- Metoprolol Succinate SR Box Behnken Design 
T able 35. Box Bnhk 3F e en- /3 L 1 D . fi SR M actor eve es1gn or 1 1 s eto_Qro o uccmate 
Polymer 
Coating Curing 
Std Order Run Order PtlJ'I>_e Level Condition Curing_ Time 
8 I 2 I 0 I 
IO 2 2 0 I -I 
2 3 2 1 -I 0 
3 4 2 -1 I 0 
13 5 0 0 0 0 
15 6 0 0 0 0 
I 7 2 -I - I 0 
9 8 2 0 -1 -I 
I I 9 2 0 -I I 
I2 IO 2 0 I I 
5 I I 2 -I 0 -I 
4 I2 2 I I 0 
14 13 0 0 0 0 
7 14 2 -1 0 1 
6 15 2 1 0 -1 
The coded variables in Table 35 represent the following: -1 is the low level, 
0 is the middle point, and 1 is the high level. A standard order (stdorder) is 
generated in accordance with the Box Behnken design; Minitab then randomizes the 
order in the Run Order column. The point type (PtType) is coded as 0 to represent 
the center point, and a 2 represents the face of the cube. The polymer coating level 
incrementally rises from the low level by 2% w/w, the exact coating levels cannot be 
described due to formulation confidentiality. The range of curing conditions was 
60°C, 60°C/50% RH, and 60°C/75% RH. The curing time range was 2 hours, 4 
hours, and 8 hours. 
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6.1. 4 Statistical Methods- Metoprolol Succinate Tablet 
T 6M able 3 . l l s etO_E_rO 0 uccmate . l T bl t 2
3 F M lf u ~art1cu ate a e . l D . actona es1gn 
Blend (MCC 
Std Order Run Order SR Po~mer level 200:102) Hardness (K_E) 
5 1 -1 I: 1 5 
6 2 1 I: 1 5 
4 3 1 3:7 2 
I 4 -1 1:1 2 
3 5 -1 3:7 2 
8 6 l 3:7 5 
2 7 1 l: l 2 
7 8 -1 3:7 5 
The standard order (Std Order) of the 23 factorial design order is given in the 
first column of Table 36, with the Minitab randomized run order in the second 
column. The coded sustained release polymer level differs by 3%, with the low 
value equivalent to the high coded value developed during phase III. The high value 
for tabletting represents the need to explore additional coating to prevent rapid 
release caused by crushing during tabletting. Both levels of coated beads were top 
coated to the same percentage weight gain with the Opadry II topcoat suspension. 
The dry blend formulation #3 was selected for the tabletting study. The ratio factor 
represents the amount of MCC 200 to MCC 102 within the excipient blend, while 
keeping all other inactive ingredient quantities constant. The tablet fill weights were 
adjusted to a concentration of 95mg Metoprolol Succinate to prevent biasing due to 
different polymer concentration application. The hardness was manually adjusted 
and determined by a DR. Schleuniger Pharmatron 6D hardness tester, prior to 
obtaining samples. 
180 
6.2 Metoprolol Succinate IR Bead DOE-Results 
Table 37. Overview of the Process Parameters and Results 
Process Parameters SJ!._herici!!_ 
H20 
Amount Kneading Spheronization Randomized Mean Std. Dev. Sphericity 
Trial ill Time_iSec) Time J.Mi'!l Order Tai-get% LOD% Observed ShaJ!._e S..e_herici~ S..e_herici~ RSD_{.0/~ 
RB005148 175 30 5 I 90.63 1.6 Dumbbells/ 1.26 17.11 Spheres 0.22 
00 
RB005149 Mostly Spherical*/ 175 30 8 2 90.92 1.6 Few Dumbbells l.34 0.19 14.2 
....... 
RB014003 165 15 5 3 90.74 1.8 Rods/ l.39 17.3 Dumbbells 0.24 
Dumbbells> 
RB014004 165 30 5 4 92.53 l.3 Rods> 1.45 14.31 
Spheres 0.21 
RB014005 165 30 8 5 91.22 1.4 Dumbbells/ l.35 17.43 Rods 0.24 
RB005150 175 15 5 6 79.83 1.5 Rounder Rods/Spheres 1.28 0.27 21.42 
RB00515 I 175 15 8 7 89.99 1.8 Mostly Spherical 1.23 0.15 12.55 
RB014006 165 15 8 8 91.37 1.5 Dumbbells/ 1.26 14.14 Spheres 0. 18 
6.2.l Statistical Results for Metoprolol Succinate DOE IR Bead Formulations 
Table 37 is an overview of the process parameters and results of the 
Metoprolol Succinate immediate release bead formulations. The table characterizes 
the visual observations and it implies that differences can be seen between rods and 
spheres to make processing decisions. Appendix 5. contains all of the full statistical 
models for the sieve sizes collected and the target yield (% ), with none of the factors 
or interactions showing statistical significance. This would imply that the particle 
size yields are not different enough that the processing parameters at these levels to 
have a significant impact. Model reduction techniques did not result in significant 
factors or improvement of the R2 values. 
It is not uncommon to find insignificant correlations between chosen 
variables and physical parameters. A 23 factorial design examining comparing high 
shear granulation impeller speed and binder flow was not statistically significant for 
three responses: Time parameter of dissolution, shape parameter of dissolution, and 
mean particle size diameter (Devay, Mayer et al. 2006). Interestingly, the mean 
particle size diameter for the responses in the study ranged from ~513-770 µm, 
which would result in retention on sieves #35 and #25 respectively. While 
statistically insignificant, the acceptance criteria set commercially may be based on 
the desired mean size retained and could imply a practically significant difference. 
Figures 61 and 62 are examples of dumbbells and rods, respectively, 
generated during the DOE. These undesirable shapes are visible with the naked eye 
or can be evaluated with a standard optical microscope. It is important to consider 
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that even in acceptable batches there may be limited formation of dumbbells and/or 
rods, and screening may not be sufficient to eliminate. Therefore it is critical to 
understand the overall shape of the batch to anticipate future problems, which may 
arise in down stream processes. 
Figure 61. Metoprolol IR Bead- Dumbbells (RB014005) 
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Figure 62. Metoprolol IR Beads-Rods (RB014005) 
Table 38. Estimated Effects and Coefficients for Mean Sphericity (Coded Units) 
M l l S . t IR B d DOE etO...£_rO 0 uccma e ea 
Term Effect Coef SE Coef T p 
Constant 1.32000 0.01031 128.06 0.000 
Water Level -0.08500 -0.04250 0.01031 -4.12 0.054 
Kneading 0.06000 0.03000 0.01031 2.91 0.101 
Time 
Spheronization -0.05000 -0.02500 0.01031 -2.43 0.136 
Time 
Water Level * 0.06500 0.03250 0.01031 3.15 0.088 
Spheronization 
Time 




S = 0.0291548 R-Sq = 95.75% R-Sq (adj)= 85.12% 
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Table 39. Analysis of Variance for Mean Sphericity (Coded Units) Metoprolol 
Succinate IR Bead DOE 
Source DF Se_g_ SS AdlSS Adj MS F p 
Main 3 0.026650 0.026650 0.0088833 10.45 0.089 
Effects 
2-Way 2 0.011650 0.011650 0.0058250 6.85 0.127 
Interactions 
Residual 2 0.001700 0.001700 0.0008500 
Error 
Total 7 0.040000 
The estimated effects in Table 38 has the water level at a P value of 0.054, 
but this does not meet the general acceptance criteria of P <0.05. This implies that 
the mean sphericity ratio range of 1.26-1.45 does not have a great enough difference 
associated with the selected factors at those ranges to be significant. The DOE did 
find significant results for processing factors with regard to the sphericity standard 
deviation and the sphericity RSD %. The standard deviation is a key measurement in 
manufacturing and is used extensively to support Six Sigma approaches for 
continuous improvement. Where Six Sigma links higher processing variability with 
product defects, and conversely lower standard deviations are associated with high 
quality performance (Welch 2003). The RSD is independent of units and is useful to 
compare the standard deviation with the mean to give an indication of the relative 
precision of the data (Gardiner and Gettinby 1998c ). 
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Table 40. Estimated Effects and Coefficients for Sphericity Standard Deviation 
(Coded U . ) M 1 1 S . IR B d DOE ruts et~ro o uccmate ea 
Term Effect Coef SE Coef T p 
Constant 0.21215 0.000451 470.78 0.001 
Water Level -0.00695 -0.00348 0.000451 -7.72 0.082 
Kneading 0.00047 0.00023 0.000451 0.52 0.696 
Time 
Spheronization -0.04488 -0.02244 0.000451 -49.80 0.013 
Time 
Water Level * -0.01173 -0.00587 0.000451 -13.02 0.049 
Kneading 
Time 
Water Level * -0.02801 -0.01400 0.000451 -31.08 0.020 
Spheronization 
Time 




S = 0.00127456 R-Sq = 99.98% R-Sq (adj)= 99.89% 
Table 41. Analysis of Variance for Standard (Coded Units) Sphericity Standard 
D . . (C d d U . ) M 1 1 S . IR B d DOE ev1at1on o e ruts eto_£ro o uccmate ea 
Source DF s~ss Acij_ SS Adj MS F p 
Main 3 0.0041252 0.00412518 0.00137506 846.45 0.025 
Effects 
2-Way 3 0.0061622 0.00616220 0.00205407 1264.43 0.021 
Interactions 
Residual 1 0.0000016 0.00000162 0.00000162 
Error 
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Figure 63. Main Effects Plot ofMetoprolol Succinate DOE Sphericity Standard 
Deviation 
Interaction Plot (data means) for Standard Deviation 
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Kneading Time -- -· 
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Figure 64. Interaction Plot for Metoprolol Succinate DOE Sphericity Standard 
Deviation 
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Tables 40 and 41 show that Spheronization is a significant main effect, and 
all three of the two-way interactions are significant factors for the sphericity standard 
deviation. The main effects plot; Figure 63 indicates that high spheronization time 
has the greatest impact on reducing the sphericity standard deviation. All of the 
interactions are statistically significant, but Figure 64 shows that kneading time and 
spheronization time have the largest interaction effect. The interaction between the 
water level and the spheronization time is the second strongest, with kneading time 
and water level the weakest. 
Table 42. Estimated Effects and Coefficients for Sphericity RSD (%)(Coded units) 
M 1 1 S . t IR B d DOE eto_Ero o uccma e ea 
Term Effect Coef SE Coef T p 
Constant 16.058 0.04000 401.44 0.002 
Water Level 0.525 0.262 0.04000 6.56 0.096 
Kneading -0.590 -0.295 0.04000 -7.38 0.086 
Time 
Spheronization -2.955 -1.478 0.04000 -36.94 0.017 
Time 
Water Level * -0.740 -0.370 0.04000 -9.25 0.069 
Kneading 
Time 
Water Level * -2.935 -1.467 0.04000 -36.69 0.017 
Spheronization 
Time 




S = 0.113137 R-Sq = 99.98% R-Sq (adj)= 99.84% 
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Table 43. Analysis of Variance for Sphericity RSD (%)(Coded units) Metoprolol 
Succinate IR Bead DOE 
Source DF Se_g_ SS Adj SS Ac!i_ MS F p 
Main 3 18.7115 18.7115 6.2372 487.28 0.033 
Effects 
2-Way 3 37.0508 37.0508 12.3503 964.87 0.024 
Interactions 
Residual 1 0.0128 0.0128 0.0128 
Error 
Total 7 55.7752 
Table 42 shows that spheronization time and all of the two-way interactions 
are significant for the sphericity RSD %. Table 43 supports the main effects and 
interaction significance with the ANOV A. Figure 65 indicates that higher 
spheronization times will yield lower RSD%, while the other factors have minimal 
effects. Figure 66 indicates that the water level and spheronization time, as well as 
the kneading time and spheronization time have nearly same interacting effects. The 
interactions depict high water level, high spheronization time, and low kneading time 
to yield the lowest RSD %. 
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Figure 65 . Main Effects Plot for Metoprolol Succinate DOE RSD (%)of Sphericity 
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Loss On Drying for Metoprolol Succinate DOE IR Beads Dried to 48°c final product 
temperature 
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Figure 67. Loss on Drying at 48°C End Drying Temperature 
Figure 67 is the LOD of the 400g-batch size experimental design trials 
separated by the amount of water added during granulation. All samples were dried 
to a product temperature of 48°C. The LOD range was from 1.3-1.8%, the low water 
level had an average LOD of 1.5% and the high water level had an average LOD of 
1.6%. The 1 Og water difference between the two formulations did not result in a 
considerable difference in the LOD's. The product temperature target of 48°C 
served as a guide when the batch size was increased to 1.0 Kg. A lack of significant 
fine particle generation, as reflected in pan retention can be seen in Appendix 3, 
supports that there was not over agitation during the drying process. 
6. 2. 2 Confirmation/Batch Size Increase of DOE Results for Metoprolol IR Beads 
T bl 44 M a e l 1 IR B d DOE R #7 C nfi eto_Qro o ea un 0 irmation T. 1 na s 
Target LOO% Mean Sphericity 
Trial %Yield @48c Sphericity Std. Dev. Sphericity RSD (%) 
RB014013 (DOE 
Confirmation 400_g) 93 .07 1.6 1.28 0.2 15.45 
RBO 14023 i_I ~ 90.52 2.2 1.19 0.16 13 .14 
RBOl4024 (1~ 91.37 2.2 1.12 0.11 10.13 
The Metoprolol Succinate IR beads were run at the same processing 
conditions to confirm the initial findings from the DOE. The confirmation trial 
yielded >93% of the beads within the desired particle size distribution. The batch 
size was then increased to 1.0 Kg, with the water amount and rate doubling. The 
yields were both >90% and the mean sphericities showed improvement over the 
400g batches. The increased batch size created better sphericity due to greater 
interactions between the material, the walls, and the spheronizer plate (Vervaet, 
Baert et al. 1995). 
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Figure 68. Metoprolol IR Bead- Round (RB014013/023/024 Blend) 
Figure 68 is an SEM of a selected bead from the blend, which displayed good 
sphericity. There are no pores or cracking to indicate a weak or damaged bead. The 
beads from the three batches (RB014013, RB014023, and RB014024) were blended 
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Figure 69. Metoprolol IR Bead Loss on Drying Curve as a Function of Time 
--RB014023 LOO% 
· RB014024 LOO% 
Figure 69 depicts the drying curve for Metoprolol IR beads for the 1.0 Kg 
batches to confirm the parameters at a higher batch load. LOD samples were taken 
every 5 minutes and after the drying cycle ended at 48°C. The values for the LOD 
(%)are presented below the RB014023 points, and above the RB014024 to avoid 
confusion. The first batch (RB014023) dried resulted in an increased LOD over the 
experimental design runs. This can be attributed to the increased load and a greater 
drying capacity required. Samples for the second batch (RB014024) were taken at 
46°C, 48°C, and 50°C to confirm the first batch and understand the range around the 
target product temperature. Batch RB014024 ' s found that at 48°C both batches 
yielded 2.2% LOD. 46°C did not yield a sufficiently dry pellet (2.8% LOD), while 
50°C yielded a preferred LOD of 1.8%. The 1.0 Kg batch size requires a product 
temperature of at least 48°C to achieve an acceptable LOD with a specification of 
not more than 2.5%. An optimal LOD range of 1.5-2.0% occurs at a temperature 
above 48°C, with an acceptable yield at 50 C. 
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6.3 Metoprolol Succinate SR Doe Results 
Table 45 . Metoprolol Succinate SR DOE Results 
Variables 
Polymer Curing Curing 
Coating Condition Time Sample ID 
Level (°CIRH%) J_Hrs) 
1 60150 2 0908305 
-1 6010 4 0908298 
1 60150 8 0908306 
0 6010 8 0908301 
0 6010 2 0908294 
1 60/75 4 0908309 
0 60150 4 0908300* 
-1 60150 8 0908310 
0 60/75 8 0908311 
0 60150 4 0908300* 
0 60150 4 0908300* 
-l 60150 2 0908312 
0 60/75 2 0908313 
-1 60/75 4 0908314 
1 6010 4 0908299 
*Denotes a center point of the experimental design 
% Metoprolol Succinate Released 
1 hr 4 hr 8 hr 12 hr 16 hr 20 hr F2 
1.41 7.44 15.21 24.99 34.94 43.64 21.35 
9.13 26.38 38.85 49.26 46.39 55.09 31 .24 
1.57 8.31 18.25 33.46 48.42 59.37 26.88 
1.74 8.98 18.99 28.55 37.74 46.56 22.95 
3.89 13 .19 23.71 33.83 43.46 51.92 26.02 
1.63 4.51 11.79 24.05 40.33 55.66 22.84 
1.51 7.83 18.43 32.73 46.50 57.59 26.21 
1.55 8.00 21.66 39.59 55.54 66.80 30.70 
2.75 5.66 10.71 21.07 34.60 49.55 21.03 
2.55 9.30 21.18 35.19 47.16 56.87 27.06 
1.79 8.33 18.57 30.45 41.44 50.31 24.17 
1.73 7.41 18.97 33.24 46.54 57.15 26.27 
3.22 7.98 17.58 30.85 45.33 58.19 25.76 
3.83 9.67 21.57 38.17 54.64 68 .60 30.76 
7.07 19.28 28.79 29.54 38.28 46.11 24.34 
Table 45 is the results of the Metoprolol Succinate sustained release Box-
Behnken design. The goal of the study was not to yield a high f2 value, because 
these beads will be further processed and the drug release is expected to increase as a 
function of the damage experienced during the tab letting process. Based on the 
exploratory tabletting study there is reason to suspect damage may occur even with 
an improved excipient blend, therefore a thicker sustained release coating was 
studied. The f2 value is given as the main indicator of dissolution profile to the brand 
product to understand the relative effects of the factors studied. 
Table 46 is the estimated regression coefficients for the Metoprolol Succinate 
f2 values, indicating that the polymer coating level is a significant factor. Table 47 
are the ANOV A for the Metoprolol Succinate f2 values, and indicates that the linear 
regression model is significant and there are no lack of fit concerns. 
Table 46. E t' s imate dR e~ess10n C ffi' tfl Mt 1 1 s oe ic1en s or e O...E_rO 0 t F2 Values uccma e 
Term Coef SE Coef T p 
Constant 24.7501 0.9201 26.899 0.000 
Po!l'...mer Coating_ Level -2.9450 0.8535 -3 .451 0.006 
Curin_g_ Conditions -0.5200 0.8535 -0.609 0.556 
Curing_ Time (Hrs) 0.0507 0.8323 0.061 0.953 
Polymer Coating Level * 2.0558 1.2495 1.645 0.131 
Po!l'...mer Coati~ Level 
S = 2.414 R-Sq = 60.0% R-Sq (adj) = 44.0% 
Tabl 47 An 1 . fV . £ M e a ys1s o ar1ance or llS. tF2Vl etO_E!O 0 uccma e a ues 
Source DF St:9. SS Allj_ SS AdlMS F p 
R~ession 4 87.329 87.3295 21.8324 3.75 0.041 
Linear 3 71.554 71.5690 23 .8563 4.09 0.039 
S_g_uare 1 15.775 15.7750 15.7750 2.71 0.131 
Residual Error 10 58.274 58.2743 5.8274 
Lack-of-Fit 8 53.862 53.8622 6.7328 3.05 0.270 
Pure Error 2 4.412 4.4121 2.2060 
Total 14 145.604 
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Contour Plots of F2 
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Figure 70. Contour Plots for F2 Values of Metoprolol Succinate SR DOE 
Figure 70 are the contour plots generated by the design of experiments for 
Metoprolol Succinate sustained release studies. The Y- axis represents the first 
factor of the title, while the X-axis represents the second factor. The polymer 
coating level was the only factor found to be statistically significant, and the plots 
show that lower coating levels can be correlated with high f2 values. The dissolution 
profiles are currently slower than the branded product and lower coating would 
increase the drug's release rate. The vertical delineations of the curing condition vs. 
the polymer concentration support that the polymer concentration is the primary 
factor in the interaction. Curing time and curing conditions indicate a reverse "C" 
curve which implies there are effects in the intermediate ranges on the f2 value, that 
the extreme points high and low do not effect. The slowest release profiles were 
seen at the high polymer coating level and low curing time. Curing for the 
intermediate and high duration for the high polymer level did not alter the effects, 
signifying a potential coalescence effect. The high-level polymer beads cured at 
60°C for 2 hours were chosen due to their low drug release rates for processing into 
multiparticulate tablets. 
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6.4 DOE Results for Metoprolol Succinate Tablets 
Table 48. Tablet Friability for the DOE Batches 
Blend Blend Tablet Fill 
Ratio LOD (%) Weight 
Polymer (MCC (mg) Hardness Acceptable 
Lot# Cone. 200:102) (kp) (%) Pass/Fail 
2.5 449.5 2 85 .56 Fail I 1: I 
3 95.57 Fail 
4 98.66 Fail 
RB0\4064 5 99.53 Pass 
-1 1:1 2.6 437 2 95.92 Fail 
RB014065 5 100 Pass 
I 3:7 2.5 449.5 2 63.33 Fail 
RB0\4066 5 98.76 Fail 
-1 3:7 2.7 437 2 98.31 Fail 
RB014067 5 99.88 Pass 
Table 48 is an overview of the friability results for the DOE batches, pass or 
fail determination is based on the USP Chapter <1216> for tablet friability, where 
not more than 1 % of weight loss is allowed (USP 2007d). The results from this 
experiment found that all of the high hardness runs except RBO 14066 passed the 
friability test. This failure (98.76%) is most likely attributed to beads incorporated in 
the walls of the tablets becoming loose. Multi particulate tablets incorporate the 
beads throughout the tablet and may create localized areas of beads towards the 
edges, which may result in a small loss of edge material during friability testing 
(Abbaspour, Sadeghi et al. 2005). It is important to consider that in a production 
environment, these tablets would receive an additional top coat, (i.e. Opadry) to 
protect against moisture, chipping, damage, and provide taste masking (Kottke and 
Rudnic 2002). Operating conditions during top coating for equipment such as pan 
coaters can be carefully selected to meet the tablet characteristics if necessary. In 
this situation, the friability data helps to support the understanding of the tablets that 
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would further be top coated, but must be considered in concert with the dissolution 
profile. Table 48 also describes the LOD (%)of the blend prior to compression and 
shows little moisture differences between the blends. The ANOV A was found to be 
not statistically significant, see Appendix 9 for the full model. 
6.4.1 SEMfor Metoprolol Succinate Tablet DOE 
Figure 71. High Polymer Coating Level with Topcoat Uncompressed 
Figure 71. is an SEM image of an uncompressed bead, which has been coated 
with a sustained release polymer and then top coated with an Opadry II suspension. 
The beads appear smooth and without defect, note that the light colored speckles are 
components of the top coating suspension. Figures 72 through 77 are the 
compressed high polymer level beads from both excipient blends with high and low 
hardness, as well as the tablet matrices they formed (for low hardness only) . 
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Figure.72. High Polymer Coating with Topcoat and a 30/70 Blend at 2kp Tabletted 
Figure 73 Metoprolol Succinate High Polymer Level with Topcoat, 30/70 Blend at 
5kp Tablet Hardness 
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Figure 74. Cross Sectioned Tablet of Metoprolol Succinate High Polymer Level with 
Topcoat with a 30/70 Blend and 2kp Hardness. 
Figure 75. Metoprolol Succinate High Polymer Level with Topcoat, 50/50 Blend 
Tabletted at 2Kp 
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Figure 76 Metoprolol Succinate High Polymer Level Top Coated with a 50/50 
Blend, Tabletted to 5kp. 
Figure 77. Metoprolol High Polymer Coating with a Topcoat 50/50 Blend at 2kp. 
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The SEM images depict varying degrees of surface cracking of the beads, 
from theoretically superficial to severe. Figure 75. the 1: 1 blend ratio of MCC at 
2Kp hardness appears to have the least amount of cracking on the surface for the 
individual bead and has some limited damage in Figure 77. in the tablet with the 
excipient blend. Bead damage is also visible in Figures 72 through 74. indicating 
that the 3 :7 ratio excipient blend may also not serve to protect the beads during 
compression. Excipients must have good compressibility attributes, and be of 
similar size to the beads being tabletted in order to provide protection from forces 
experienced during compression (Abbaspour, Sadeghi et al. 2005). 
The bead's sphericity has an important impact on the final dosage form. 
Research examining the effects of a granule's shape and porosity on final tabletting 
characteristics concluded the following: 1) Irregular shaped granules result in more 
complex behavior during compression and can induce granule fracturing. 2) Bed 
void space was increased as a function of irregular shaped granules to facilitate 
deformation during compression resulting in higher tablet tensile strength. 3) 
Lubricants provide less protection for irregularly shaped granules due to incomplete 
coverage and/or rupturing during compression (Johansson and Alderbom 2001). The 
void space created by the beads and excipient particles may be filled more 
effectively with the MCC PH-102 at a ratio of 1: 1, than at 3 :7 which does not contain 
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Figure 78. Metoprolol Succinate SR Tablets at High and Low Hardness with and without #25 Beads Loaded 
Figure 78 compares the theoretical "best case" scenario for the tabletting 
study. Based on the SEM images and the dissolution profiles from the sustained 
release DOE, one could make the assumption that: the MCC 1: 1 ratio and the high 
polymer concentration would create the best scenario for protecting the beads during 
compression. The tablets of the best-case scenario are compared with and without 
loading the sieve size #25 (the largest) beads of the blend. The best results are 
obtained for the formulation, which does not contain the #25 sieve sized beads 
compressed at 2 Kp. Interestingly, there is no significant difference between the 
formulations at the higher hardness, indicating that crushing of the beads is still 
occurring. A reduction in the particle size of the immediate release bead could have 
a positive effect on the final tablet product. The smaller sized beads would require 
more coating due to an increased surface area but would theoretically be able to fill 
the void spaces that are created during compression (Dashevsky, Kolter et al. 2004). 
(Badawy, Lee et al. 2000) found that a finer grade of active ingredient can alter the 
size of immediate release beads yielded and achieve a shift to a smaller particle size 
distribution. 
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Chapter 7 Conclusions 
7.1 Establishment of Target Product Profiles 
The first step of the ICH Q8 Annex was to establish the chemical and 
physical target product profiles. The current marketed competitors for propranolol 
HCl and metoprolol succinate extended release products were deformulated to 
establish targets to guide process development. The dissolution profiles served as an 
important target throughout the intermediate sustained release bead, and final 
multi particulate extended release tablet development. Evaluation of variability and 
trends in drug release profiles within the USP acceptance criteria supported 
development decisions. SEM imaging provided visual indicators about the 
manufacturing practices, materials, and characteristics of the intermediate materials 
used by the marketed competition. The imaging determined uniform bead aspect 
ratios -1.0, indicating the production of spherical immediate release beads. Sieving 
studies found a tailored particle size distribution for both products and guided 
immediate release bead size targets. Additional physical characterization supported 
fill weight and tooling decisions for tablets and capsules. 
7.2 CQA Identification 
Identification of the CQAs for this developmental process was selected based 
on the ICH Q8 annex guidelines, product deformulation characterization, current 
literature and available equipment. Particle size distribution, particle sphericity, IR 
bead moisture content, and the sustained release dissolution profile were selected as 
the CQA's to be studied. The particle size distribution dictates both the surface area 
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available for polymer coating, and means particle size of beads during compression. 
Sphericity was chosen to facilitate bead flow through down stream process, and 
support even polymer coating application. High moisture contents have been 
identified as potentially causing long-term instability and potential microbial growth. 
Understanding the impacts of process and formulation changes on the dissolution 
profile during development is essential for guiding changes in the future. 
7.3 Linking CQA's to Process Parameters 
The general linear model of the process parameters and the yield determined 
statistically significant main effects. Particle size distribution was calculated based 
on individual sieve size retention and as a total yielded percentage. The amount of 
granulating water was found to be statistically significant for determining the particle 
size yield for both Propranolol HCl and metoprolol succinate. Identification of the 
water level is the critical process parameter because it will directly effect all 
downstream processing. During high shear granulation, controlling the process 
parameters to adjust the distribution of the water is important to facilitate extrusion 
and control the particle size distribution generated. Metoprolol succinate immediate 
release beads also found spheronization speed to be a significant factor for the 
determination of particle size distribution. Determination of an appropriate 
spheronization speed early in the process to create an optimal rope like formation 
and avoid irregular flow patterns of the beads must be carefully evaluated to avoid 
agglomeration and oversized bead generation. 
209 
Sphericity was measured as the mean aspect ratio and the standard deviation 
between the mean aspect ratio measurements. Kneading time and spheronization 
time were statistically significant for both mean sphericity and standard deviation of 
metoprolol succinate. Additionally, the granulation water amount was statistically 
significant for mean sphericity. Kneading time and granulating water can be directly 
attributed to the distribution and quantity of water available in the system to enhance 
the formulation's plasticity during processing. Longer durations of spheronization 
are associated with greater mean sphericity and lower sphericity variability due to 
increased particle interactions within the system. 
The incorporation of HPMC into the aqueous ethylcellulose dispersion could 
not provide an adequate sustained release coating system for Propranolol HCl. 
Humidified and other extreme curing conditions stressed the polymeric coating and a 
lack of a uniform coating ultimately resulted in an unstable product. In contrast, an 
organic coating solution did not exhibit the same instability when humidified and 
extreme curing conditions were studied. Initial stability studies not presented in this 
work, suggest that the organic coated beads were stable and exhibited little changes 
over time to the dissolution profile. 
The Aqueous dispersion studied for Metoprolol Succinate sustained release 
coating did not contain HPMC and provided a reliable and adaptable system. Curing 
conditions did impact the product, but to lesser degree than the Propranolol HCl 
sustained release beads. The sustained release bead profile was initially matched to 
the brand profile to understand a baseline level needed for coating. The polymer 
coating levels were then raised two to three times the initial polymer level in order to 
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compensate for potential bead crushing during tabletting. Incremental increases of 
polymer level yielded an anticipated decrease in the drug release profile. 
Bead top-coating experiments identified a medium level of coating to add 
adequate plasticity and extra degree of protection, without adversely affecting the 
drug release profile. High levels of top coating can result in beads growing to an 
unacceptably large size, which may have a negative impact during compression. A 
practical concern for the generation of oversized beads for a tailored system is the 
diminished product yield, which has financial and processing ramifications. 
Preliminary tabletting studies for metoprolol succinate identified the variable 
levels of protection provided by the different excipient granule blends. A mixed 
excipient blend of microcrystalline cellulose provided the greatest protection to the 
sustained release beads. Larger excipient particle sizes match the active beads and 
provide structural support, while smaller sized excipients fill void spaces created due 
to deformation during compaction. Tablet hardness ranges were established from 
2kp to 5kp, at the low end of the acceptable range for passing tablet friability testing. 
7.4 Supporting Elements of a Design Space 
The metoprolol succinate immediate release beads utilized a 23 full factorial 
design to evaluate granulating water amount, kneading time, and spheronization time 
for the effects of these process conditions on the identified CQA's. These 
experiments yielded greater than 80% of the target particle size but found none of the 
factors or interactions statistically significant. The findings indicated that the factor 
levels had little effect on the final output and support an acceptable processing range. 
211 
The factors were also insignificant for the mean sphericity of the IR beads, but found 
spheronization time and all of the interactions significance in the relative and 
standard deviation of the sphericity measurements. This supported earlier work 
where longer spheronization times contributed to more uniformly round particles due 
to greater particle-particle and particle-system interactions. All of the trials met the 
moisture content specification of not more than 2.5%, and indicated that drying was 
within acceptable processing ranges. The IR bead with the lowest sphericity ratio 
was chosen for further development. 
The Box-Behnken experimental design studied the polymer coating level, the 
humidification level during curing, and the duration of curing. Polymer coating level 
was statistically significant for the calculated f2 of the dissolution profile. Contour 
plots depict the range and identified high polymer coating levels and short durations 
of curing were associated with low f2 values. In contrast, high f2 values are found for 
low polymer coating levels, intermediate curing duration, and low/medium levels of 
humidification. Understanding the range of the f2 values was critical during 
development to support adjustment decisions to the sustained release profile. 
A 23 full factorial experimental design was utilized to study the blend ratio of 
two microcrystalline cellulose particle sizes within the excipient blend, the amount 
of sustained release polymer coating applied to the active beads, and the hardness of 
the tablets. Friability studies indicated that 2kp hardness resulted in significant tablet 
breakage, while 5 kp hardness was acceptable. Visualization of bead damage during 
compression was performed with SEM, with significant damage to polymer coatings 
seen at 5kp hardness, and at the lower ratio of MCC 200: 102. Therefore the "best 
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case" processing parameters for the tablets were further examined through 
dissolution testing. The dissolution profile was faster than the branded competitor 
but showed improvement over the previous experimental samples. Additionally, 
improvement was seen when beads retained on sieve #25 , the largest mean particle 
size for the active beads was removed. This improvement indicated the importance 
of particle size during tabletting, and would support movement in the target particle 
size distribution to a smaller size. Smaller sized beads fill void spaces more 
thoroughly and support plastic deformation during compression. The results from 
both the exploratory and DOE batches of immediate release beads indicate that a 
marked shift to a smaller particle size distribution would require a smaller extrusion 
screen and/or a micronized API with a smaller mean particle size distribution. 
7.5 Exploratory Traditional Methods vs. QbD 
The traditional methods promote local optimization, when an acceptable 
outcome is found ; minor adjustments are made to optimize that outcome. This 
approach can be cost and time effective if the formulation scientist is able to discover 
an acceptable result in a timely fashion. If a complex interaction occurs or a problem 
arises in a formulation, it can be difficult to identify and quantify the cause and 
solution to the problem. Utilizing an appropriate design can improve the overall 
understanding of the system and aid in finding a global optimum. 
It is important to consider that statistical significance is not equivalent to 
practical significance. Prudent judgment should be employed when analyzing results 
of the statistical methods to appropriately interpret the results and their implications. 
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The P value is a useful tool for determining significance but should not be the only 
guide to interpretation. A blended approach to drug development will save time 
where elaborate study designs are not necessary and support processing 
understanding to solve problems and changes to the system. 
7.6 Study Limitations 
Due to financial and resource constraints, not all generated samples could be 
tested and in certain situations the theoretical best guess batch was characterized. 
This limited the understanding of the design space edge of failure, as batches with 
negative traits were less likely to undergo full testing. Industrial pharmaceutical 
research often does not incorporate repetition into their statistical design due to the 
related costs associated. Therefore it is difficult to truly understand the product 
ranges and traits, especially in the event of a batch or analytical anomaly. The 
results found in the study cannot be generalized to cover all drugs, but may help to 
describe other drugs with similar physical characteristics. 
7.7 Future Studies 
Future work to establish point-to-point in vitro relationships and establish a 
level A bioequivalency rating should be pursued to support the commercialization of 
both of these products. Investigation of raw material physical characteristics and 
inter batch variability would be a useful tool to identify potential issues prior to 
beginning the process. Aspects oflong term stability, pharmacokinetics, and scale 
up offer good opportunities to examine the relationships found in this study to a real 
world application for FDA approval. Other drugs with similar characteristics should 
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lnderal LA 160mg Capsule Dissolution Profiles 
Batch# 1.5 3.5 
Inderal 808468 14.4 38.9 
Inderal 808468 13.4 35.7 
lnderal 808468 14.0 33.2 
Inderal 808468 13 .5 32.6 
lnderal 808468 14.1 36.7 
Inderal 808468 15.7 37.7 
Mean 14.2 35.8 
Std Dev 0.8 2.3 
APPENDIX 1 
% Pro_..e_ranolol Released Over Time J_hrtl_ 
5.5 7.5 10 22 24 
55 .0 63.7 75.1 90.6 93.2 
50.5 60.8 70.3 85.4 86.6 
47.4 57.7 68 .0 84.4 85 .6 
46.9 57.1 67.5 83.8 85 .1 
51.8 62.6 74.1 89.5 89.6 
52.I 63.l 72.5 88.1 89.2 
50.6 60.8 71.3 87.0 88.2 
2.8 2.6 2.9 2.6 2.8 
APPENDIX2 
Propranolol IR ANOV A 
Propranolol IR ANOV A Sieves #14-Pan 
Factor T__yp_e Levels Values 
H20 Amount Coded Fixed 3 High, Low, 
Medium 
H20 Addition Coded Fixed 2 High, Low 
Kneading Time Coded Fixed 2 High, Low 
Spheronization RPM Fixed 2 High, Low 
Coded 
Spheronization Time Fixed 2 High, Low 
Coded 
Analysis of Variance for 14, using Adjusted SS for Tests 
Source DF Seq.SS Adj. Adj. F p 
SS MS 
H20 Amount Coded 2 27.50 39.78 19.89 0.75 0.506 
H20 Addition Coded 1 0.93 37.84 37.84 1.43 0.271 
Kneading Time Coded 1 29.32 2.56 2.56 0.10 0.765 
Spheronization RPM 1 19.13 19.87 19.87 0.75 0.415 
Coded 
Spheronization Time 1 77.73 77.73 77.73 2.94 0.130 
Coded 
Error 7 185.33 185.33 185.33 26.48 
Total 13 339.94 
S = 5.14539 R-Sq = 45.48% R-Sq (Adj.)= 0.00% 
Analysis of Variance for 16, using Adjusted SS for Tests 
Source DF Seq.SS Adj. Adj. F p 
SS MS 
H20 Amount Coded 2 156.54 9.50 4.75 0.08 0.924 
H20 Addition Coded 1 18.26 90.65 90.65 1.52 0.258 
Kneading Time Coded 1 151.24 3.13 3.13 0.05 0.826 
Spheronization RPM 1 58.45 59.36 59.36 0.99 0.352 
Coded 
Spheronization Time 1 38.88 38.88 38.88 0.65 0.446 
Coded 
Error 7 417.74 417.74 59.68 
Total 13 841.11 
S = 7.72510 R-Sq = 50.33% R-Sq (Adj.)= 7.76% 
229 
Analysis of Variance for 18, using Adjusted SS for Tests 
Source DF Seq.SS Adj. SS Adj. F p 
MS 
H20 Amount Coded 2 4463.83 1188.96 594.48 6.76 0.023 
H20 Addition Coded 1 37.54 8.53 8.53 0.10 0.765 
Kneading Time Coded 1 2.28 105.51 105.51 1.20 0.310 
Spheronization RPM 1 77.77 79.80 79.80 0.91 0.373 
Coded 
Spheronization Time 1 145.45 145.45 145.45 1.65 0.239 
Coded 
Error 7 615.88 615.88 87.98 
Total 13 5342.75 
S = 9.37995 R-Sq = 88.47% R-Sq (Adj.) = 78.59% 
Analysis of Variance for 20, using Adjusted SS for Tests 
Source DF Seq.SS Adj. Adj. F p 
SS MS 
H20 Amount Coded 2 831 .7 106.0 53.0 0.28 0.762 
H20 Addition Coded 1 0.6 221.1 221 .1 1.18 0.313 
Kneading Time Coded 1 183.3 53 .5 53.5 0.29 0.610 
Spheronization RPM 1 244.7 251.5 251.5 1.34 0.284 
Coded 
Spheronization Time 1 519.1 519.1 519.1 2.77 0.140 
Coded 
Error 7 1310.5 1310.5 187.2 
Total 13 3089.8 
S = 13.6824 R-Sq = 57.59% R-Sq (Adj.)= 21.23% 
Analysis of Variance for 25, using Adjusted SS for Tests 
Source DF Seq.SS Adj. Adj. F p 
SS MS 
H20 Amount Coded 2 414.464 85 .009 42.505 7.25 0.020 
H20 Addition Coded 1 0.725 11 .353 11.353 1.94 0.207 
Kneading Time Coded 1 5.465 1.540 1.540 0.26 0.624 
Spheronization RPM 1 7.181 7.381 7.381 1.26 0.299 
Coded 
Spheronization Time 1 15.271 15.271 15.271 2.61 0.150 
Coded 
Error 7 41.020 41.020 5.860 
Total 13 484.127 
S = 2.42074 R-Sq = 91.53% R-Sq (Adj.)= 84.26% 
230 
Analysis of Variance for Pan, using Adjusted SS for Tests 
Source DF Seq.SS Adj. Adj. F p 
SS MS 
H20 Amount Coded 2 1473.02 575.35 287.68 3.26 0.100 
H20 Addition Coded I 1.08 0.12 0.12 0.00 0.971 
Kneading Time Coded I 0.12 2.55 2.55 0.03 0.870 
Spheronization RPM 1 6.72 6.74 6.74 0.08 0.790 
Coded 
Spheronization Time 1 0.21 0.21 0.21 0.00 0.962 
Coded 
Error 7 617.62 617.62 88.23 
Total 13 2098.77 
S = 9.39319 R-Sq = 70.57% R-Sq (Adj.)= 45.3% 
A I . fV . na!Y_SIS 0 ariance f T or ai:g_et 0A y· Id 0 1e , usm_g_ Ad" ~uste d SSf T or es ts 
Source DF Se_q SS Adj SS Adj MS F p 
H20 Amount 2 1752.7 1684.2 842.1 3.89 0.073 
Coded 
H20 Addition I 28.8 142.8 142.8 0.66 0.443 
Coded 
Kneading 1 226.4 8.8 8.8 0.04 0.846 
Time Coded 
Spheronization 1 46.6 48.0 48.0 0.22 0.652 
RPM Coded 
Spheronization 1 115.0 115.0 115.0 0.53 0.490 
Time Coded 
Error 7 1515.6 1515.6 216.5 
Total 13 3685.0 






Metoprolol Succinate IR Bead Design of Experiments Results 
Process Parameters % Retained Sieve # 
Spheroniz 
H20Amt Kneading ation Time Random 
Trial (g) Time_{_Sec}_ _{_Min}_ Order 20 25 30 35 45 60 
RB005148 175 30 5 I 1.87 6.5 56 19.98 14.65 I 
RB005149 175 30 8 2 1.31 7.7 58.75 21.24 10.93 0.06 
RBOl4003 
165 15 5 3 1.6 5.22 52.76 21.48 16.5 2.44 
RBOl4004 165 30 5 4 0.51 3.93 56.07 20.42 16.04 3.03 
RBOl4005 165 30 8 5 0.26 6.04 54.75 19.42 17.05 2.44 
RB005150 175 15 5 6 9.71 10.4 55.32 18.35 6.16 0.06 
RB005151 175 15 8 7 1.12 8.57 54.06 21.94 13.99 0.32 
RBOl4006 165 15 8 8 0.5 6.76 54.53 20.75 16.09 1.33 
Sj>_herici!)' 
Target LOD Mean Std. Dev. Sphericity 
Pan % % Observed Shl!J!.e ~erici!t_ S_p_heric!!r_ RSDJ.o/~ 
Dumbbells/ 
0 90.63 1.6 ~eres 1.26 0.22 17.11 
Mostly Spherical*/ 
0 90.92 1.6 Few Dumbbells 1.34 0.19 14.2 
Rods/ 
0 90.74 1.8 Dumbbells 1.39 0.24 17.3 
Dumbbells> 
Rods> 
0 92.53 1.3 Sj>_heres 1.45 0.21 14.31 
Dumbbells/ 
0 91.22 1.4 Rods 1.35 0.24 17.43 
Rounder 
0 79.83 1.5 Rods/Sj>_heres 1.28 0.27 21.42 
0 89.99 1.8 Mostly_• Sj>_herical 1.23 0.15 12.55 
Dumbbells/ 




Metoprolol IR Bead Exploratory Batches Results 
Processi'!&_ Parameters 
H20 Final 
H20 Addition Kneading Prod. 
Amt g/min Time Spheronizer Spheronizer Temp 
Trial (g) batch J.mi'!}_ RPMJ.A~ Time J_mi'!}_ oc 
RB005077 153 50 2 6801550 2.5 45.2 
RB005081 200 80 I 300/628 117 51.6 
RB005107 180 90 I 680 5 51.3 
RB005108 190 95 2 800 4 51.6 
RB005109 170 85 I 600 2 51.1 
RBOOSl 19 180 180 0 5001767 016 50.5 
RB005120 140 120 40 sec 800 7 50.2 
RB005122 150 150 15 Sec 800 5 50 
RB005123 160 160 30 sec 800 9 48.6 
80 for 1.5 
min, 200 for 
RB005124 170 15 sec 15 sec 772 8 48.2 
160 for 1.5 
min, 400 for 
RB005128 340 15 sec 15 sec 772 8 50 
% Retained Sieve # 
LOD 
J."ltl. 20 25 30 35 45 
1.2 16 21 47.7 12.4 3.3 
1.2 3.01 5.2 60.8 20.5 10.4 
1.3 5.09 8.4 58.6 17.6 10.3 
1.3 4.14 42 42.4 9.12 2.05 
I 0.54 1.5 66 16.2 12.1 
1.9 4.62 22 52.8 15 6 
1.6 0.38 10 56 15.5 11.2 
1.4 0.19 2.3 61 16.6 12.8 
1.7 0.34 8.2 56.4 15.5 13.9 
1.6 0.27 6.2 56 19.8 16.7 
2.3 0.67 13 51.5 21.7 12.9 
Si>_herici_t) 
Target Observed Mean Stand. 
60 Pan % Notes Sh!!E_e ~heric!!I_ Dev. RSDJ.0/tl_ 
300g 
Reshaped/ Rods/dumbbel 
0 0 63 .36 ReSjlheronized Is 1.36 0.28 20.46 
Reextruded More 
0.1 0 91.77 ReSJlheron ized dumbbells 1.31 0.28 25.8 
More 
Rods/Some 
0.1 0 86.47 Stra!B!it run dumbbells 1.35 0.29 21.58 
0 0 53 .53 Straig_ht run Too big_ 1.39 0.3 21.74 




then good Round/few 




4.9 1.9 82.7 side than Rods 1.52 0.28 18.48 
Fast Addition- Dumbbell 
5.5 1.6 90.4 Straig!it Batch sh~d 1.58 0.33 20.67 
Fast Addition-
5.3 0.3 85.78 Straig!it Batch Dumbbells 1.32 0.2 15.03 
Slow, then fast 
I 0.1 92.41 addition Good ~eres 1.2 0.15 12.16 
800g- Slow 
water, then 




Metoprolol Succinate IR Bead Design of Experiments Confirmation Results 
% Retained 
Sieve# 




40Qg) 0.3 5.46 52.73 23.47 16.87 1.17 0 
RBOl4023 
(I~ 0.49 8.9 54.66 25.88 9.98 0.07 0.02 
RB014024 
(I~ 0.39 8.18 58.32 23.95 9.1 0.04 0.01 
LOD Sphericity Sphericity 
Tar__g_et % @48c S_E_herici!Y_ Std. Dev. RSD (%) 
93.07 1.6 1.28 0.2 15.45 
90.52 2.2 1.19 0.16 13.14 
91.37 2.2 1.12 0.11 10.13 
APPENDIX4 
Full Model- Metoprolol Succinate Exploratory Batch 
General Linear Model: Mean Spheric, Std. Dev. vs. H20 Coded, H20 Addition 
Factor Tfte Levels Values 
H20 Coded Fixed 2 H!_g_h, Low 
H20 Addition Coded Fixed 2 H!.g!1, Low 
Kneading Time Fixed 2 High, Low 
Coded 
Spheronizer RPM Fixed 2 High, Low 
Coded 
Spheronizer Time Fixed 2 High, Low 
Coded 
Analysis of Variance for Target%, using Adjusted SS for Tests 
Source DF s~ss Adi SS Adi MS F p 
H20 Coded 1 282.6 569.5 569.5 4.11 0.180 
H20 Addition I 48.8 I 8.8 I 8.8 0. 14 0.748 
Coded 
Kneading Time I 24.4 28.0 28.0 0.20 0.697 
Coded 
Spheronizer RPM 1 483.5 502.9 502.9 3.63 0.197 
Coded 
Spheronizer Time 1 111 .5 111.5 I 11.5 0.81 0.464 
Coded 
Error 2 276.8 276.8 138.4 
Total 7 1227.6 
S = 11.7643 R-Sq = 77.45% R-Sq (adj)= 21.08% 
Analysis of Variance for Mean Sphericity, using Adjusted SS for Tests 
Source DF s~ss A~SS A~MS F p 
H20 Coded I 0.112813 0.164413 0. 164413 27.17 0.035 
H20 Addition 1 0.078204 0.002801 0.002801 0.46 0.566 
Coded 
Kneading Time 1 0.001453 0.012043 0.012043 1.99 0.294 
Coded 
Spheronizer RPM I 0.000518 0.000226 0.000226 0.04 0.865 
Coded 
Spheronizer Time I 0.031297 0.031297 0.031297 5.17 0.151 
Coded 
Error 2 0.012103 0.012103 0.006052 
Total 7 0.236388 
S = 0.0777921 R-Sq = 94.88% R-Sq (adj)= 82.08% 
235 
Analysis of Variance for Std. Dev., using Adjusted SS for Tests 
Source DF s~ss A<ii_ SS A<ii_MS F p 
H20 Coded 1 0.001513 0.009016 0.009016 4.99 0.155 
H20 Addition 1 0.013538 0.000617 0.000617 0.34 0.618 
Coded 
Kneading Time 1 0.000002 0.001417 0.001417 0.78 0.469 
Coded 
Spheronizer RPM 1 0.000494 0.000350 0.000350 0.19 0.703 
Coded 
Spheronizer Time 1 0.006528 0.006528 0.006528 3.61 0.198 
Coded 
Error 2 0.003613 0.003613 0.001806 
Total 7 0.125688 
S = 0.0425024 R-Sq = 85.94% R-Sq (adj)= 50.77% 
Analysis of Variance for RSD (%),using Adjusted SS for Tests 
Source DF Se_g_ SS AdlSS AdlMS F p 
H20 Coded 1 15.96 0.17 0.17 0.01 0.919 
H20 Addition 1 27.86 4.40 4.40 0.35 0.616 
Coded 
Kneading Time 1 0.17 0.46 0.46 0.04 0.867 
Coded 
Spheronizer RPM 1 2.21 2.18 2.18 0.17 0.7 19 
Coded 
Spheronizer Time 1 0.04 0.04 0.04 0.00 0.962 
Coded 
Error 2 25.34 25.34 12.67 
Total 7 71.58 
S = 3.55963 R-Sq = 64.60% R-Sq (adj)= 0.00% 
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APPENDIX5 
Metoprolol Succinate IR DOE Results 
Estimated Effects and Coefficients for 20 (coded units) 
Term Effect Coef SE Coef T p 
Constant 2.110 0.8975 2.35 0.256 
Water Level 2.785 1.393 0.8975 1.55 0.256 
Kneading_ Time -2.245 1.393 0.8975 1.55 0.364 
Spheronization -2.625 -1.313 0.8975 -1.46 0.382 
Time 
Water Level * -1.580 -0.790 0.8975 -0.88 0.541 
Kneading Time 
Water Level* -1.950 -0.975 0.8975 -1.09 0.474 
Spheronization 
Time 
Kneading Time 2.220 1.110 0.8975 1.24 0.433 
* Spheronization 
Time 
S = 2.53851 R-Sq = 90.56% R-Sq (adj)= 33.93% 
Analysis of Variance for 20 (coded units) 
Source DF Seq SS Adj SS Adj_MS F p 
Main 3 39.374 39.374 13.125 2.04 0.466 
Effects 
2-Way 3 22.455 22.455 7.485 1.16 0.578 
Interactions 
Residual 1 6.444 6.444 6.444 
Error 
Total 7 68.272 
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Estimated Effects and Coefficients for 25 (coded units) 
Term Effect Coef SE Coef T p 
Constant 6.8900 0.3075 22.421 0.028 
Water Level 2.8050 1.4025 0.3075 4.56 0.137 
Kneading -1.6950 -0.8475 0.3075 -2.76 0.222 
Time 
Spheronization 0.7550 0.3775 0.3075 1.23 0.435 
Time 
Water Level * -0.6900 -0.3450 0.3075 -1.12 0.463 
Kneading 
Time 
Water Level * -1.0700 -0.5350 0.3075 -1.74 0.332 
Spheronization 
Time 




S = 0.869741 R-Sq = 97.32% R-Sq (adj)= 81.25% 
Analysis of Variance for 25 (coded units) 
Source DF Se_q SS AdlSS Adi MS F p 
Main 3 22.6222 22.6222 7.5407 9.97 0.228 
Effects 
2-Way 3 4.8620 4.8620 1.6207 2.14 0.456 
Interactions 
Residual 1 0.7564 0.7564 0.7564 
Error 
Total 7 28.2406 
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Estimated Effects and Coefficients for 30 (coded units) 
Term Effect Coef SE Coef T p 
Constant 55.2800 0.8875 62.29 0.010 
Water Level 1.5050 0.7525 0.8875 0.85 0.552 
Kneading 2.2250 1.1125 0.8875 1.25 0.429 
Time 
Spheronization 1.4850 0.2425 0.8875 0.27 0.830 
Time 
Water Level * 1.4600 0.2300 0.8875 0.26 0.839 
Kneading 
Time 
Water Level * 0.2600 0.1300 0.8875 0.15 0.907 
Spheronization 
Time 




S = 2.51023 R-Sq = 71.18% R-Sq (adj)= 0.00% 
Analysis of Variance for 30 (coded units) 
Source DF s~ss A<!i_ SS Adj MS F p 
Main 3 14.9017 14.9017 4.9672 0.79 0.658 
Effects 
2-Way 3 0.6642 0.6642 0.2214 0.04 0.987 
Interactions 
Residual 1 6.3013 6.3013 6.3013 
Error 
Total 7 21.8672 
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Estimated Effects and Coefficients for 35 (coded units) 
Term Effect Coef SE Coef T p 
Constant 20.4475 0.2575 79.41 0.008 
Water Level -0.1400 -0.0700 0.2575 -0.27 0.831 
Kneading -0.3650 -0.1825 0.2575 -0.71 0.607 
Time 
Spheronization 0.7800 0.3900 0.2575 1.51 0.372 
Time 
Water Level * 0.8300 0.4150 0.2575 1.61 0.354 
Kneading 
Time 
Water Level * 1.6450 0.8225 0.2575 3.19 0.193 
Spheronization 
Time 




S = 0.728320 R-Sq = 94.52% R-Sq (adj)= 61.67% 
Analysis of Variance for 35 (coded units) 
Source DF Seq SS Adj SS Adj MS F p 
Main 3 1.5224 1.5224 0.5075 0.96 0.618 
Effects 
2-Way 3 7.6348 7.6348 2.5449 4.80 0.321 
Interactions 
Residual 1 0.5305 0.5305 0.5305 
Error 
Total 7 9.6877 
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Estimated Effects and Coefficients for 45 (coded units) 
Term Effect Coef SE Coef T p 
Constant 13.926 1.621 8.59 0.074 
Water Level -4.988 -2.494 1.621 -1.54 0.367 
Kneading 1.483 0.741 1.621 0.46 0.727 
Time 
Spheronization 1.178 0.589 1.621 0.36 0.778 
Time 
Water Level * 1.233 0.616 1.621 0.38 0.769 
Kneading 
Time j1 
Water Level * 0.878 0.439 1.621 0.27 0.832 
Spheronization 
Time 




S = 4.58559 R-Sq = 77.95% R-Sq (adj)= 0.00% 
Analysis of Variance for 45 (coded units) 
Source DF s~ss Adj SS Adj MS F p 
Main 3 56.92 56.92 18.973 0.90 0.630 
Effects 
2-Way 3 17.41 17.41 5.802 0.28 0.847 
Interactions 
Residual 1 21.03 21.03 21.028 
Error 
Total 7 95.35 
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Estimated Effects and Coefficients for 60 (coded units) 
Term Effect Coe[ SE Coef T p 
Constant 1.3350 0.2150 6.21 0.102 
Water Level -1.9500 -0.9750 0.2150 -4.53 0.138 
Kneading 0.5950 0.2975 0.2151 1.38 0.398 
Time 
Spheronization -0.5950 -0.2975 0.2150 -1.38 0.398 
Time 
Water Level * -0.2550 -0.1275 0.2150 -0.59 0.659 
Kneading 
Time 
Water Level * 0.2550 0.1275 0.2150 0.59 0.659 
Spheronization 
Time 




S = 0.608112 R-Sq = 96.19% R-Sq (adj)= 73.34% 
Analysis of Variance for 60 (coded units) 
Source DF s~ss Adi SS Adj MS F p 
Main 3 9.0211 9.0211 3.0070 8.13 0.251 
Effects 
2-Way 3 0.3179 0.3179 0.1060 0.29 0.841 
Interactions 
Residual 1 0.3698 0.3698 0.3698 
Error 
Total 7 9.7088 
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Estimated Effects and Coefficients for Pan (coded units) 
Term Effect Coef SE Coef T p 
Constant 0.003750 0.003750 1.00 0.500 
Water Level -0.007500 -0.003750 0.003750 -1 .00 0.500 
Kneading -0.007500 -0.003750 0.003750 -1.00 0.500 
Time 
Spheronization 0.007500 0.003750 0.003750 1.00 0.500 
Time 
Water Level * 0.007500 0.003750 0.003750 1.00 0.500 
Kneading 
Time 
Water Level * -0.007500 -0.003750 0.003750 -1.00 0.500 
Spheronization 
Time 




S= 0.0106066 R-Sq = 85.71 % R-Sq (adj)= 0.00% 
Analysis of Variance for Pan (coded units) 
Source DF s~ss Adj SS Adi MS F p 
Main 3 0.0003375 0.0003375 0.0001125 1.00 0.609 
Effects 
2-Way 3 0.0003375 0.0003375 0.0001125 1.00 0.609 
Interactions 
Residual 1 0.0001125 0.0001125 0.0001125 
Error 
Total 7 0.0007875 
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Estimated Effects and Coefficients for Target% (coded units) 
Term Effect Coef SE Coef T p 
Constant 89.654 0.9912 90.45 0.007 
Water Level -3.623 -1.811 0.9912 -1.83 0.319 
Kneading 3.343 1.671 0.9912 1.69 0.341 
Time 
Spheronization 2.443 1.221 0.9912 1.23 0.434 
Time 
Water Level * 2.522 1.261 0.9912 1.27 0.424 
Kneading 
Time 
Water Level * 2.782 1.391 0.9912 1.40 0.394 
Spheronization 
Time 




S = 2.80368 R-Sq = 93.11 % R-Sq (adj)= 51.74% 
Analysis of Variance for Target% (coded units) 
Source DF s~ss A<!i_ SS Adj MS F p 
Main 3 60.521 60.521 20.174 2.57 0.423 
Effects 
2-Way 3 45 .645 45.645 15.215 1.94 0.476 
Interactions 
Residual 1 7.861 7.861 7.861 
Error 
Total 7 114.027 
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Full Model 
Estimated Effects and Coefficients for Mean Sphericity (coded units) 
Term Effect Coef SE Coef T p 
Constant 1.32000 0.01250 105.60 0.006 
Water Level -0.08500 -0.04250 0.01250 -3.40 0.182 
Kneading 0.0600 0.03000 0.01250 2.40 0.25 1 
Time 
S pheronization -0.0500 -0.02500 0.01250 -2.00 0.295 
Time 
Water Level * -0.01500 -0.00750 0.01250 -0.60 0.656 
Kneading 
Time 
Water Level * 0.06500 0.03250 0.01250 2.60 0.234 
Spheronization 
Time 




S = 0.0353553 R-Sq = 96.88% R-Sq (adj)= 78.12% 
Analysis of Variance for Mean Sphericity (coded units) 
Source DF Seq SS Adj SS Adj MS F p 
Main 3 0.026650 0.026650 0.008883 7.11 0.267 
Effects 
2-Way 3 0.012100 0.012100 0.004033 3.23 0.383 
Interactions 
Residual 1 0.001250 0.001250 0.001250 
Error 
Total 7 0.040000 
245 
Estimated Effects and Coefficients for Standard (coded units) 
Term Effect Coef SE Coef T p 
Constant 0.21215 0.000451 470.78 0.001 
Water Level -0.00695 -0.00348 0.000451 -7.72 0.082 
Kneading 0.00047 0.00023 0.000451 0.52 0.696 
Time 
Spheronization -0.04488 -0.02244 0.000451 -49.80 0.013 
Time 
Water Level * -0.01173 -0.00587 0.000451 -13.02 0.049 
Kneading 
Time 
Water Level * -0.02801 -0.01400 0.000451 -31.08 0.020 
Spheronization 
Time 




S = 0.00127456 R-Sq = 99.98% R-Sq (adj)= 99.89% 
Analysis of Variance for Standard (coded units) 
Source DF s~ss Adi SS Adj MS F p 
Main 3 0.0041252 0.00412518 0.00137506 846.45 0.025 
Effects 
2-Way 3 0.0061622 0.00616220 0.00205407 1264.43 0.021 
Interactions 
Residual 1 0.0000016 0.00000162 0.00000162 
Error 
Total 7 0.0102890 
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Estimated Effects and Coefficients for RSD (%)(coded units) 
Term Effect Coef SE Coef T p 
Constant 16.058 0.04000 401.44 0.002 
Water Level 0.525 0.262 0.04000 6.56 0.096 
Kneading -0.590 -0.295 0.04000 -7.38 0.086 
Time 
Spheronization -2.955 -1.478 0.04000 -36.94 0.017 
Time 
Water Level * -0.740 -0.370 0.04000 -9.25 0.069 
Kneading 
Time 
Water Level * -2.935 -1.467 0.04000 -36.69 0.017 
Spheronization 
Time 




S = 0.113137 R-Sq = 99.98% R-Sq (adj)= 99.84% 
Analysis of Variance for RSD (%)(coded units) 
Source DF s~ss Adj SS Adj MS F p 
Main 3 18.7115 18.7115 6.2372 487.28 0.033 
Effects 
2-Way 3 37.0508 37.0508 12.3503 964.87 0.024 
Interactions 
Residual 1 0.0128 0.0128 0.0128 
Error 
Total 7 55.7752 
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Reduced Model 
Estimated Effects and Coefficients for Mean Sphericity (coded units) 
Term Effect Coef SE Coef T p 
Constant 1.32000 0.01031 128.06 0.000 
Water Level -0.08500 -0.04250 0.01031 -4.12 0.054 
Kneading 0.06000 0.03000 0.01031 2.91 0.101 
Time 
Spheronization -0.05000 -0.02500 0.01031 -2.43 0.136 
Time 
Water Level * 0 0 0 0 0 
Kneading 
Time 
Water Level * 0.06500 0.03250 0.01031 3.15 0.088 
Spheronization 
Time 




S = 0.0291548 R-Sq = 95.75% R-Sq (adj)= 85.12% 
Analysis of Variance for Mean Sphericity (coded units) 
Source DF s~ss AdlSS Adj MS F p 
Main 3 0.026650 0.026650 0.0088833 10.45 0.089 
Effects 
2-Way 2 0.011650 0.011650 0.0058250 6.85 0.127 
Interactions 
Residual 2 0.001700 0.001700 0.0008500 
Error 





Propranolol HCI Aqueous SR Results 
Coating Coating 
Batch# Level Cone. Curing Method 
(Coded) (Coded) 
RB005026 2 High 2hrs@ 60c Vacuum Oven 
RB005026 5 High 2hrs@ 60c Vacuum Oven 
RB005026 6 High 2hrs @ 60c Vacuum Oven 
RB005026 6 High 2hrs @ 60c Vacuum Oven 
RB005026 6 High 2hrs@60c Vacuum Oven 
RB005051 I Low 2hrs @ 60c Vacuum Oven 
RB005051 3 Low 2hrs @ 60c Vacuum Oven 
RB005053 2 Low 2hrs @ 60c Vacuum Oven 
RB005053 4 Low 2hrs @ 60c Vacuum Oven 
RB005053 4 Low 2hrs @ 60c Freas Oven 
RB005059 4 High 2hrs @ 60c Chamber 2 
RB005061 2 Low 2hrs @ 60c Chamber 2 
APPENDIX6 
% Propranolol Released Over Time (hrs) 
1.5 3.5 5.5 7.5 10 22 24 F2 Value 
29.4 57.4 72.9 80.6 87.4 95.3 97.5 38.6 
JO.I 26.4 41.1 51.9 63.9 82.4 82.4 56.3 
5.8 17.3 26.7 35.3 45.8 66.2 68 33.7 
10.3 34 28.6 38.4 45.7 74.8 76.9 38.9 
37.4 58.3 68.6 75.7 82.9 95.4 96.5 39.3 
27 62.8 80.5 89.7 96.7 101.4 102.3 32 
22.6 54.5 71.9 81.4 90.5 99.4 100.5 38.7 
14 35.5 50.5 61.1 69.9 87.8 87.7 96.3 
16.5 33.6 45 53.7 62.3 77.9 80 58.2 
11.9 30.1 41.1 46.4 53.4 64.6 65.3 40.5 
44.5 63.8 71.6 76.5 80.7 88.9 88.8 36.2 




Propranolol Organic SR Dissolution Results 
Coating 
Level 
Batch# Coded Curil!K_ Method 
RBOOS064 1 Uncured 
RBOOS064 2 Uncured 
RBOOS064 2 24hrs _@ 60c Chamber 2 
RBOOS064 2 24hrs @ 60c/SO% RH Chamber 2 
RBOOS064 2 24hrs _@ SOc Chamber 2 
RBOOS064 2 24hrs@ S0c/SO% RH Chamber 2 
RBOOS064 2 6hrs _@ SOc Chamber 2 
RBOOS064 2 6hrs@ S0c/SO% RH Chamber 2 
RBOOS064 2 6 hrs _@60c Freas 
RBOOS064 2 24 hrs @ 60c Freas 
RBOOS064 2 2 hrs_@_ SOC Freas 
RBOOS064 2 24 hrs @ SOC Freas 
RBOOS064 2 18 hrs@ SOC Freas 
RBOOS064 2 18 hrs_@ 60C Freas 
RBOOS072 1 24 hrs_@ SOC Freas 
RBOOS072 1 24 hrs @ SOC Chamber 2 
RBOOS072 1 24 hrs @4SC Chamber 2 
RBOOS072 1 2 hrs_@_ 4SC Chamber 2 
RBOOS072 1 6 hrs_@_ 4SC Chamber 2 
RBOOS072 1 18 hrs @ 4SC Chamber 2 
























3.5 5.5 7.5 10 22 24 F2 Value 
22.7 37.3 49.2 61.S 83.6 8S.3 S0.4 
20.4 34.0 44.2 SS.7 79.5 82.6 44.5 
S0.9 70.3 81.S 91.1 102.S 103.S 40.S 
62.0 81.4 92.2 98.8 103.2 104.4 32.0 
41.2 S8.0 69.5 82.2 100.S 102.6 S4.2 
4S.9 6S.S 76.9 86.5 97.6 97.4 46.7 
29.S 4S. l S6.9 70.l 92.7 9S.3 6S.5 
46.9 68.6 81.8 93.9 109.9 111.1 39.0 
37.4 S4.S 67.S 79.0 97.1 99.9 61.5 
49.4 70.6 82.9 93 .6 106.0 107.3 38.9 
28.8 46.7 60.4 72.0 94.3 9S.8 64.8 
36.2 S4.8 67.S 80. l 99.8 100.3 S7.7 
30.4 44.8 SS.6 6S.4 83.l 8S.6 64.3 
46.4 64.0 73.8 83 .8 93 .2 94.3 S0.6 
37.6 S7.2 72.1 84.4 100. l 101.1 S2.8 
40.0 61.2 74.1 87.3 101.3 104.3 48.7 
38.1 S7.6 70.4 83.9 100.6 103 .0 S2.9 
36.S SS.1 68 .7 79.9 99.9 103.7 S6.8 
39.9 61.6 73 .1 84. 1 103.6 lOS.3 48.9 
39.S S7 .7 69.9 82. 1 100.4 101.1 S3 .8 
3S.4 S2.9 64.3 7S .O 92.2 92.7 72.0 
APPENDIX8 
Metoprolol SR Full Model Response Surface Regression/ANOVA 
Response Surface Regression: Estimated Regression Coefficients for 1 hr 
Term Coef SE Coef T p 
Constant 2.00750 1.1367 1.766 0.138 
Polymer Coatin_g Level -0.53053 0.6546 -0.810 0.454 
Curing Conditions -1.16079 0.6546 -1.773 0. 136 
Curi~ Time (Hrs) -0.33000 0.6380 -0.517 0.627 
Polymer Coating Level * 1.06500 0.9391 1.134 0.3 08 
PolYmer Coating Level 
Curing Conditions * Curing 2.40000 0.9391 2.556 0.051 
Conditions 
Curing Time (Hrs)* Curing -1.50750 1.0833 -1.392 0.223 
Time (Hrs) 
Polymer Coating Level * -0.03500 0.9023 -0.039 0.971 
Curing Conditions 
Polymer Coating Level * 0.23684 0.8782 0.270 0.798 
Curing Time (Hrs) 
Curing Conditions * Curing 0.83526 0.8782 0.951 0.385 
Time (Hrs) 
S = 1.805 R-Sq = 77.2% R-Sq (adj)= 36.1 % 
Analysis of Variance for 1 hr 
Source DF St:.9_SS Adj SS Adj MS F p 
R~ession 9 55.0820 55.0820 6.1202 1.88 0.252 
Linear 3 18.8032 13.2508 4.4169 3.39 0.111 
S_g_uare 3 33.0913 33.0913 11.0304 3.39 0.111 
lnteraction 3 3.1874 3.1874 1.0625 0.33 0.807 
Residual Error 5 16.2822 16.2822 3.2564 
Lack-of-Fit 3 15.7030 15.7030 5.2343 18.07 0.053 
Pure Error 2 0.5792 0.5792 0.2896 
Total 14 71.3642 
E . t dR stama e ~ress1on c ffi . oe 1c1ents t lb or r usm_g d d d ata m unco e um ts 
Term Coef 
Constant -1.63000 
Poly_mer Coating Level -0.925263 
Curin_g Conditions -2.55289 
Cur~ Time (Hrs) 1.56500 
Pob'_mer Coatin_g Level * Pob'_mer Coatil!& Level 1.06500 
Cur~ Conditions * Curin_g_ Conditions 2.40000 
Curing Time (Hrs) * Curing Conditions -0.167500 
Curin_g Time (Hrs)* Curin_g_ Time (Hrs) -0.0350000 
Po~er Coatin_g Level * Curing Time (Hrs) 0.0789474 
Curin_g_ Conditions * Curing Time (Hrs) 0.278421 
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Response Surface Regression: 4 hr 
Estimated Regression Coefficients for 4 hr 
Term Coef SE Coef T p 
Constant 8.6680 2.622 3.306 0.021 
Po~er Coatil!_g_ Level -1.3961 1.510 -0.925 0.398 
Curin_g_ Conditions -4.7757 1.510 -3.163 0.025 
Curin_g_ TimelHrs) -0.6337 1.472 -0.431 0.685 
Polymer Coating Level * 2.6554 2.166 1.226 0.275 
Po!Y!ner Coatil!_g_ Level 
Curing Conditions * Curing 3.8179 2.166 1.763 0.138 
Conditions 
Curing Time (Hrs) *Curing -3.5334 2.498 -1.414 0.216 
Time (Hrs) 
Polymer Coating Level * 0.4850 2.081 0.233 0.825 
Curin_g_ Conditions 
Polymer Coating Level * 0.5637 2.026 0.278 0.792 
Curin_g_ Time (Hrs) 
Curing Conditions * Curing 1.3536 2.026 0.668 0.534 
Time (Hrs) 
S = 4.162 R-Sq = 80.6% R-Sq (adj)= 45.7% 
Analysis of Variance for 4 hr 
Source DF Seg_SS Adj SS Adj MS F p 
R~ession 9 359.951 359.951 39.9945 2.31 0.185 
Linear 3 229.313 191.358 63.7859 3.68 0.097 
S_g_uare 3 120.619 120.619 40.2065 2.32 0.192 
Interaction 3 10.018 10.018 3.3393 0.19 0.897 
Residual Error 5 86.616 86.616 17.3231 
Lack-of-Fit 3 85.498 85.498 28.4994 51.02 0.019 
Pure Error 2 1.117 1.117 0.5586 
Total 14 446.566 
Estimated Regression Coefficients for 4 hr using data in uncoded units 
Term Coef 
Constant -0.0908333 
Polymer Coating_ Level -2.33553 
Curin_g_ Conditions -7.03158 
Curing_ Time (Hrs) 3.71479 
Po!_rmer Coating_ Level * Po!_rmer Coatin_g_ Level 2.65542 
Curing_ Conditions * Curin_g_ Conditions 3.81792 
Curif!.g_ Time (Hrs) * Curin_g_ Conditions -0.392604 
Curing_ Time (Hrs) * Curing_ Time (Hrs) 0.485000 
Po!_rmer Coating_ Level * Curing_ Time (Hrs) 0.187895 
Curin_g_ Conditions * Curing_ Time (Hrs) 0.451184 
252 
Response Surface Regression: 8 hr 
The analysis was done using coded units. 
Estimated Regression Coefficients for 8 hr 
Term Coef SE Coef T p 
Constant 19.6420 2.970 6.614 0.001 
Po!r_mer Coatin_g_ Level -3.2791 1.710 -1.917 0.113 
Curin_g_ Conditions -6.0404 1.710 -3.532 0.017 
Curin_g_ Time (Hrs) -0.7325 1.667 -0.439 0.679 
Polymer Coating Level * 3.3158 2.454 1.351 0.234 
Po~er Coatin_g_ Level 
Curing Conditions * Curing 2.5408 2.454 1.036 0.348 
Conditions 
Curing Time (Hrs)* Curing -4.4353 2.830 -1.567 0.178 
Time (Hrs) 
Polymer Coating Level * 0.0700 2.357 0.030 0.977 
Curing_ Conditions 
Polymer Coating Level * 0.5830 2.295 0.254 0.810 
Curin_g_ Time (Hrs) 
Curing Conditions * Curing 0.2751 2.295 0.120 0.909 
Time (Hrs) 
S = 4.715 R-Sq = 82.7% R-Sq (adj)= 51.7% 
Analysis of Variance for 8 hr 
Source DF S«:_q SS Aclj_ SS Adj MS F p 
R~ession 9 532.770 532.770 59.197 2.66 0.147 
Linear 3 403.497 363.307 121.102 5.45 0.049 
S_g_uare 3 127.499 127.499 42.500 1.91 0.246 
Interaction 3 1.774 1.774 0.591 0.03 0.993 
Residual Error 5 111.146 111.146 22.229 
Lack-of-Fit 3 106.347 106.347 35.449 14.78 0.064 
Pure Error 2 4.798 4.798 2.399 
Total 14 643 .916 
Estimated Regression Coefficients for 8 hr using data in uncoded units 
Term Coef 
Constant 8.54250 
Po!r_mer Coating_ Level -4.25079 
Curing_ Conditions -6.49895 
Curin_g_ Time (Hrs) 4.68396 
Po!r_mer Coatin_g_ Level * Po!r_mer Coatin_g_ Level 3.31583 
Curin_g_ Conditions * Curi~ Conditions 2.54083 
Curin_g_ Time (Hrs) * Curin_g_ Conditions -0.492812 
Curin_g_ Time (Hrs) * Curi~ Time (Hrs) 0.0700000 
Po!l'_mer Coati~ Level * Curing_ Time (Hrs) 0.194342 
Curing_ Conditions * Curin_g_ Time (Hrs) 0.0917105 
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Response Surface Regression: 12 hr 
Estimated Regression Coefficients for 12 hr 
Term Coef SE Coef T p 
Constant 33.1944 3.688 9.001 0.000 
Po!_rmer Coatin_g_ Level -5.8158 2.124 -2.739 0.041 
Curin_g_ Conditions -3.5174 2.124 -1 .656 0.159 
Curin_g_ Time (Hrs) -0.0300 2.070 -0.014 0.989 
Polymer Coating Level * 3.3550 3.047 I.IOI 0.321 
Po!_rmer Coati~ Level 
Curing Conditions * Curing -0.8900 3.047 -0.292 0.782 
Conditions 
Curing Time (Hrs)* Curing -3 .7294 3.514 -1.061 0.337 
Time (Hrs) 
Polymer Coating Level * I .4000 2.927 0.478 0.653 
Curin_g_ Conditions 
Polymer Coating Level * 1.2703 2.849 0.446 0.674 
Curin_g_ Time (Hrs) 
Curing Conditions * Curing -0.8242 2.849 -0.289 0.784 
Time (Hrs) 
S = 5.854 R-Sq = 74.2% R-Sq (adj)= 27.6% 
Analysis of Variance for 12 hr 
Source DF s~ss A<!i_ SS A<!i_MS F p 
R~ession 9 491.79 491.79 54.643 1.59 0.316 
Linear 3 384.55 351.09 117.030 3.41 0.110 
S_g_uare 3 89.71 89.71 29.905 0.87 0.514 
Interaction 3 I 7.52 17.52 5.840 0.17 0.912 
Residual Error 5 171.36 I 71.36 34.273 
Lack-of-Fit 3 160.13 160.13 53.375 9.50 0.097 
Pure Error 2 11.24 11 .24 5.620 
Total 14 663.15 
Estimated Regression Coefficients for 12 hr using data in Uncoded units 
Term Coef 
Constant 22.8850 
Pob'._mer Coatin_g_ Level -7.93289 
Curin_g_ Conditions -2.14368 
Curin_g_ Time (Hrs) 4.13375 
Polymer Coatin_g_ Level * Polymer Coating_ Level 3.35500 
Curin_g_ Conditions * Curin_g_ Conditions -0.890000 
Curin_g_ Time (Hrs) * Curirig_ Conditions -0.414375 
Curirig_ Time (Hrs)* Curin_g_ Time (Hrs) 1.40000 
Pob'._mer Coatin_g_ Level * Curin_g_ Time (Hrs) 0.423421 
Curil!_g_ Conditions * Curin_g_ Time (Hrs) -0 .274737 
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Response Surface Regression: 16 hr 
Estimated Regression Coefficients for 16 hr 
Term Coef SE Coef T p 
Constant 45 .5223 4.190 10.865 0.000 
Po!l_mer Coatin_g_ Level -4.9413 2.413 -2.048 0.096 
Curin_g_ Conditions 0.8549 2.413 0.354 0.738 
Curing_ Time (Hrs) 0.7538 2.352 0.321 0.762 
Polymer Coating Level * 2.9771 3.462 0.860 0.429 
Pob'._mer Coatin_g_ Level 
Curing Conditions * Curing -3.1004 3.462 -0.896 0.411 
Conditions 
Curing Time (Hrs)* Curing -2.1394 3.993 -0.536 0.615 
Time (Hrs) 
Polymer Coating Level * -1.5500 3.326 -0.466 0.661 
Curing_ Conditions 
Polymer Coating Level * 1.2071 3.237 0.373 0.725 
Curing_ Time (Hr& 
Curing Conditions * Curing -1.6433 3.237 -0.508 0.633 
Time (Hrs) 
S = 6.651 R-Sq = 60.4% R-Sq (adj)= 0.0% 
Analysis of Variance for 16 hr 
Source DF St:9._ SS Adj SS AdlMS F p 
R~ession 9 337.42 337.42 37.491 0.85 0.610 
Linear 3 223.64 195.67 65 .222 1.47 0.328 
S_quare 3 86.61 86.61 28.872 0.65 0.615 
Interaction 3 27.16 27.16 9.055 0.20 0.889 
Residual Error 5 221.21 221.21 44.242 
Lack-of-Fit 3 201.63 201 .63 67.209 6.86 0.130 
Pure Error 2 19.59 19.59 9.793 
Total 14 558.64 
Estimated Regression Coefficients for 16 hr using data in uncoded units 
Term Coef 
Constant 38.3233 
Po!l_mer Coatin_g_ Level -6.95316 
Curin_g_ Conditions 3.59368 
Curing_ Time (Hrs) 2.62833 
Po!l_mer Coatin_g_ Level* Po!l_mer Coatin_g_ Level 2.97708 
Curin_g_ Conditions * Curing_ Conditions -3 .10042 
Curing_ Time (Hrs) * Curing_ Conditions -.0237708 
Curin_g_ Time (Hrs)* Curin_g_ Time (Hrs) -1.55000 
Poll_mer Coatin_g_ Level * Curin_g_ Time (Hrs) 0.402368 
Curin_g_ Conditions * Curin_g_ Time (Hrs) -0.547763 
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Response Surface Regression: 20 hr 
Estimated Regression Coefficients for 20 hr 
Term Coef SE Coef T p 
Constant 55 .6439 4.412 12.612 0.000 
Po.!l'.!!!_er Coati'!&_ Level -5.1111 2.541 -2 .012 0.100 
Curi'!&_ Conditions 3.8197 2.541 1.503 0.193 
Curin__g_ Time (Hrs) 1.4225 2.476 0.574 0.591 
Polymer Coating Level * 3.3133 3.645 0.909 0.405 
Po!i'._mer Coati'!&_ Level 
Curing Conditions * Curing -1.8717 3.645 -0.513 0.629 
Conditions 
Curing Time (Hrs)* Curing -2.2172 4.204 -0.527 0.621 
Time (Hrs) 
Polymer Coating Level * -0.9900 3.502 -0.283 0.789 
Curi'!&_ Conditions 
Polymer Coating Level * 1.4787 3.409 0.434 0.683 
Curin_g_ Time (Hrs) 
Curing Conditions * Curing -1.3216 3.409 -0.388 0.714 
Time (Hrs) 
S = 7.004 R-Sq = 65.4% R-Sq (adj)= 3.1 % 
Analysis of Variance for 20 hr 
Source DF St:_q SS Adj SS Adj MS F p 
R~ession 9 463.79 463 .79 51.533 1.05 0.507 
Linear 3 370.67 325.61 108.536 2.21 0.205 
S_guare 3 72.60 72.60 24.199 0.49 0.702 
Interaction 3 20.53 20.53 6.842 0.14 0.932 
Residual Error 5 245.28 245 .28 49.056 
Lack-of-Fit 3 213.10 213 .10 71.033 4.41 0.190 
Pure Error 2 32.18 32.18 16.092 
Total 14 709.08 
Estimated Regression Coefficients for 20 hr using data in uncoded units 
Term Coef 
Constant 47.1142 
Pob'_mer Coati'!&_ Level -7.57553 
Curing_ Conditions 6.02237 
Curin_g_ Time (Hrs) 2.93771 
Pob'r!i_er Coatin_g_ Level * Pob'r!i_er Coatin_g_ Level 3.31333 
Curin_g_ Conditions * Curin__g_ Conditions -1.87167 
Curi'!&_ Time (Hrs) * Curin_g_ Conditions -0.246354 
Curin_g_ Time (Hrs) * Curin__g_ Time (Hrs) -0.990000 
Pob'_mer Coati'!&_ Level * Curin_g_ Time (Hrs) 0.492895 
Curin_g_ Conditions * Curi~ Time (Hrs) -0.440526 
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Response Surface Regression: F2 
Estimated Regression Coefficients for F2 
Term Coef SE Coef T p 
Constant 26.0939 1.946 13.409 0.000 
Pob:'_mer Coati~ Level -2.8616 1.121 -2.554 0.051 
Curin__g_ Conditions -0.5868 1.121 -0.524 0.623 
Curin_g_ Time (Hrs) 0.2700 1.092 0.247 0.815 
Polymer Coating Level * 1.9208 1.608 1.195 0.286 
Pob:'_mer Coati~ Level 
Curing Conditions * Curing -0.4392 1.608 -0.273 0.796 
Conditions 
Curing Time (Hrs)* Curing -1.7147 1.854 -0.925 0.398 
Time (Hrs) 
Polymer Coating Level * -0.2550 1.545 -0.165 0.875 
Curin_g_ Conditions 
Polymer Coating Level * 0.5005 1.503 0.333 0.753 
Curin__g_ Time (Hrs) 
Curing Conditions * Curing -0.4011 1.503 -0.267 0.800 
Time (Hrs) 
S = 3.089 R-Sq = 67.2% R-Sq (adj)= 8.2% 
Analysis of Variance for F2 
Source DF s~ss AdlSS AdlMS F p 
R~ession 9 97.884 97.884 10.8760 1.14 0.467 
Linear 3 71.554 65.434 21.8114 2.29 0.196 
~uare 3 24.333 24.333 8.1109 0.85 0.523 
Interaction 3 1.997 1.997 0.6657 0.07 0.974 
Residual Error 5 47.720 47.720 9.5439 
Lack-of-Fit 3 43.308 43.308 14.4358 6.54 0.135 
Pure Error 2 4.412 4.412 2.2060 
Total 14 145.604 
Estimated Regression Coefficients for F2 using data in uncoded units 
Term Coef 
Constant 20.8808 
Polymer Coatin_g_ Level -3 .69579 
Curin_g_ Conditions 0.0815789 
Curi~ Time (Hrs) 1.99521 
Po~er Coati~ Level * Po!l_mer Coatin__g_ Level 1.92083 
Curi~ Conditions * Curin_g_ Conditions -0.439167 
Curin_g_ Time (Hrs) * Curi~ Conditions -0.190521 
Curi~ Time (Hrs) * Curin_g_ Time (Hrs) -0.255000 
Po!l_mer Coati~ Level * Curin_g_ Time (Hrs) 0.166842 
Curin_g_ Conditions * Curi~ Time (Hr~ -0.133684 
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APPENDIX9 
ANOV A of Tablet DOE Friability 
Full Model 
General Linear Model: % Usable versus SR Polymer l, Blend (MCC 2) 
Factor Typ_e Levels Values 
SR Pob:'._mer Level Fixed 2 -1 , I 
Blend (MCC 200:102) Fixed 2 1:1, 3:7 
Hardness (K_E) Fixed 2 2, 5 
Analysis of Variance for% Usable, using Adjusted SS for Tests 
Source DF s~ss Adj SS Adj MS F p 
SR Po.!i'_mer Level I 274.83 274.83 274.83 3.81 0.301 
Blend (MCC 200: I 02) I 53.92 53.92 53.92 0.75 0.546 
Hardness (KJD I 378.26 378.26 378.26 5.25 0.262 
SR Polymer Level * I 80.07 80.07 80.07 I. I I 0.483 
Blend (MCC 200:102) 
SR Polymer Level * I 238.82 238.82 238.82 3.31 0.320 
Hardness (KJD 
Blend (MCC 200:102) * I 45.08 45.08 45.08 0.63 0.574 
Hardness _Q<.JD 
Error I 72.06 72.06 72.06 
Total 7 1143.05 
S = 8.48882 R-Sq = 93.70% R-Sq (adj)= 55.87% 
Reduced Model 
General Linear Model:% Usable versus SR Polymer l, Blend (MCC 2, ... ) 
Factor T..l'.£.e Levels Values 
SR Po.!i'_mer Level Fixed 2 -I , I 
Blend (MCC 200: I 02) Fixed 2 I : 1, 3:7 
Hardness (K_E) Fixed 2 2,5 
Analysis of Variance for% Usable, using Adjusted SS for Tests 
Source DF s~ss AdjSS A<!i_MS F p 
SR Pob:'._mer Level I 274.83 274.83 274.83 4.69 0.163 
Blend (MCC 200: 102) I 53.92 53 .92 53.92 0.92 0.439 
Hardness (K_E) I 378.26 378.26 378.26 6.46 0.126 
SR Polymer Level * I 80.07 80.07 80.07 1.37 0.363 
Blend (MCC 200: I 02) 
SR Polymer Level * I 238.82 238.82 238.82 4.08 0.181 
Hardness (Kp) 
Error 2 I 17.14 I I 7.14 58.57 
Total 7 I 143.05 
S = 7.65302 R-Sq = 89.75% R-Sq (adj)= 64.13% 
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